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Abstract 
Introduction  
Prolonged exposure to diesel particulate matter (PM) has been linked to inflammation and 
oxidative stress, which can lead to the development and progression of chronic obstructive 
pulmonary disease (COPD). A common strategy to reduce diesel PM is the substitution of 
diesel fuel with biodiesel or a fuel additive. The use of biodiesels or fuel additives effective ly 
lower diesel particulate emissions. However, very little is known about the health effects of 
these alternative diesel emissions. Furthermore, antioxidant treatment may be a potential 
therapeutic intervention to protect the lungs by maintaining oxidative balance and preventing 
oxidative stress after diesel emission exposure; however, this has not previously been 
comprehensively tested. Understanding the cell response within the lungs after air pollut ion 
exposure and how air pollution interacts with the diseased lungs of COPD patients would 
facilitate development of preventive strategies for COPD.    
 
Aim  
The main objectives of this PhD program were to investigate adverse effects of diesel emission 
with varied physical and chemical compositions on human bronchial epithelial cells, to test the 
effectiveness of antioxidant therapy to protect against adverse effects, and to identify potential 
novel targets in the COPD lung transcriptome for interventions aimed at protecting vulnerab le 
lungs from air pollution exposure.    
 
Methods  
This project incorporates three different study designs:  
1. Diesel and biodiesel toxicity studies  characterized human bronchial epithelial cells 
(HBECs) responses to diesel and biodiesel emissions with varied chemical and physical 
compositions. HBECs were cultured and differentiated at an air-liquid interface (ALI) 
for 28 days. After exposure, bioassays measured cell metabolism, cell death and 
cytokine secretion. Gene expression assays measured biomarkers for apoptosis, anti-
apoptosis, xenobiotic metabolism and oxidative stress responses.   
2. An antioxidant intervention was tested for attenuation of HBECs responses to diesel 
emissions. Cell response testing measured cell proliferation, cell death, oxidative stress, 
inflammation and xenobiotic metabolism. The effect of the diesel emissions with or 
without intervention on transcriptomic changes was assessed using Nanostring GX 
Intracellular Signalling and Immunology panels.  
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3. Transcriptomic profiling of the COPD lung was assessed using RNAseq using the 
Ion Torrent technology. Comparative data analysis was used to isolate potential targets 
for preventative cell response intervention.   
 
Results  
This PhD program identified 6 key findings:  
1. Both organic content and residual components of diesel emissions were important in 
determining HBEC responses in vitro.  
2. Biodiesel blends worsened primary HBEC response to diesel emission exposure.  
3. Diesel fuel substitution with raw coconut oil reduced the adverse effects of diesel 
emission on 16HBE cells when percentage substitution is controlled.  
4. NAC intervention potentiated, rather than reduced, adverse cellular responses of 
immortalised 16HBE cells to diesel emission exposure.   
5. NAC intervention may be effective intervention against the adverse effects of diesel 
emission exposure in primary HBECs from a COPD cohort.  
6. Transcriptomic profiling of the COPD lung identified 8 differentially expressed genes, 
when compared to the non-COPD lung, which may be potential targets for intervention 
against diesel emission exposure and COPD progression.   
 
Conclusions  
This thesis has investigated two potential strategies to reduce the adverse effects of diesel 
emissions on HBECs; the addition of coconut oil in diesel fuel and the administration of NAC 
as a therapeutic antioxidant. These coconut oil derived alternative diesel emissions showed 
highly differential effects on HBEC responses, despite the similarities in diesel composition. 
By studying the effects of diesel emissions with varied physical and chemical compositions, 
this thesis has improved current understanding of how HBECs respond to diesel, biodiesel and 
alternative diesel emissions. Moreover, an antioxidant treatment with 5 mM NAC had 
differential effects on HBECs after diesel emission exposure. NAC intervention was toxic to 
immortalized 16HBE cells after diesel emission exposure. When tested on primary HBECs 
from a COPD cohort, NAC did not significantly reduce the adverse effects of diesel emission 
exposure, however there was a trend for attenuation. 
 This thesis has highlighted the importance of toxicity testing for novel diesel 
alternatives, as minor differences in composition can alter HBEC responses and the potential 
for negative health impacts. Furthermore, intervention studies showed no significant 
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improvement of HBEC responses with the administration of an antioxidant therapy, despite 
oxidative stress being a known driver of diesel-induced injury. This thesis has identified a 
limitation in our understanding of diesel emission toxicity and how to effectively intervene and 
protect the airways from diesel emission exposure.   The COPD lung transcriptome displayed 
potential novel targets for future intervention studies. Future research will look to validate these 
potential targets and assess their potential for intervention. Future diesel toxicity studies should 
continue to explore alternative diesel blends that reduce diesel pollution and the adverse effects 
of diesel emission exposure.  
 Intervention studies should investigate the toxicity of NAC on immortalised cell 
lines and the potential to protect against pre-malignant cells after diesel emission exposure. 
These findings provide a scientific basis for the development of strategies to protect vulnerab le 
populations from diesel emissions.   
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Chapter 1:  Literature review 
 
1.1 Airway structure and function 
The airway epithelium is a physical barrier that protects the airways from inhaled agents. Its 
protective functions include mucociliary clearance to remove inhaled agents and the initiat ion 
of the innate immune responses. The airway epithelium is made up of pseudostratified layer 
where the cells rest on a basement membrane, but differ in both height and nuclei [1]. Bronchia l 
epithelium is made up of basal cells, ciliated cells and mucus goblet cells [1]. Basal cells are 
highly abundant within the bronchial epithelium and are somewhat undifferentiated, offering 
stem-cell like properties in that they can self-renew and give rise to secretory and ciliated 
epithelial cells after injury [1]. Ciliated epithelial cells are abundant throughout the airways. 
Each ciliated cell can have up to 300 cilia and have a large number of mitochondria close to 
the apical surface, providing energy for ciliary beating [1]. Mucus goblet cells secrete mucus 
to catch and clear inhaled agents from the airways through mucociliary clearance [1].  The 
regulation of both the mucociliary clearance and the innate immune signalling of epithelia l 
cells are critical for normal lung function [1]. Long-term exposure to reactive inhaled toxins 
such as diesel emissions can cause a dysfunction of these processes [2, 3] leading to chronic 
lung disease including chronic obstructive pulmonary disease (COPD) [4].  
 
1.2 Global burden of COPD 
COPD is characterised by persistent airflow limitation that is usually progressive. The 
development and progression of COPD is associated with an enhanced chronic inflammation 
in the airways and the prolonged interaction between the lungs with noxious particles or gases 
including diesel emissions [5]. Exacerbations and comorbidities contribute to the overall 
severity of this disease in individual patients. The Australian Bureau of Statistics has reported 
at an estimated 5.1% of Australians over the age of 45 have COPD [6].  It is estimated that 328 
million people world-wide have COPD [7]. WHO estimates that 3 million people die of COPD 
each year, and that COPD will become the third leading cause of death worldwide by 2020 [8]. 
Disease severity, exacerbations and comorbidities contribute the economic and social burden 
of COPD. Hospitalisation for COPD exacerbations cost the United States health care system 
$18 billion annually [9]. It is estimated that the total cost of COPD in the EU is €38.7 billion 
annually [7] and Singapore is $9.9 million [10]. Additionally, chronic respiratory disease 
accounts for 4.7% of global disability-assisted living years (DALY) and 6.3% of years lost to 
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disability (YLD). The largest contributor was COPD, accounting for 29.4 million YLD. COPD 
accounted for 2.9 million YLDs [11]. These costs emphasise the need for effective 
interventions to delay progression and prevent exacerbations of COPD.  
 
 
1.3 Diesel exhaust: a risk factor for COPD 
COPD arises from the prolonged interaction between the airways and noxious inhalants such 
as cigarette smoke and air pollution, and the gene-environmental interaction. Cigarette smoke 
is considered the major risk factor for COPD [5, 7, 12]. Nonetheless, there are a range of other 
risk factors linked to COPD including occupational exposures to noxious fumes and dust, 
indoor air pollution and outdoor air pollution [13-16], particularly in the urban environment. A 
major contributor to outdoor air pollution in the urban environment is traffic and diesel 
emissions which have been linked to increased mortality of COPD [4, 17, 18]. In a cohort study 
of 467,994 residents in Vancouver, Canada, exposure to ambient air pollution, especially black 
carbon from traffic and woodsmoke, was associated with an increased risk of COPD mortality 
and hospitalisation. Traffic and diesel emissions are high in particulate matter, a major 
contributor to urban air pollution. In a systematic review and meta-analysis, it was shown that 
a short-term increase in PM2.5 by 10µg/m3 can increase COPD hospitalisation by 3.1% and 
mortality by 2.5% [21]. DeVries (2017) showed similar findings where ambient concentration 
of PM2.5, NO2 and SO2 were significantly and positivity correlated to morbidity and mortality 
in COPD [22]. Chen (2004) found that PM exposure had a positive effect on COPD 
hospitalisations and that this relationship was dependant on its interaction with co-pollutants 
[20]. This interaction between co-pollutants can be a hindrance in isolating the effects of 
specific pollutants on human health. Hence, occupational studies offer the model to study 
specific pollutants, without the confounding factor of co-pollutant interaction. Research has 
shown that occupational exposure to particulate matter is an important risk factor for COPD 
[23, 24]. Diesel emissions are a major contributor to particulate matter pollution [18] and are a 
common pollutant in many occupational settings, such as the mining and transport industries  
 
Diesel exhaust is a complex mixture of particulate matter and gases, and includes particles less 
than 1 micron in diameter with mutagenic and polycyclic aromatic hydrocarbon (PAH) 
carcinogenic compounds absorbed to the carbon core and ultrafine particles made up of 
condensed organics [18]. Various occupations involve exposure to diesel emissions, includ ing 
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transportation (railroads, trucks and buses), construction, mining and maintenance. The US 
Third National Health and Nutrition examination study (NHANES III) examined the 
association between COPD (defined by lung function) and 25 occupational categories. This 
study found an increased odd ratio for COPD in industries with likely diesel emission exposure 
including construction (OR: 1.3, 95% CI: 0.8-2.3) and transportation and trucking (OR 1.2, 
95%CI: 0.8–2.0). The odds ratios were higher in never smokers (construction OR 3.5; 95%CI 
0.9–14.0, transportation and trucking OR 2.0; 95%CI 0.3–15.0). These odds ratios were 
adjusted for age, sex, race/ethnicity, BMI, smoking (status and pack years), education levels 
and socioeconomic status [25]. Another study looking at the risk of COPD associated with 
diesel emission exposure showed that occupational exposure to diesel emissions had an OR of 
1.9 compared to no exposure and adjusted for age and sex. For never smoker, the OR was 6.4 
[26]. Understanding how diesel emissions interact in the airways and the COPD lung would 
help to develop intervention for COPD to prevent adverse health effects caused by air pollut ion 
exposure and to reduce the progression and mortality of COPD. 
 
 
1.4 Effects of diesel particulate matter on airway epithelium 
Diesel emissions are a major source of air pollution; more specifically, particulate matter 
pollution [18]. The lung’s response to diesel emission exposure is highly dependent on the 
physical and chemical diesel PM composition of the emissions. There are several factors that 
can affect the composition of diesel PM including the fuel composition [27], the emissions 
source and atmospheric interactions with co-pollutants. This complex and dynamic nature of 
diesel emissions composition is a consistent challenge in diesel exposure studies and their 
application in translational medicine. 
 
Previous research has shown that, when inhaled into the airways, diesel PM is deposited in the 
airways in a size-dependent manner [18, 28]. Ultrafine (<0.1μm) diesel PM can penetrate the 
mucosal layer protecting the airways and aggregate in the bronchial epithelium [29, 30]. 
Exposure to diesel PM triggers the release of pro-inflammatory cytokines including tumour 
necrosis factor- (TNF), interleukin-8 (IL-8) and interleukin-6 (IL-6) [28, 30-34]. Exposure 
to diesel emissions can cause the recruitment of immune cells to the airways [35], which can 
trigger acute exacerbations of COPD [36]. Also, the internalization of ultrafine diesel PM 
introduces exogenous ROS that, when uncontrolled, leads to oxidative stress and mitochondria l 
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dysfunction within the cell [37]. Oxidative stress is thought to be one of the main drivers of 
tissue injury from diesel emission exposure [38] and can be caused by altered cell metabolism 
[39] or persistent inflammation [40]. For example, the activity of inflammatory proteins, 
infiltrating immune cells and xenobiotic metabolizing enzymes, such as CYP1A1, can produce 
ROS [39, 41, 42]. Oxidative stress can lead to cell death as well as alter DNA methylation, 
causing epigenetic changes associated with chronic lung diseases including COPD [4].  
 
Oxidative stress is the imbalance between reactive oxygen species (ROS) levels and the ability 
to neutralize ROS through antioxidant activity [43]. Exposure to diesel emissions can cause 
oxidative stress through the endogenous production of ROS by active inflammatory cells and 
xenobiotic metabolism [44]. Levels of ROS can increase from exogenous sources includ ing 
the surface of diesel PM. ROS has been shown to promote airway remodelling, stimulate mucus 
secretion, cause apoptosis and regulate cell proliferation [43, 45]. ROS has also been implica ted 
in initiating inflammatory responses through NF-kB activation [46]. This process can 
exacerbate oxidative stress, as inflammatory responses produce ROS. The chronic 
inflammation attributed to COPD involves persistent initiation and activation of inflammato ry 
cells, resulting in continual ROS production and oxidative stress. Oxidative stress in COPD 
can lead to mucus hypersecretion, remodelling of the extracellular matrix, apoptosis and DNA 
damage [47]. Preventative interventions that reduce oxidative stress in the airways may help 
protect against the chronic lung diseases including COPD. Diesel emissions exposure, if 
prolonged, can have a severe impact on the airway epithelium, causing inflammation, oxidative 
stress and tissue injury [38, 40]. Damage to the airway epithelium is a key driver of the 
pathogenesis and progression of COPD. An effective therapeutic intervention to protect the 
airway epithelium from diesel emission exposure may prevent inflammation and oxidative 
stress in the airways, and potentially, the progression of COPD [18, 48, 49]. Unfortunate ly, 
there are currently no targeted interventions to protect the airways from diesel emission 
exposure.  
 
1.5 Cell culture models for testing diesel emission effects 
Until recently, the conventional in vitro method for investigating the effects of diesel PM in 
the airways was to suspend diesel PM in culture medium and administer directly onto an 
epithelial cell monolayer [50, 51]. A major limitation of this type of in vitro model is the lack 
of physiological relevance of testing cells in submerged culture. In the in vivo system, the 
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epithelial cells grow and function at an ALI where the apical surface is exposed to inhaled air 
and the basal surface interacts with other respiratory cell types (endothelial cells, fibroblasts 
and smooth muscle cells) [1]. Developing an in vitro system that accurately represents the 
epithelium in vivo has been a constant challenge in translational respiratory research.  
 
Air-liquid interface (ALI) cultures of bronchial epithelial cells [51-54] effectively mimic the 
in vivo environment of the bronchial epithelium (See Figure 1-2). In the ALI model, bronchia l 
epithelial cells are cultured on a porous membrane, suspended over growth media, and allowed 
to grow into a 3-dimensional morphology (See Figure 1-1). With addition of supplemented 
media, the cells differentiate to a functional mucociliary cell layer. This in vitro model offers 
a more physiological relevant platform for respiratory studies and allows the administration of 
an aerosol exposure method that mimics the inhalation of pollutants from the urban 
environment in vivo. Previous studies have compared ALI models to conventional exposure 
model and demonstrated a significant difference in cellular responses between the two in vitro 
models [55]. Aufderheide (2000) demonstrated that epithelial cells produced a significant 
decrease in metabolic activity when exposed to diesel PM, and this response was stronger in 
the ALI model [56]. Holder (2008) also demonstrated a significant difference in epithelial cell 
sensitivity between ALI and conventional exposure methods when exposed to diesel PM [55]. 
These studies demonstrate that a physiologically relevant exposure method is essential for in 
vitro aerosol exposure studies. Recent studies have used ALI to investigate the effects of 
environmental exposures, including cigarette smoke and vehicle emissions, on primary HBECs 
[57, 58]. This biologically relevant model provides insight about changes in gene and protein 
expression at the bronchial epithelium interface, which may prove to be useful as biomarkers 
of airway wall damage from air pollutants. The model could be adapted to monitor effects of 
multiple air pollutants on the airways in real-time, allowing accurate investigation of HBEC 
responses to air pollution and the link to chronic lung disease.  
 
In conjunction with the development of the ALI model, there has been development of aerosol 
delivery systems designed to facilitate the delivery of aerosols directly to the cell layer at ALI. 
These delivery systems include the electronic aerosol in vitro exposure system (EAVES), 
Vitrocell ® Exposure systems and the Cultex RFS. These aerosol delivery systems were 
originally developed to improve the physiological relevance of cigarette smoke toxicity 
research. However, these instruments have been further developed to test other hazardous 
aerosols. For instance, the the CULTEX Radial Flow System® (RFS) is a common aerosol 
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delivery system used in particulate matter exposure studies {Aufderheide, 2011 #47}{Tsukue, 
2010 #48}. The CULTEX RFS is innovative technology that allows the basic in vivo cell 
conditions to be satisfied. The basal module is insulated with a heated water chamber, which 
maintains the basal chamber at 37°C via an external water bath. The apical module is designed 
to flow air directly over cells using an external vacuum pump. In recent years, several studies 
have used the CULTEX RFS® as an aerosol delivery system to cells at ALI and have 
demonstrated that exposure to pollutants leads to an increase in oxidative stress, a reduction in 
cell viability and changes in cytokine secretion [51-53].  
 
 
Figure 1-1: comparison of submerged (a) and ALI culture models (b). 
As observed in vitro, epithelial cells in submerged culture (a) are adhered to the bottom of a 
culture vessel (24-well plate) while interacting with the media on the apical surface of the 
cells. Whereas, in ALI culture (b), the cells are adhered to a Transwell insert sitting inside 
the well allowing interaction with cell culture media on the basal cell surface and air on the 
apical cell surface. 
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Figure 1-2: Morphology of primary organotypic culture of human bronchial epithelial 
cells shown after Hematoxylin/Eosin staining (A), Alcian Blue-Periodic Acid Schiff 
staining (B), and p63 immunostaining (C).  
As observed in vivo, this in vitro culture model forms a multilayered pseudo-stratified 
epithelium composed of ciliated cells (A, arrows indicating cilia), goblet cells located on the 
apical side (B, asterisks), nonciliated cells (C, arrows indicating nonciliated epithelial cells), , 
and basal cells (C, arrow heads indicating p63-positive basal cells). Scale bar equals 30μm. 
[59]. 
 
1.6 Current interventions to reduce diesel particulate matter pollution 
There are several interventions commonly used to reduce the level of diesel particulate matter 
pollution. These interventions include after-treatment devices (ATD) such as a diesel 
particulate filter (DPF) paired with a diesel oxidation catalyst (DOC), the substitution of diesel 
fuel with a biodiesel [60], or the addition of a fuel addictive such as triacetin. 
Research has demonstrated the DPFs when paired with a DOC can effectively reduce 
particulate mass, CO, HC, NOx and CO2 in diesel emissions [49]. However, even though the 
particulate mass is reduced, the particulate number increases [49], suggesting that the use of 
ATDs may result in higher levels of ultrafine particles than untreated diesel emissions. These 
ultrafine particles are considered to be highly respirable and biologically reactive particles [18].  
ATDs are often used in conjunction with biodiesels and fuel additives- emerging interventions 
to address global increases in fuel consumption, global warming and the adverse effects of 
fossil fuels [61, 62]. Biodiesels are produced from vegetable oils or animal fats which have 
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been transesterified. These biodiesels are added to diesel fuel in order to reduce greenhouse 
gas emissions and preserve fossil fuel resources [63, 64].  Biodiesel supplementation has also 
been shown to reduce diesel particulate matter pollution [63, 65] [61]. Fuel additives includ ing 
triacetin are often added to biodiesels to increase oxygen content of the fuel, improving engine 
efficiency and further reducing emissions [61, 66, 67]. Research has consistently demonstrated 
that these interventions alter the physical and chemical composition of diesel emissions [61], 
but unfortunately, very little is known about biological effects associated with these alternat ive 
emissions. Furthermore, these interventions do not address current air pollution levels, and the 
potential benefits of these interventions will take years to appear. Therefore, there is an urgent 
need for a therapeutic interventions to protect vulnerable airways from exposure to air pollution.  
 
1.7 Interventions to prevent COPD  
Smoking cessation has proven to be the most effective intervention for disease prevention and 
for reducing the progression of COPD [8]. Current therapeutic interventions for COPD include 
long-acting bronchodilators, corticosteroids, antibiotics and pulmonary rehabilitation [8]. 
These interventions are very effective disease management therapies. However, with the 
prevalence of COPD continuing to rise [8], there is a growing demand for additiona l 
interventions to improve disease management and further reduce disease progression and 
mortality. Additional therapeutic interventions that target the adherent cellular processes 
involved in the progression of COPD, such as oxidative stress and inflammation, may prove to 
be an effective method of reducing disease progression and mortality [57].  
 
Oxidative stress is a key driver of tissue injury associated with both diesel emissions exposure 
and chronic lung diseases such as COPD [6, 68]. NAC is an antioxidant drug used as a 
mucolytic for COPD patients [69]. NAC has been shown to reduce ROS and oxidative stress-
induced DNA deletion in mammalian cells [70], as well as inhibiting a NF-kB activated 
pathway and subsequent phospholipid metabolism, pro-inflammatory cytokine release and 
protease activity [71]. Through the regulation of oxidative stress, NAC has the potential to 
protect the airways against diesel emissions exposure and prevent adverse cellular responses 
from the airway epithelium associated with COPD development and progression. 
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1.8 Rationale 
Diesel emission exposure is a risk factor for COPD, especially for never smokers. Novel studies 
comparing the effect of diesel emissions with varied chemical and physical compositions on 
primary HBEC lines at ALI will improve the current understanding of how exposure to diesel 
emissions may lead to COPD. Also, preventing injury from diesel emission exposure can 
reduce the susceptibility, progression and severity of COPD. Oxidative stress is a key driver of 
tissue injury associated with both diesel emissions exposure and COPD. An effective 
intervention to prevent oxidative stress would reduce adverse effects of diesel emissions on the 
airways, to prevent COPD and protect patients from complications of COPD. Current 
therapeutic interventions for COPD include bronchodilators, antibiotics and corticosteroids [8]. 
These interventions work to reduce airflow obstruction, suppress inflammation and prevent 
exacerbation. There are currently no therapeutic interventions to protect vulnerable lungs from 
the adverse effects of diesel emission exposure. Environmental exposures have been shown to 
have a strong impact on the gene expression profiles of lung tissue. For instance, the lungs of 
smokers have a similar gene expression profile to patients with moderate COPD [72]. Studying 
the transcriptomic profile of the COPD lung may identify potential targets for protective 
interventions to prevent the pathogenesis of COPD. This research project will test a potential 
intervention to decrease oxidative stress within the bronchial epithelial cell after exposure to 
diesel emissions and investigate the transcriptomic profile of the COPD lung in order to 
identify novel targets for interventions. 
 
1.9 Hypothesis 
From the three main objectives stated above, it is predicted that: 
1. Exposure to diesel emissions will result in decreased cell viability, increased 
inflammation and oxidative stress in primary HBECs, and the magnitude of these 
responses will be dependent on the physical and chemical composition of the emissions,  
2. NAC intervention will attenuate the loss of cell viability, decrease inflammation and 
prevent oxidative stress after exposure to diesel emissions 
3. The transcriptomic profile of the COPD lung will present potential targets for 
intervention to protect against diesel emission exposure. 
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1.10 Aims  
This PhD program has three main objectives: Firstly, to investigate the effects of diesel 
emissions with varied physical and chemical compositions on primary HBECs.. Secondly, to 
test the efficacy of NAC as a protective intervention against the adverse effects of diesel 
emission exposure with varied physical and chemical compositions. Thirdly, to identify novel 
targets in COPD transcriptomes for interventions aimed at protecting against air pollut ion 
exposure. These objectives will be addressed through 6 key aims: 
Aim 1: to investigate the role of diesel organic content on mediating cellular responses of 
primary HBECs cultured at ALI.  
Aim 2: to compare the effects of biodiesel and triacetin/biodiesel emission exposure on 
primary HBECs compared to neat diesel emission exposure at ALI.  
Aim 3: to test whether coconut oil substitution in diesel fuel reduces the adverse effect of diesel 
emission exposure on immortalised bronchial epithelial cells, 16HBE.  
Aim 4: to test the effectiveness of an antioxidant, N-acetylcysteine (NAC), post-exposure 
treatment in reducing the adverse effects of diesel emission exposure on immortal ised 
bronchial epithelial cells, 16HBE, at ALI.  
Aim 5: to test the effectiveness of a therapeutic antioxidant, N-acetylcysteine (NAC), as a 
protective intervention against the adverse effect of diesel emission exposure on 
primary HBECs from a COPD cohort.  
Aim 6: to investigate potential novel targets for intervention by transcriptomic profiling of the 
COPD lung.  
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Chapter 2:  Methods  
 
2.1 Establishing primary HBEC lines 
Primary HBECs were isolated and cultured from surgical resection tissue donated by lung 
cancer patients at The Prince Charles Hospital, with written informed consent. This study was 
approved by the Human Research Ethics Committees of The Prince Charles Hospital and The 
University of Queensland. Briefly, a bronchial ring was isolated from the lung resection 
specimen and incubated in a dissociation mix containing Pronase (Roche, Penzberg, Germany), 
Minimal Essentials Media-alpha (MEMα, Invitrogen, USA), amphotericin B (Invitrogen), 
penicillin, streptomycin and L-glutamine (PSG, Invitrogen) for 24 hours at 4°C, based on a 
published method [73]. The epithelial cell layer was harvested from the bronchial ring, and 
centrifuged for 5 min at 500xg. The cell pellet was resuspended in 4 mL of Keratinocyte Serum-
Free Media (KSFM, Invitrogen), expanded in submerged culture until confluent and stored in 
liquid nitrogen until needed.  
 
2.2 Air-liquid interface culture 
Primary HBECs were grown and differentiated using a Bronchial-Air Liquid Interface (B-ALI) 
BulletKit (Lonza, Basel, Switzerland), according to the manufacturer’s instructions. Briefly, 
the HBECs were seeded onto a porous collagen-coated membrane on a 6.5mm Corning 
Transwell® (Corning®, Corning, USA) insert at a density of 50,000 cells per insert. The cells 
were grown until confluent in B-ALI growth media on the apical and basal surfaces. The apical 
media was then removed to achieve air lift, and the basal media was replaced with 
supplemented B-ALI differentiation media. The cells were maintained at ALI for at least 28 
days before exposure to engine emissions. The basal media was changed 3 times per week, and 
the apical surface of the cell layer was washed at least once a week with 150μL of phosphate 
buffered saline (PBS) solution.  
 
2.3 HBEC characterization 
Mucus secretion 
Alcian blue staining was used to qualitatively assess the presence of mucus-secreting HBECs. 
Prior to staining, the apical surface of the cell layer was washed with 150μL of PBS. 100μL of 
Alcian blue dye was pipetted onto the cell layer and incubated for 30 seconds at room 
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temperature. The dye was removed and the apical surface was photographed at 10x 
magnification.  
 
Immunofluorescence staining for β-tubulin 
The presence of ciliated HBECs was confirmed using immunofluorescence staining targeting 
β-tubulin. The Transwell® membrane was fixed with cold methanol and incubated with an 
anti-β-tubulin antibody conjugated to fluorescein isothiocyanate (FITC) and 4',6-diamidino-2-
phenylindole (DAPI). The membrane was incubated with each stain separately for 5 minutes 
at 37°C and washed in between stains with 150μL of PBS. The Transwell® membrane was 
then cut away from the insert and mounted onto a glass slide. The apical surface of the cell 
layer was observed under fluorescent microscopy (Axio Imager Z1, Zeiss, Jena, Germany) and 
photographed using AxioVision LE microscopy software (Zeiss). 
 
2.4 Engine emission generation and characterization 
Refer to experimental chapters for fuel specifications, experimental set-up, engine emissions 
generation and characterisation (chapters 3-8). The term ‘engine emissions’ is used as a generic 
descriptive of emission exposure. The specific emissions (diesel, biodiesel etc.) are indicated 
in the experimental chapters.  
 
2.5 Cell exposure 
Primary HBECs were cultured at ALI and exposed to engine emissions through the CULTEX® 
Radial Flow System (CULTEX® Laboratories GmbH, Hannover, Germany), which contains 
three cell exposure chambers allowing simultaneous exposure in triplicate. The apical module 
directs air flow at 0.025 L/min directly over the cell layer using an external vacuum pump. The 
Transwell® insert containing the cell layer sits on the basal module, which is filled with 25mL 
of PBS solution heated to 37°C by an external water bath. The Cultex RFS allows for the direct 
exposure of aerosols to the cell layer, however the deposition of particles onto the cell layer 
was not measured throughout these studies. This requires specialised equipment and the 
application of predictive formulas for this equipment. Although our collaborators have the 
expertise to generate and use the formulas, we did not have access to the equipment. 
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2.6 Cell responses 
After completion of exposure, 250L of cell culture media was added to the apical surface of 
the cell layer and incubated at 37C in 5% CO2. For incubation times, see the methods section 
of each experimental chapter. This media was then collected and stored at -80ºC as supernatant 
to test for cell death (LDH assay) and ELISA analysis of cytokine secretion. The intact cell 
layer was used to measure of cellular metabolism (WST-1 cell proliferation assay). After 
testing cellular metabolism, the cell layer was lysed and stored at -80ºC for RNA extraction 
and qRT-PCR.  
 
2.7 Cellular metabolism 
After removal of the supernatant, a water-soluble tetrazolium-1 (WST-1) cell proliferat ion 
assay (Roche Applied Sciences, Penzberg, Germany) was used to measure cellular metabolism. 
WST-1 is a salt solution that is metabolised by mitochondrial dehydrogenase to produce 
formazan, causing a measurable colour change. Reagent stock was diluted 1:10 with cell 
culture media, added to the surface of the cell layer in the Transwell®, and incubated at 37°C 
in 5% CO2. After 30-minutes incubation, WST-1 sample solution was transferred to 96-well 
plate alongside incubated control wells containing 10μL of WST-1 plus 90μL of cell culture 
media. Absorbance was measured and quantified using a microplate reader (FLUOstar Omega) 
with software (Omega v1.2), at wavelength 450nm against background control (blank) and 
corrected for interference at 620nm. Cell viability was expressed as percentage relative to the 
filtered air control samples, which were deemed to be 100% viable. This assay was performed 
prior to cell lysis and gene expression analysis. It is possible (although unlikely) that the WST-
1 assay could influence gene expression. There is no published evidence to suggest WST-1 can 
meaningfully alter gene expression. However, because each experimental group underwent the 
same assay conditions prior to gene expression analysis, it is expected that any observed change 
in gene expression is a result of the experimental conditions i.e. the effect of the aerosol 
exposure.  
 
2.8 Live cell percentage 
Live cell percentage was measured using cytotoxicity detection kit (Roche, Penzberg) 
measuring lactate dehydrogenase (LDH) released from damaged cells into the apical 
supernatant. The cytotoxicity detection assay was performed as per the manufacturer’s 
instructions with minor adjustments. Briefly, 50µL of the apical supernatant and 50µL of the 
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reaction mixture was added to a well of a 96-well plate. A cell lysis sample, representing 100% 
cell death, was also tested. The plate was protected from the light and incubated for 10 minutes 
at room temperature. Absorbance was measured and quantified using a microplate reader 
(FLUOstar Omega, BMG LABTECH, Ortenberg, Germany) with software (Omega v1.2), at 
wavelength 450 nm against background control (media only) and corrected for interference at 
570 nm. A linear regression analysis was performed between the filtered air control (100% live 
cells) and the cell lysis sample (100% dead cells). Using the linear regression equation and 
absorbance readings of experimental samples, percentage cell death was calculated in 
Microsoft Excel.  
 
2.9 Inflammation 
Enzyme-linked immunosorbent assays (ELISA) were used to measure the inflammato ry 
cytokine secretion of HBECs in response to engine emission exposure at ALI in the CULTEX 
RFS (Hannover, Germany). The supernatants were collected from the apical wells of the 
Transwell insert 24-well plate and stored at -80C until analysis of cytokine secretion. The 
concentrations (pg/mL) of cytokines in the supernatant were measured using either R&D 
Systems Quantikine or Thermo Fisher Scientific Novex ELISAs, according to manufacturer’s 
instructions (refer to chapter methods for specifics). Colour intensity was measured and 
quantified using a plate reader (FLUOstar Omega, BMG LABTECH, Ortenberg, Germany) 
with software for quantification (Omega v1.2). The standard curves were generated using a 4-
parameter logarithmic curve fit in Prism6.0c. For accurate comparison between experimenta l 
groups, the cytokine concentrations were corrected for percentage cell death to show data 
representative of a 100% viable cell layer. The specific inflammatory cytokines measured using 
ELISA are outlined in the experimental chapters.  
 
2.10 Gene expression 
RNA extraction  
Total RNA was extracted from cells using the Qiagen AllPrep kit (Qiagen, Limburg, 
Netherlands). The cell layer was homogenised by adding 200μL of RLT buffer to the apical 
surface of the cell layer, placed on a shaker and incubated at room temperature for 20 minutes. 
The homogenised lysate samples were collected into Eppendorf tubes and an additional 150μL 
of RLT buffer was added to make up the 350μL needed for RNA extraction. The samples were 
stored at -80°C until RNA extraction. During the RNA extraction protocol, the RNA samples 
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were cleaned of genomic DNA using an RNase-free DNase kit (Qiagen) as per the 
manufacturer’s instructions. RNA was quantified using a NanoDrop Spectrophotometer 
(Thermo Scientific, DE, USA). Quality assessment was performed by measurement of 
A260/A280 (>1.75 indicating good quality) and A260/A230 ratios (>1.75 indicating good 
quality), representing RNA/protein and RNA/contaminant absorbance, respectively.  
 
Quantitative real-time PCR (qRT-PCR)  
qRT-PCR was used to assess the changes in HMOX-1, CYP1A1, IL-8 and TNF-α gene 
expression after engine emission exposure. cDNA was prepared by reverse transcrib ing 
extracted RNA samples using Superscript III First Strand Synthesis kits (Qiagen) as per the 
manufacturer’s instructions. TaqMan Gene expression assays were performed, and compared 
to the expression of a housekeeper gene, GAPDH. The specific gene targets are specified in 
the experimental chapters (chapter 3-8). RT-PCR was performed using the ViiA 7 Real-time 
PCR system (Applied Biosciences) or the CFX384 (BioRad) with the following PCR cycling 
conditions: 50°C for 2 minutes, 95°C for 10 minutes, followed by 40 cycles of 95°C for 15 
seconds and 60°C for 1 minute. The change in gene expression was expressed as fold change 
relative to the filtered air controls using the comparative quantification algorithm, -ΔΔCt. 
 
Nanostring nCounter Vantage 3D Intracellular Signalling and GX Immunology panels  
Gene expression profiling of intracellular signalling and immune signalling pathways of 
HBECs from lung cancer patients with or without COPD in response to diesel emission 
exposure with or without NAC intervention was assessed using Nanostring nCounter Vantage 
3D Intracellular Signalling and GX Immunology panels, as per the manufacturer’s 
instructions (chapter 7). Briefly, total RNA samples were hybridised to the reporter and capture 
probes over a 16-hour incubation at 65C. The samples were loaded onto the Nanostring Sprint 
cartridge and the panels were run on the Nanostring nCounter SPRINT Profiler. The 
Nanostring nCounter Vantage 3D Intracellular Signalling panel has 594 gene targets and 
15 housekeeper genes and the Nanostring nCounter GX Immunology panel has 180 gene 
targets and 12 housekeeper genes.  
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2.11 Statistical analysis 
A one-way ANOVA (two tailed) with Tukey’s multiple comparisons post-test between all 
experimental groups was used to assess the effects of the experimental challenge on the 
measured cellular responses (inflammatory cytokine secretion, cell viability or gene 
expression). In the graphs, an asterisk (*) directly above the bar indicates a statistica lly 
significant difference when compared to the filtered air control. A connecting line between two 
bars and an asterisk above indicates a significant difference between the indicated experimenta l 
groups. Statistical analysis was performed using Prism v6.0c. P values <0.05 (two-tailed) were 
considered statistically significant. 
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Chapter 3:  Removal of organic content from diesel exhaust 
particles alters cellular responses of primary human bronchial 
epithelial cells cultured at an air-liquid interface 
 
3.1 Rationale 
Epidemiological studies have linked air pollution exposure to increased respiratory and 
cardiovascular morbidity and mortality [17, 18, 74]. The World Health Organization has 
reported that 7 million deaths world-wide in 2012 were attributed to air pollution exposure, 
with 31% of these deaths from respiratory disease [75]. The three main air pollutants are 
particulate matter, ozone and nitrogen dioxide [18]. Research has shown a strong association 
between particulate matter exposure and adverse respiratory health effects [50, 76, 77]. Diesel 
emissions are one of the major contributors to particulate matter [18]. Diesel PM consists of 
partially combusted carbon particles, which have organic content absorbed to the particle 
surface [18]. Diesel PM can vary in composition and size depending on the emissions source 
[18]. Inhaled diesel particles of smaller size display higher deposition in the lower airways, 
higher percentage of organic content and increased surface area to mass ratio, making smaller 
particles more biologically active and toxic within the lungs [78].  
 
The first line of defence against inhaled diesel PM is the bronchial epithelium, a cellula r 
structural barrier lining the airways [1]. The main mechanisms of defence mediated by the 
bronchial epithelium are mucociliary clearance, initiation of inflammatory response and 
degradation of inhaled agents [1]. When diesel PM are inhaled into the airways, the ultrafine 
diesel PM can penetrate the mucus layer, then internalise and aggregate in the epithelium [29, 
30]. In vitro studies have shown this diesel PM aggregation triggers cellular responses 
including the secretion of pro-inflammatory cytokines TNF-α, IL-8 and IL-6 [28-32, 34], as 
well as triggering xenobiotic metabolism [79, 80], oxidative stress [81] and ultimately loss of 
cell viability [82, 83]. Xenobiotic metabolism is the degradation of foreign agents within an 
epithelial cell by a xenobiotic metabolising enzymes, such as cytochrome P450 1A1 (CYP1A1) 
[84]. CYP1A1 expression is triggered by the activation of the aryl hydrocarbon receptor (AhR) 
by diesel particulate organic content [79, 84]. These defence mechanisms of bronchia l 
epithelial cells are critical for normal functioning of the lungs; however, very little is known 
about how exposure to diesel PM alters these defensive cellular responses. 
 
 
 39 
 
A major challenge in aerosol toxicity research is finding an accurate in vitro representation of 
diesel exposure to the airways in vivo. Previous studies have used a conventional, submerged 
cell exposure model, in which diesel PM are dissolved in cell culture media and administe red 
to a monolayer of immortalised epithelial cells [55]. However, this model lacks the 
physiological relevance needed for diesel toxicity studies, as the diesel composition is 
potentially altered by the suspension in media [83] and the interaction between the diesel and 
the cell layer is not occurring directly at an air-liquid interface (ALI). Additionally, the use of 
immortalised bronchial epithelial cells is a limitation, as these cells may not accurately 
represent the mucociliary phenotype of the in vivo cell population [1]. The use of primary 
human bronchial epithelial cells (HBECs) cultured at ALI, and differentiated into a mucocilia ry 
epithelial cell layer, effectively mimics the in vivo environment of the bronchial epithelium [52, 
85, 86]. This more physiologically relevant platform models the inhalation of pollutants in vivo, 
and enables the composition of diesel emissions to be modified experimentally, in order to 
accurately assess the effects of different diesel PM components on bronchial epithelial cell 
responses.  
 
The aim of this study was to investigate the effect of removing organic content from diesel 
emissions, on the cellular responses of primary HBECs cultured at ALI. It was hypothesised 
that exposure to residual diesel emissions (without organic content) would result in attenuated 
HBECs responses, when compared to neat (unmodified) diesel emission exposure. 
 
 
3.2 Methods 
Cell culture and HBEC characterization 
Primary HBECs were isolated and cultured from surgical resection tissue (left lower lobe) 
donated, with written informed consent, by a 57-year-old male patient with lung 
adenocarcinoma who was a current smoker with a 70 pack-year history of smoking and forced 
expiratory volume (FEV1) of 83% predicted (see Chapter 2: Methods, section 2.1). These 
primary HBECs were cultured at ALI (see Chapter 2: Methods, section 2.2). The mucocilia ry 
phenotype was confirmed through cytological and immunofluorescence staining for mucus 
secretion and the presence of cilia (see Chapter 2: Methods, section 2.3).  
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Diesel emissions generation and characterization 
Diesel emissions were generated on a Euro III common rail Cummins diesel engine, coupled 
to a dynamometer. Fuel used in this study was commercial diesel purchased from Caltex. 
Running mode was at 25% load at 1500 rpm. The experimental set-up is shown in Figure 3-1.   
 
The raw exhaust was subjected to one stage dilution through partial flow dilution. A centrifuga l 
pump drew HEPA-filtered ambient air into the dilution tunnel. Gas analysers, which consisted 
of a NDIR (Non-destructive infra-red) CAI 600 series CO2 and CO analyser and a CAI 600 
series CLD (Chemiluminescence detector) NOx analyser, measured CO, CO2 and NOx 
concentrations before the dilution system. To determine the dilution ratio, a SABLE CA-10 
CO2 analyser was used to measure CO2 concentrations after the dilution. A Scanning Mobility 
Particle Sizer (SMPS) TSI 3080 electrostatic classifier, with a 3025 Condensation Particle 
counter measured the size distribution and number concentration of diesel PM. The semi-
volatile organic content was removed by passing the polydisperse aerosol stream through a TSI 
3065 thermodenuder. To take into account particle losses inside the thermodenuder [87], all 
the tests were done with the thermodenuder in the system. Neat (nDE) diesel emissions were 
sampled through the thermodenuder at room temperature, while residual diesel emissions (rDE) 
were generated by sampling through the thermodenuder set to 300oC [67]. Dustrak (model TSI 
8520) was used for PM2.5 measurements (particulate matter measuring ≤2.5μm in diameter). 
Dustrak mass concentration data were converted to gravimetric mass concentrations as 
measured by the tapered element oscillating microbalance based on the equation provided in 
[80]. 
 
Central flow of 1 L/min was used to avoid agglomeration and loss of small particles. The tubing 
was kept as short as possible to further minimize diffusion losses. The deposition efficiency of 
the CULTEX is influenced by three processes: sedimentation, diffusion and electrical forces. 
Deposition of nanoparticles (diameter < 0.1µm), is mainly controlled by electrical forces. The 
deposition efficiency calculated was 0.81. Detailed discussion on the theoretical and practical 
aspect of the efficiency of the CULTEX® RFS is provided in [52]. 
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Figure 3-1: Set-up for diesel emissions generation and analysis 
Exhaust gas is first sampled from the exhaust line, and exhaust gas is then mixed with HEPA 
(High-Efficiency Particulate Air Filter) air. After the dilution stage, it passes through a 
thermodenuder where the volatile organic fraction of DIESEL PM is stripped off. A Scanning 
Mobility Particle Sizer (SMPS) gives the size distribution of the exhaust gas. Dustrak measures 
particulate mass. The CULTEX system is used for cell exposure. CO2 analysers are used before 
and after dilution system to calculate the dilution ratio.  
 
Cell exposure and measurement of HBEC responses 
Primary HBECs were exposure to neat diesel emissions (nDE) and residual diesel emissions 
(rDE) for 30 and 60 minutes (see Chapter 2: Methods, section 2.5). The negative controls were 
unexposed, incubated cells (B: baseline) and filtered laboratory air (FA). The positive control 
was a 3 hour exposure to 300µg/mL of cigarette smoke condensate (CSC). nDE are unaltered 
diesel emissions and rDE have had the organic content removed from the diesel particula te 
matter. After exposure, B-ALI differentiation media was added to the apical surface of the cell 
layer and incubated for 24 hours (see Chapter 2: Methods, section 2.6). The media was collated 
and stored at -80ºC as supernatant for ELISA analysis. Cell viability (cellular metabolism) was 
measured using the WST-1 assay, which was prepared using B-ALI differentiation media and 
incubated for 3 hours (see Chapter 2: Methods, section 2.7). The cell layer was lysed, collected 
and stored at -80ºC for RNA extraction and gene analysis. At a later date, the concentration of 
TNFα, IL-6 and IL-8 was measured using R&D systems Quantikine ELISAs (see Chapter 2: 
Methods, section 2.9). RNA was extracted from the cell lysate and TaqMan gene expression 
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analysis measured the expression of HMOX-1, CYP1A1, TNFα and IL-8 mRNA on the Thermo 
Fisher Scientific Viia7 Real-Time PCR system (see Chapter 2: Methods, section 2.10).  
 
3.3 Results 
HBEC differentiation 
ALI cultures of primary human bronchial epithelial cells were used to generate a mucocilia ry 
epithelial cell layer that is representative of the in vivo situation. Figure 3-2 shows 
immunofluorescence stains of the cell layer after 0 and 28 days at ALI at 20x magnification. 
DAPI is a nucleic acid stain used to show the overall cell population by highlighting the nuclei. 
The cilia were stained using a β-tubulin antibody conjugated to the green fluorescent compound 
FITC. Comparison between day 0 and day 28 confirmed the presence of cilia after 
differentiation at ALI, shown by the positive β-tubulin stain at day 28 and not day 0. Figure 
3-3 shows Alcian blue stains of the apical surface of the cell layer at 10x magnification. Alcian 
blue targets mucopolysaccharides and the increase in blue colour intensity between day 0 and 
day 28 at ALI confirmed the mucosecretory phenotype of the cell layer.  
 
 
Figure 3-2: Immunofluorescence staining of primary HBECs for cilia using an anti-β-
tubulin antibody conjugated with FITC, co-stained with DAPI on HBECs at day 0 (a-c) 
and day 28 (d-f). From top to bottom: DAPI, β-tubulin and merged, respectively. 
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Figure 3-3: Alcian blue stain for mucus secretion from primary HBECs at day 0 and day 
28. a-b) Apical surface of the cell layer prior to staining; c-d) Apical surface of the HBEC 
layer after Alcian blue stain. 
 
Diesel exhaust generation and characterization of particles 
Size distribution and particle number concentrations (#/cm3) of emitted particles can be seen 
in Figure 3-4. Emitted mass of particles corrected for the losses inside the thermodenuder as 
well as concentration of NO, NO2, CO and CO2 in the raw gas are presented in the Table 3-1. 
The concentrations of particle number, mass and gases remained consistent between the 30 and 
60 minute exposures for both nDE and rDE. There was a notable loss in the concentration of 
particles when comparing between the nDE and rDE exposures, which is due to thermophoret ic 
losses. Mass concentration dropped as well, but the decrease in the mass was not as large, since 
the carriers of the mass are mainly larger particles whose number was reduced by only 10-20%. 
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Figure 3-4: Size distribution of neat diesel emissions (nDE) and residual diesel emissions 
(rDE). 
Particle number distributions were measured with a scanning mobility particle sizer (SMPS) 
consisting of a TSI 3071A classifier (EC) and a TSI 3010 condensation particle counter (CPC). 
Particles within a 10-400nm size range were measured. For the neat diesel tests, 15 SMPS 
scans were taken, and at least 15 scans were taken for tests involving residual diesel exhaust. 
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Table 3-1: Average particle concentration, mass concentration and gas concentration 
(NO, NO2, CO and CO2) during 30 and 60 minute exposures of primary HBECs to nDE 
and rDE at ALI. 
 
 
Particle 
concentration 
Mass 
concentration 
NO (ppm) NO2 (ppm) CO (ppm) CO2 (%) 
 (number/cm3) (μg/m3)         
 30 minutes 
FA - - - - - - 
nDE 1.1x106 232 247 16.8 279 7.3 
rDE 7.6x105 210 205 14.2 322 6.8 
  60 minutes 
FA  - - - - - 
nDE 1.05x106 222 238 12.4 273 7.3 
rDE 7.8x105 192 224 15.0 266 6.9 
 
 
Cell viability 
The percentage of viable cells was assessed using a WST-1 cell proliferation assay for primary 
HBECs exposed to nDE and rDE for 30 and 60 minutes. A 30 minute exposure to nDE caused 
a significant reduction in HBEC viability when compared to the filtered air negative control 
(P=0.01), whereas exposure to rDE resulted in no change in viability (Figure 3-5). A 60 minute 
exposure to nDE resulted in a similar magnitude of reduction in cell viability as the 30 minute 
exposure; however this did not reach statistical significance (P=0.08). Exposure to the rDE for 
60 minutes resulted in a statistically significant reduction in HBEC viability when compared 
to filtered air (P=0.0001) and 30 minutes rDE exposure (P<0.0001). As a positive control, high 
dose CSC exposure showed the largest decrease in cell viability when compared to baseline 
and filtered air controls (P=0.0001). 
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Figure 3-5: WST-1 assay measuring the cell viability of primary HBECs after exposure 
to filtered air (FA), neat diesel emissions (nDE) and residual diesel emissions (rDE) for 
30 and 60 minutes, and 300µg/mL cigarette smoke condensate (CSC) for 3 hours. 
* indicates a statistically significant difference (P<0.05). Error bars indicate SEM (n=3): One 
cell line (1 subject), 3 replicates. Values are relative to 100% baseline (B). B: baseline - 
unexposed, incubated primary HBECs. 
 
Cytokine secretion 
Figure 3-6 shows the cytokine secretion levels for TNF-α (a), IL-8 (b), and IL-6 (c) quantified 
using ELISA analysis of supernatant collected 24 hours after exposure and corrected for the 
percentage of viable cells. 30 minute exposure to nDE or rDE did not significantly alter IL-8, 
TNF-α and IL-6 secretion when compared to the filtered air control. Similarly, there was no 
significant change in IL-8, TNF-α and IL-6 secretion after a 60 minute exposure to nDE, 
compared to the filtered air control (P>0.05). In contrast, there were statistically significant 
increases in IL-8, TNF-α and IL-6 secretion after 60-minute exposure to rDE when compared 
to filtered air (P=0.007, P=0.01 and P<0.0001, respectively). In the 60 minute exposures, TNF-
α and IL-6 concentrations were also significantly higher after exposure to rDE, compared to 
nDE (P=0.008 and P=0.0002, respectively). High dose CSC exposure resulted in statistica lly 
significant increases in IL-8 and TNF-α secretion, when compared to filtered air (P<0.0001). 
For accurate comparison between experimental groups, the cytokine concentrations were 
corrected for cell viability to show data representative of a 100% viable cell layer.  
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Figure 3-6: Cytokine secretion of (a) TNF-α, (b) IL-8, and (c) IL-6 from primary HBECs 
after exposure to filtered air (FA), neat diesel emissions (nDE), residual diesel emissions 
(rDE) for 30 and 60 minutes and cigarette smoke condensate (CSC) for 3 hours. 
* indicates a statistically significant difference (P<0.05). Error bars indicate SEM (n=3): One 
cell line (1 subject), 3 replicates. Concentrations are corrected for cell viability. B: baseline - 
unexposed, incubated primary HBECs. 
 
 
 48 
Gene expression 
Gene expression analysis was performed using quantitative real-time PCR targeting CYP1A1, 
HMOX-1, TNF-α and IL-8 mRNA (Figure 3-7). The data were normalised to the housekeeper 
gene glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and expression levels were 
calculated relative to the baseline control group.  Figure 3-7a shows the relative gene 
expression levels of CYP1A1, which is a xenobiotic metabolizing enzyme responsible for 
metabolizing polycyclic aromatic hydrocarbons (PAHs). Whilst exposure to rDE for 30 or 60 
minutes tended to increase CYP1A1 gene expression, there were no significant changes in gene 
expression after 30 or 60 minute exposure to nDE or rDE (P>0.05). For the positive control, 
high dose CSC exposure resulted in a marked increase in CYP1A1 expression (P<0.0001).  
 
For gene expression of HMOX-1 (Figure 3-7b), an antioxidant protein expressed in response 
to oxidative stress, 30 minute exposure to nDE or rDE did not significantly change HMOX-1 
expression (P>0.99 and P=0.99, respectively). In the 60 minute exposures, There was a trend 
for HMOX-1 expression to increase with nDE and to a lesser extent rDE; however these did 
not reach statistical significance when compared to filtered air (P=0.3 and P=0.95, respectively). 
Furthermore, high dose CSC did not alter HMOX-1 expression in these experiments (P>0.99).  
 
The gene expression of inflammatory cytokines TNF-α (Figure 3-7c) and IL-8 (Figure 3-7d) 
were measured in conjunction with levels of protein secretion. 30 minute exposure to nDE did 
not change significantly in TNF-α and IL-8 mRNA expression, compared to the filtered air 
control (P=0.87 and P=0.91, respectively). Exposure to rDE for 30 minutes did not alter TNF-
α or IL-8 expression (P>0.99 and P=0.99, respectively). 60 minute exposure to nDE and rDE 
did not change in the relative expression of TNF-α and IL-8 (P>0.05). High dose CSC caused 
minor changes in TNF-α and IL-8 mRNA expression, but both were not statistically significant 
when compared to the filtered air controls (P=0.54 and P=0.94, respectively).  
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Figure 3-7: Gene expression levels of CYP1A1 (a), HMOX-1 (b), TNFα (c) and IL-8 (α) 
from primary HBECs after exposure to filtered air (FA), neat diesel emissions (nDE), 
residual diesel emissions (rDE) for 30 and 60 minutes, and cigarette smoke condensate 
(CSC) for 3 hours. 
Gene expression is relative to the baseline control group (B) and relative expression is 
normalized to GAPDH. * indicates a statistically significant difference (P<0.05). Error bars 
indicate SEM (n=3): One cell line (1 subject), 3 replicates. B: baseline - unexposed, incubated 
primary HBECs. 
 
 
3.4 Discussion 
Main findings 
Diesel emissions are a major source of air pollution within the urban environment and long-
term exposure has been linked to an increase in respiratory disease morbidity and mortality [17, 
18, 74]. Diesel emissions are made up of gas and particulate matter, the latter of which is 
considered a highly toxic component [18]. The diesel particulate composition can vary greatly 
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depending on the emissions source [50, 76, 77], therefore it is important to understand the 
potential those different components have in triggering biological responses. The primary 
objective of this study was to investigate the effect removing the diesel organic compounds 
from diesel PM has on primary HBECs using direct air-to-cell exposure at ALI. This study has 
demonstrated that the removal of organic content from diesel emissions can alter cellula r 
responses with three main findings. Firstly, nDE and rDE triggered differential effects on the 
HBEC responses (cell viability, inflammation, xenobiotic metabolism and oxidative stress) 
when comparing between 30 and 60 minute exposures; cell viability changes were comparable 
to cytokine secretion, but not the levels of HMOX-1 expression (oxidative stress marker); and 
finally, in contrast to previous literature [79, 88], there was an increase in CYP1A1 expression 
in the absence of organic content. These findings have built upon the current understanding of 
how bronchial epithelial cells respond to diesel emissions in vitro and offer new insight into 
how diesel emissions may trigger adverse health effects in relation to epithelial cell response.  
 
The effect of removing organic content on diesel emissions toxicity as measured by cell 
viability 
Previous studies have shown that exposure to diesel emissions can be highly toxic to airway 
epithelial cells in vitro [83] and that the organic content present on the diesel particulate matter 
plays a key role in this toxicity [82]. In accordance with previous studies we showed reduced 
cell viability after exposure to nDE [83]. The removal of organic content appeared to attenuate 
the effect on cell viability for the 30 minute exposure. In contrast, the removal of organic 
content resulted in a stronger reduction in cell viability after the 60 minute exposure, compared 
to the 30 minute exposure and the nDE exposure. This somewhat unexpected result challenges 
the notion that organic content is the major contributor to the toxicity of diesel emissions. 
Previous research has shown that cell viability can be attenuated with the removal of organic 
content [30, 79, 82, 88], however many of these studies used the submerged culture method for 
diesel emission exposure in which the diesel components are suspended in media, with the 
possibility that suspension of diesel allows for alterations in chemical composition [55].  
Because we used direct aerosol exposure to measure the effects of organic content on diesel 
toxicity, we have minimised interference by apical cell culture media. These methods provide 
evidence for the contribution of other diesel components (residual after the removal of organic 
content) to the toxic effects of diesel emissions exposure on human bronchial epithelial cells.  
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The effect of removing diesel organic content on oxidative stress and inflammation 
Diesel emissions toxicity is associated with oxidative stress, a common adverse effect of 
environmental toxins on cells [89]. Oxidative stress can be caused by inflammatory activity 
[90], xenobiotic metabolism [84] and/or endogenous reactive oxygen species (ROS) from 
diesel PM [91], and this oxidative stress often leads to a reduction in cell viability [92-94]. 
HMOX-1 is a cytoprotective antioxidant protein and increases in expression in response to 
oxidative stress [95, 96]. After the 30 minute exposure to nDE and rDE, there were limited 
HBEC responses of cytokine (protein or mRNA) secretion, and no major changes in HMOX-1 
mRNA expression. After the longer 60 minute exposures, cytokine protein secretion increased 
significantly with rDE, whereas cytokine mRNA expression and HMOX-1 mRNA expression 
did not change with either rDE or nDE. These results highlight the importance of diesel 
emissions composition and the differential effects of organic content on HBEC responses after 
30 and 60 minutes exposure. 
 
The effect of removing diesel organic content on xenobiotic metabolism 
Previous research has shown that the presence of organic content on diesel emission particles 
trigger the expression of xenobiotic metabolizing enzyme, CYP1A1 [79, 88]. The classica l 
method of CYP1A1 expression activation, in reference to diesel emission exposure, requires 
the activation of the AhR receptor by diesel organic content [84]. We showed that nDE 
exposure had limited effect on CYP1A1 expression. This could be due to inadequate exposure 
duration, as in previous studies CYP1A1 expression increased after 60 minutes of diesel 
emission exposure [81]. However, there was some increase in CYP1A1 expression after 
exposure to rDE (without organics) when compared to both the filtered air controls and the 
nDE, although this did not reach statistical significance. In accordance with this, a study by 
Totlandsdal and colleagues (2012) used the conventional particle/media suspension method of 
exposure to show that residual diesel particles (without organics) can trigger an upregulat ion 
of CYP1A1 expression from the immortalized bronchial epithelial cell line BEAS-2B [82]. This 
suggests that during diesel emissions exposure, the upregulation of CYP1A1 expression is not 
dependent only on the organic content and may be triggered by other diesel PM components. 
Although direct conclusions regarding the mechanistic background of toxic behaviour of 
residual diesel particles cannot be drawn from these measurements, the results imply that it is 
likely that some new pathways may be responsible for the observed effects.  
 
 
 
 
 52 
The advantages of direct air-to-cell diesel emissions exposure 
To our knowledge, this study is the first to test the effects of different diesel emissions 
components on differentiated HBECs using a direct air-to-cell exposure method. Much of the 
previous research in this area has used an experimental model where diesel PM are suspended 
in media and administered to a submerged immortalized epithelial cell monolayer [80, 88]. 
This experimental model lacks true physiological relevance [55] as the physical and chemica l 
composition of the diesel PM change in suspension [55, 81] and the bronchial epithelial cell 
monolayer is not representative of the airway epithelium in vivo. In contrast, we observed 
successful differentiation of primary HBECs into a mucociliary epithelial cell layer.  This 
culture technique then provided the platform for direct diesel emission exposure through the 
CULTEX® RFS and supported closer modelling of the adverse effects of diesel emissions on 
airway epithelial cells. Through use of physiologically relevant exposure model, our 
experiments provide new insight into the mechanisms by which air pollution can affect HBECs.  
Organic content on PM has been proved to hold a toxic potential as a result of its chemica l 
compositions and related reactivity [97, 98]. However, at the same time, organic coating is 
disabling the reactivity of carbon surface that is yet to be explored in this context [18, 99]. By 
removing it, this large carbon surface area and many active sites on the surface become 
available and may trigger some other reactions within cells that may become more prominent 
after longer exposure [18, 99]. This concept has yet to be fully explored by research(ers) in the 
field. Another scenario is somewhat controversial yet probable and necessary for future 
consideration. As argued by Rothenbacher and colleagues, thermodenuded particles may have 
the altered stability of soot agglomerates that can  lead to  further decomposition by the 
breakage of solid bridges of other substructures formed during the dilution process and related 
Brownian coagulation [99]. The probability of fragmentation of agglomerated diesel particles 
under various conditions depends on many factors and should be further explored for its 
potential role in electrochemical processes in cell fluid suspensions [99]. Furthermore, in either 
of these cases the dose or a threshold value may be a key determinant in switching on a certain 
response [99]. That may be relevant for different responses of residual diesel after 30 minutes 
and 60 minute exposures. In addition, kinetics of reactions involving organic compounds and 
activated soot surface area, as well as smaller units of diesel agglomerates, may be completely 
different having various implications in cells being ultimately coupled to the exposure time.  
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Limitations 
The study of aerosol toxicity in the airways has always been challenging due to the complex 
composition of different pollutants and an inaccurate representation of the airway epithelium. 
Although this study has used direct aerosol exposure to a differentiated epithelial cell layer to 
attempt to overcome these major limitations, some limitations remain. Firstly, the primary 
HBECs used were established from airway tissue collected from a single patient with lung 
cancer who smoked.  Results obtained in this experimental system may not be generalisable to 
other individuals.  While these considerations do not interfere with the internal validity of the 
findings, additional experiments on other primary cell lines should be performed in the future.  
Secondly, the sample size was n=3. Although this is a common sample size for comparable 
studies [1, 2], the sample size limits the robustness of the data. Future studies should consider 
testing a larger sample size. Thirdly, the time-points for gene expression analysis were fixed - 
HBECs were lysed and RNA extracted after the 24 hour incubation and supernatant collection. 
Each gene of interest may have different expression patterns in response to diesel emissions 
exposure. For CYP1A1 mRNA expression analysis, the time-point of gene expression analysis 
was validated by the CSC exposure (positive control), which showed a significant increase in 
mRNA expression. This result showed that regulated changes in CYP1A1 mRNA expression 
are sustained 24 hours after diesel emission exposure. However, this significant difference was 
not demonstrated for HMOX-1, TNFα and IL-6 mRNA expression. Lastly, it has been shown 
that apoptotic processes can suppress inflammation [100], therefore we considered it important 
to correct cytokine secretion for loss of cell viability in order to provide a more biologica lly 
relevant snapshot of responses under various diesel exposure conditions per viable cell. 
 
3.5 Conclusions 
The results of this study indicate that both the organic content and residual components of 
diesel emissions play an important role in mediating bronchial epithelial cell response in vitro. 
Cell viability and pro-inflammatory cytokine secretion (IL-8 and TNF-α) showed comparable 
changes, indicating that inflammatory responses may be a key mechanism of response to diesel 
emissions, more so than oxidative stress. While rDE (without organic content) can trigger 
CYP1A1 expression, this is may also be regulated by the residual components of diesel PM. 
Together these findings provide new insight into bronchial epithelial cell responses to diesel 
emissions. Future studies could be directed at defining the active signalling pathways and 
testing interventions against the adverse health effects of air pollution.   
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Chapter 4:  Primary human bronchial epithelial cell 
responses to diesel and biodiesel emissions at an air-liquid 
interface 
4.1 Rationale 
Diesel emissions have a high level of particulate matter which is associated with adverse 
respiratory effects including inflammation and oxidative stress in the airways. [18, 68, 101]. A 
common strategy to reduce diesel particulate matter is the addition of a biodiesel to diesel fuel. 
Coconut oil is a common biodiesel [63]. Coconut-biodiesel, a common biodiesel in Asia, is 
cost effective, has close properties to diesel and is globally available [63, 64]. Combustion of 
coconut oil biodiesel has been shown to decrease CO, hydrocarbon content, polycyclic 
aromatic hydrocarbon (PAH) and decrease total PM from diesel emissions [63, 65]. Another 
strategy to reduce diesel particulate matter is to use a fuel additive to improve the combustion 
and energy efficiency of biodiesel [102]. Triacetin in a common fuel additive. It is made from 
the acetylation of glycerol, which is a by-product of biodiesel transesterification [66]. 
Therefore, this addictive is a cost-effective feedstock to add to biodiesel fuels. Triacetin 
increases the oxygen content of fuel [61], which improves the combustion efficiency and 
reduces emissions [102].  
 
Biodiesel and fuel additives are emerging interventions to address increasing fuel consumption, 
global warming and the adverse effect of fossil fuels [62].  Research has shown that coconut 
oil biodiesel can reduce mutagenicity of diesel emissions [65]. However, very little is known 
about the potential health effect of coconut oil biodiesel and triacetin as a fuel addictive to 
biodiesel. The aim of this study was to compare the effect of biodiesel and triacetin/biodiese l 
on pHBECs compared to neat diesel at an air liquid interface. 
 
4.2 Methods 
Cell culture 
Primary HBECs were isolated and cultured from surgical resection tissue donated, with written 
informed consent, from two patients with lung adenocarcinoma (see Chapter 2: Methods, 
section 2.1). These cells were cultured at ALI for at least 28 days prior to exposure (see Chapter 
2: Methods, section 2.2).  
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Engine specifications 
The engine used to generate emissions was a 6 cylinder, common-rail, turbo-charged diesel 
engine coupled to an electronically-controlled hydraulic dynamometer, which controlled 
engine load. Technical specifications of the engine are depicted in Table 4-1.  
 
Table 4-1: Diesel engine specifications 
Model      Cummins ISBe220 
Cylinders  6 in-line 
Capacity (L)  5.9 
Bore × stroke (mm)  102 × 120 
Maximum power (kW/rpm)  162/2500 
Maximum torque (N m/rpm)  820/1500 
Compression ratio    17.3 
Aspiration  Turbocharged and after cooled 
Fuel injection  Common rail 
Emissions certification  Euro III 
ATD DOC and DPF 
Emissions certification after ATD Euro VI 
 
Operating parameters were a quarter load where maximum torque was 820 Nm and speed of 
1500 rpm (rated power 162 KW at 2500 rpm). For each test, the engine was started and warmed 
up for at least 30 minutes. Prior to running the engine with a new fuel, remaining fuel was 
drained out and the lines were flushed to remove any residual fuel left in the combustion 
chamber or lines. 
 
Fuel blends 
Commercial diesel fuel purchased from Caltex (Australia) was compared to commercial diesel 
blended with biodiesel (transesterified coconut oil) or biodiesel blended with triacetin. 
Triacetin is a potential addictive to biodiesel which enhances biodiesel yields after 
interesterification [66]. The fuel compositions are outlined in Table 4-2. 
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Table 4-2: Fuel specifications 
 
Name Diesel (%) Biodiesel 
(%)* 
Triacetin 
(%) 
D100 100   
B20 80 20  
B50 50 50  
B90  90 10 
B96  96 4 
B100  100  
*transesterified coconut oil 
 
Diesel and biodiesel sampling procedure  
The engine exhaust was diluted in a partial flow dilution tunnel by HEPA-filtered laboratory 
air. Dilution ratio was calculated using measured concentrations of CO2 before and after the 
dilution tunnel using the following equation: 
 
𝐷𝑖𝑙𝑢𝑡𝑖𝑜𝑛 𝑅𝑎𝑡𝑖𝑜 (𝐷𝑅) =
𝐶𝑂2 (𝑅𝑎𝑤) − 𝐶𝑂2(𝐵𝑎𝑐𝑘𝑔𝑟𝑜𝑢𝑛𝑑, 𝐶𝐴𝐼)
𝐶𝑂2 (𝐷𝑖𝑙𝑢𝑡𝑒𝑑) − 𝐶𝑂2(𝐵𝑎𝑐𝑘𝑔𝑟𝑜𝑢𝑛𝑑, 𝑆𝐴𝐵𝐿𝐸)
 
 
A CAI (California Analytical Instruments) gas analyser was connected before the dilut ion 
tunnel to measure the gases in raw exhaust. We used a NDIR (non-dispersive infra-red) CAI 
600 CO2 and CO analyser and a CAI 600 CLD (chemiluminescence detector) NOx detector to 
measure concentrations of CO2, CO and NOx. A second CO2 meter (SABLE, CA-10) was used 
to record the CO2 concentration from the diluted exhaust. Background corrected CO2 was used 
as a tracer gas to calculate the dilution ratio. TSI Dustrak (model 8530) measured the mass of 
particles with a PM2.5 impactor installed. Measured PM2.5 masses were converted into 
gravimetric mass using the correction factor explained in [103]. A scanning mobility particle 
sizer (SMPS) was used to characterize size distribution and concentration of particles. A 
schematic of the sampling equipment set-up is provided in Figure 4-1. 
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Figure 4-1: Schematic of the experimental set-up 
 
HBEC exposure and cell response testing 
Primary HBECs were exposure to diesel (D100), biodiesel (B20, B50 and B100) and 
triacetin/biodiesel (B90 and B96) for 30 minutes through the Cultex RFS (see Chapter 2: 
Methods, section 2.5). After exposure, MEMα was added to the apical surface of the cell layer 
and incubated for 6 hours (see Chapter 2: Methods, section 2.6). The media was collated and 
stored at -80ºC as supernatant for LDH assay and ELISA analysis. Cell viability (cellula r 
metabolism) was measured using the WST-1 assay, which was prepared using MEMα and 
incubated for 30 minutes (see Chapter 2: Methods, section 2.7). The cell layer was lysed, 
collected and stored at -80ºC for RNA extraction and gene expression analysis. At a later date, 
the concentration of IL-6 and IL-8 was measured using Thermo Fisher Scientific Novex 
ELISAs (see Chapter 2: Methods, section 2.9). RNA was extracted from the cell lysate and 
TaqMan gene expression analysis measured the expression of HMOX-1, CYP1A1, CASP3 and 
BCL2 mRNA on the BioRad CFX 384 Tough Real-Time PCR Detection System (see Chapter 
2: Methods, section 2.10). CASP3 was selected as an end-point biomarker for apoptotic cell 
death, and BCL2 was selected as a common biomarker for anti-apoptotic signalling. 
 
4.3 Results 
Characterisation of fuel and emissions 
The gas concentrations, average particle mass and average particle number for conventiona l 
diesel emissions, biodiesel emissions and triacetin/biodiesel emissions is stated in Table 4-3. 
The change in diesel emissions composition with different percentages of biodiesel and 
triacetin content is shown in Figure 4-2. In Figure 4-2a, there was a decrease in particle mass 
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and particle number with an increase in percentage biodiesel in diesel fuel. In Figure 4-2b, 
there as a decrease in particle mass and an increase in particle number with an increase in 
triacetin. Figure 4-2c shows an increase in CO2 and NOx with an increase in biodiesel in diesel 
fuel. Figure 4-2d shows a decrease in CO2 and NOx concentrations with an increased 
percentage of triacetin in biodiesel fuel. The particle size distribution graphs show nucleat ion 
mode particles generated by D100, B50 and B90 fuels. 
 
 
Table 4-3: Average gas concentrations (CO2 and NOx), diesel particle mass (DPM) and 
particle number (PN) during diesel engine combustion of diesel, biodiesel and 
triacetin/biodiesel fuel blends. 
 
 
 
 
 
 
 
 
 
 
 
 
Fuel CO2 (%) NOx (ppm) DPM (µg/m3) PN (#/cc) 
D100 0.74 29.36 0.80 5.50E+05 
B20 1.09 45.79 0.42 2.27E+05 
B50 1.30 52.71 0.19 2.24E+05 
B90 1.02 54.16 0.06 2.25E+05 
B96 1.21 65.43 0.11 1.39E+05 
B100 1.11 63.95 0.10 1.59E+05 
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Figure 4-2: The changes in diesel particle mass (DPM), particle number (PN) and gas 
concentrations (CO2 and NOx) with increased percentage of biodiesel and triacetin in 
the different biodiesel blends. 
a) the average particle mass (left axis) and particle number (right axis) with increasing 
biodiesel content (%) in diesel fuel. b) the average particle mass (left axis) and particle number 
(right axis) with increasing triacetin content (%) in biodiesel fuel. c) the concentration of CO2 
(left axis) and NOx (right axis) with increased biodiesel content in diesel fuel. d) the 
concentration of CO2 (left axis) and NOx (right axis) with increased triacetin content in 
biodiesel fuel. 
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Figure 4-3: Particle size distribution of diesel and biodiesel emissions. 
a) comparison of diesel (D100) and biodiesel blends with diesel (B20, B50 and B100). b) 
comparison of diesel (D100) to biodiesel/triacetin blends and pure biodiesel (B90, B96 and 
B100). 
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metabolism, cell death, CASP3 mRNA expression and BCL2 mRNA expression (Figure 4-4: 
diesel vs biodiesel and Figure 4-5: diesel vs triacetin/biodiesel). D100 exposure resulted in a 
significant decrease in cellular metabolism (P=0.012) and suppression of CASP3 and BCL2 
mRNA expression (P<0.0001 and P<0.0001), when compared to the filtered air control.  Of 
the biodiesel fuel blends, exposure to B50 significantly increased in cell death, when compared 
to the filtered air control and D100 exposure (P=0.017 and P=0.024, respectively). B20 and 
B50 exposures significantly attenuated the suppression of CASP3 mRNA expression 
(P<0.0001 and P<0.0001, respectively) and significantly increased the suppression of BCL2 
mRNA expression caused by D100 exposure (P<0.0001 and P<0.0001, respectively).  
 
 
Figure 4-4: Measurement of cell viability markers after exposure to diesel and biodiesel 
emissions: (a) cellular metabolism, (b) cell death, (c) CASP3 mRNA expression and (d) 
BCL2 mRNA expression. 
Measurements were taken after 30-minute exposure to diesel and biodiesel emissions. * 
indicates a statistically significant difference (P<0.05), when compared to the filtered air (FA) 
control. * over an indented bar indicates a significant difference between the two groups 
(P<0.05). P values are given in the text. Error bars indicate SEM (n=6): Two cell lines from 
two subject, 3 replicates. Cell proliferation values are relative to the filtered air control, which 
was deemed 100% viable. D100: conventional diesel. B20: 20% biodiesel and 80% diesel. B50: 
50% biodiesel and 50% diesel. B100: 100% biodiesel. Biodiesel is waste cooking oil. 
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Of the triacetin/biodiesel fuel blends, B90 exposure significantly increased cellular metabolism 
and increased cell death, when compared to the filtered air control (P=0.015 and P=0.007, 
respectively) and D100 exposure (P=0.001 and P=0.004, respectively). There was no change 
in CASP3 mRNA expression. However, there was a significant suppression of BCL2 mRNA 
expression, when compared to the filtered air control and D100 exposure (P<0.0001 and 
P<0.0001, respectively). B96 exposure significantly suppressed CASP3 and BCL2 mRNA 
expression when compared to the filtered air control (P<0.0001 and P<0.0001, respectively). 
Exposure to B100 significantly increased cell death when compared to the filtered air control 
and 100 exposure (P=0.034 and P=0.024, respectively). There was also a significant increase 
in CASP3 and BCL2 mRNA expression, when compared to the filtered air control and D100 
exposure (P<0.0001 and P<0.0001, respectively).  
 
 
Figure 4-5: Measurement of cell viability markers after exposure to diesel and 
triacetin/biodiesel emissions: (a) cellular metabolism, (b) cell death, (c) CASP3 mRNA 
expression and (d) BCL2 mRNA expression. 
Measurements were taken after 30-minute exposure to diesel and biodiesel emissions. * 
indicates a statistically significant difference (P<0.05), when compared to the filtered air (FA) 
control. * over an indented bar indicates a significant difference between the two groups 
(P<0.05). P values are given in the text. Error bars indicate SEM (n=6): Two cell lines from 
two subjects, 3 replicates. Cell proliferation values are relative to the filtered air control, which 
was deemed 100% viable. D100: conventional diesel. B90: 90% biodiesel and 10% triacetin. 
B96: 96% biodiesel and 4% triacetin. B100: 100% biodiesel. Biodiesel is waste cooking oil. 
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Antioxidant production 
The effect of diesel, biodiesel and triacetin/biodiesel emission exposure on oxidative stress was 
assessed by the measurement of gene expression of antioxidant, HMOX-1 (Figure 4-6). D100 
exposure significantly suppressed HMOX-1 mRNA expression (P<0.0001). B20, B50 and B90 
exposures significantly upregulated HMOX-1 mRNA expression, when compared to both the 
filtered air control and D100 exposure (P<0.0001 for all comparisons mentioned). B96 
significantly suppressed HMOX-1 expression, when compared to the filtered air control 
(P<0.0001). B100 exposure resulted in a minor but statistically significantly suppression of 
HMOX-1, when compared to the filtered air control (P=0.011).  
 
 
 
Figure 4-6: Gene expression of antioxidant, HMOX-1, after exposure to diesel, biodiesel 
(a) and triacetin/biodiesel (b) emissions. 
Measurements were taken after 30-minute exposure to diesel and biodiesel emissions. * 
indicates a statistically significant difference (P<0.05), when compared to the filtered air (FA) 
control. * over an indented bar indicates a significant difference between the two groups 
(P<0.05). P values are given in the text. Error bars indicate SEM (n=6): Two cell lines from 
two subjects, 3 replicates. Cell proliferation values are relative to the filtered air control, which 
was deemed 100% viable. D100: conventional diesel. B20: 20% biodiesel and 80% diesel. B50: 
50% biodiesel and 50% diesel. B90: 90% biodiesel and 10% triacetin. B96: 96% biodiesel and 
4% triacetin. B100: 100% biodiesel. Biodiesel is waste cooking oil. 
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Inflammation 
The level of inflammation from pHBECs after exposure to diesel, biodiesel and 
triacetin/biodiesel emissions was assessed through the measurement of IL-8 and IL-6 secretion 
(Figure 4-7). Exposure to D100 produced no change in IL-8 and IL-6 secretion. B90 exposure 
significantly increased IL-8 and IL-6 secretion, when compared to D100 exposure (P=0.008 
and P=0.012, respectively). B100 exposure significantly increased IL-8 secretion, when 
compared to D100 exposure (P=0.0007). 
 
 
Figure 4-7: Measurement of inflammation: IL-8 and IL-6 secretion after exposure to 
diesel and biodiesel blends. 
Measurements were taken after 30-minute exposure to diesel, biodiesel and triacetin/biodiesel 
emissions. * indicates a statistically significant difference (P<0.05), when compared to the 
filtered air (FA) control. * over an indented bar indicates a significant difference between the 
two groups (P<0.05). P values are given in the text. Error bars indicate SEM (n=6): Two cell 
lines from two subjects, 3 replicates. IL-8 and IL-6 secretion values are fold change from the 
filtered air control. D100: conventional diesel. B20: 20% biodiesel and 80% diesel. B50: 50% 
biodiesel and 50% diesel. B90: 90% biodiesel and 10% triacetin. B96: 96% biodiesel and 4% 
triacetin. B100: 100% biodiesel. Biodiesel is waste cooking oil. 
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expression (Figure 4-8). D100 and B96 exposure significantly suppressed CYP1A1 mRNA 
expression, when compared to the filtered air control (P<0.0001 and P<0.0001, respectively). 
B20, B50 and B100 effectively attenuated the suppression of CYP1A1 mRNA expression 
caused by D100 exposure (P<0.0001, P<0.0001 and P<0.0001, respectively). B90 exposure 
significantly increased CYP1A1 mRNA expression when compared to the filtered air control 
(P=0.0007). 
 
 
Figure 4-8: Gene expression of xenobiotic metabolism biomarker, CYP1A1, after 
exposures to diesel, biodiesel and triacetin/biodiesel emissions. 
Measurements were taken after 30-minute exposure to diesel and biodiesel emissions. * 
indicates a statistically significant difference (P<0.05), when compared to the filtered air (FA) 
control. * over an indented bar indicates a significant difference between the two groups 
(P<0.05). P values are given in the text. Error bars indicate SEM (n=6): Two cell lines from 
two subjects, 3 replicates.  Cell proliferation values are relative to the filtered air control, 
which was deemed 100% viable. D100: conventional diesel. B20: 20% biodiesel and 80% 
diesel. B50: 50% biodiesel and 50% diesel. B90: 90% biodiesel and 10% triacetin. B96: 96% 
biodiesel and 4% triacetin. B100: 100% biodiesel. Biodiesel is waste cooking oil. 
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4.4 Discussion 
Main results 
The results of this study indicate that biodiesel and triacetin/biodiesel fuel blends are more 
detrimental to pHBECs than neat diesel emissions. This was demonstrated through four main 
findings. Firstly, D100, B50 and B90 fuel blends produced emissions containing nucleat ion 
mode particles from a diesel engine with a DOC and DPF after treatment device. Secondly, 
biodiesel blended with diesel can reduce cell viability, and increased oxidative stress, in 
comparison to diesel emissions. Thirdly, biodiesel blended with triacetin can decrease cell 
viability, increase oxidative stress increase inflammation and increase xenobiotic metabolism 
compared to diesel emissions. Lastly, biodiesel alone can reduce cell viability, increase IL-8 
secretion and increase xenobiotic metabolism, compared to diesel emissions. These findings 
suggest that biodiesel and triacetin increases the adverse effects of diesel emission on pHBECs 
at ALI.  
 
The effect of biodiesel and triacetin on diesel particulate matter  
Diesel particulate matter is associated with adverse respiratory effects such as inflammation 
and oxidative stress in the airways. Hence, effective strategies to reduce the particulate matter 
content of diesel emissions is needed to prevent adverse health effects of associated with 
exposure to diesel emissions. Research has shown that coconut oil biodiesel has a decreased 
level of solid particulate matter when compared to diesel emissions [65]. However, the total 
particulate matter is comparable, and the soluble particulate organic content is higher than 
diesel emissions [65]. The present study has shown that both particle mass and particle number 
decrease with increased percentages of biodiesel in diesel fuel. The addition of triacetin in 
biodiesel has been shown to decrease both particle mass and particle number of biodiesel 
emissions [61]. However, this study showed that particle mass decreases and particle number 
increases as the percentage of triacetin increases. This suggests that as the particle number 
increases, the particle size decreases, allowing for the decrease in particle mass. Particle size is 
a critical parameter which governs diesel PM deposits in the human respiratory tract [18]. 
Ultrafine particles have a greater deposition rate in the lower airways, have a greater reactivity 
in the airways [104] and are associated with inflammation and oxidative stress in the airways 
[18, 79]. The size distribution graphs (Figure 4-3) of diesel, biodiesel and triacetin/biodiese l 
emissions indicate the presence of ultrafine particles and nucleation mode particles.  
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Nucleation mode particles are liquid nanoparticles smaller than 50nm in size and largely 
consist of semi-volatile organics as well as water and sulphur compounds. These particles are 
believed to be formed during the dilution of the gas in the emissions.  [18, 105]. The organic 
content in diesel emissions are considered the more toxic component of diesel emissions do 
their biological reactivity [18]. The organic fraction of diesel particulate matter contributes to 
diesel particulate matter toxicity through the induction of oxidative stress [106, 107]. More 
especially, diesel organic content can induce inflammation and mitochondrial dysfunction, 
which leads to oxidative stress [98, 108, 109]. Biodiesel emissions have an increased 
proportion of organics in the particulate matter of conventional diesel emissions [110]. Hence, 
the creation of nucleation mode particles and a reduced particle size suggests that the addition 
of biodiesel to diesel and triacetin to biodiesel alters the diesel particulate matter composit ion 
in a manner that increases the reactivity of the particles and increases the risk of adverse effects 
such as inflammation, oxidative stress and a loss of cell viability. This is supported by the 
heightened cellular responses to B90 and B50 emissions which resulted in cell death, 
inflammation and increased antioxidant production, in comparison to D100.  Interestingly, 
D100 had an overall higher particle number and particle mass, and the particle size distribution 
showed a higher proportion of nucleation mode particles when compared to the alternat ive 
emissions. Therefore, the adverse effects associated with the alternative diesel emissions may 
not be related to particulate matter compositions.  
 
Another explanation for these adverse responses may be related to the gas-phase of the 
emissions. Only recently has the gas-phase been considered an important source of ROS and 
oxidative potential [111]. Furthermore, it is thought that the nucleation process may assist 
gaseous compounds to condense onto pre-existing particles to create new reactive surfaces, or 
to form entirely new reactive particles [105, 112]. In a recent study, Ebersviller (2012) 
discusses the concept of “newly toxic” PM formed through the process of “effect modification”, 
where the toxic potential of gaseous compounds shifts to PM which is otherwise non-toxic in 
primary form [113]. In a physiological context, this allows reactive gas phase compounds to 
reach remote regions of the lungs which they otherwise would not. It may be that the unique 
composition of these alternative emissions promotes this effect modification, increasing the 
toxicity of PM, resulting in heightened adverse effects in comparison to conventional diesel 
emissions. 
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The effect of coconut oil biodiesel emissions on pHBECs at ALI  
Coconut oil biodiesel is cost effective and globally available. Emission composition and 
characterisation studies have shown that coconut oil biodiesel emissions have lower levels of 
CO, total PM and hydrocarbon content, and higher levels of NOx and CO2, compared to 
conventional diesel emissions. Unfortunately, very few studies have been performed which 
investigate the potential health effects of these biodiesel emissions. Bürger (2016) has shown 
that coconut oil biodiesel is less mutagenic that other vegetable oil derived biodiesels. However, 
this level of mutagenicity was comparable to conventional diesel emissions [65]. To our 
knowledge, this is the first study to look at the effects of coconut oil biodiesel emissio ns on 
cytotoxicity, inflammation and gene expression from HBECs, when compared to conventiona l 
diesel emissions. This study has shown that 50% and 100% biodiesel blends resulted in a 
significant reduction in cell viability and increased in oxidative stress of pHBECs, when 
compared to conventional diesel. The finding of the study indicates that despite the reduced 
emissions from coconut oil biodiesel, these emissions can have a severe adverse effect of 
pHBECs.  
 
The effect of triacetin addition to biodiesel emission on pHBECs at ALI 
Biodiesels have similar fuel properties to diesel. Yet some of the challenges when working 
with biodiesel are the higher viscosity and low volatility of this fuel compare to diesel. Triacetin 
is a full additive that increases the oxygen content of the fuel to improve combustion and engine 
efficiently. Previous research has shown that increased oxygen content of biodiesel from the 
addition of triacetin results in an increase in CO, HC, PN in the biodiesel emissions, and a 
decrease in CO2, NOx and PM [61]. When compared to conventional diesel emissions, 
triacetin/biodiesel decreases CO2, CO, HC, PM and PN, while NOx increased [61]. Also, by 
increasing the oxygen content, the accumulation mode shifted to show smaller particle sizes 
[61]. In accordance with previous research, this study has shown that triacetin decreases CO2 
and NOx in the biodiesel emissions. Whilst there was a decrease in particle mass, there was 
also an increase in particle number and the production if nucleation mode particles. These 
finding suggest that the oxygenation of biodiesel fuel with triacetin results in smaller particles 
with a higher proportion of organic content which may increase the reactivity of these 
emissions in the airways. This is supported by the increase in cell death, inflammation, 
antioxidant production and xenobiotic metabolism from pHBECs after exposure. Therefore, 
the addiction of triacetin to biodiesel fuel increased the adverse effects of diesel and biodiesel 
emission exposure to pHBEC at ALI. 
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Limitations 
This study has some limitations that need to be considered. Firstly, the effect of conventiona l 
diesel with the addition of triacetin was not assessed. Triacetin is used to improve the properties 
of biodiesel for better engine combustion and performance. Triacetin can be a made from a by-
product of biodiesel production, so the use in biodiesel to maximise yield and profitability is 
more favourable. A common challenge when using biodiesels is the high viscosity and low 
volatility of biodiesels compared to conventional diesel [60]. This study was designed to test 
the effects of triacetin as a method to reduce these challenges and associated biological effect. 
As these challenges are not present for conventional diesel, the comparison with triacetin/diese l 
was deemed unnecessary. Lastly, only two primary cell lines were used. The small sample size 
may have interpersonal variability, limiting the robustness of the results. However, the reported 
findings were inherently consistent and reproducible.  
 
4.5 Conclusions 
Although biodiesel fuels and fuel additives can reduce the pollutant loan in diesel emissions, 
very little is understood about the potential health impacts of this research. This study has 
shown that biodiesel and triacetin/biodiesel can increase the adverse effects of diesel emissions 
of pHBECs. This has provided insight into the effect of these diesel fuel alternative on pHBECs, 
and suggests that further studies of the risks and benefits of these novel fuels on human lung 
health be undertaken.  
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Chapter 5:  The effect of coconut oil-substituted diesel 
emissions on bronchial epithelial cells at an air-liquid interface. 
5.1 Rationale 
Current diesel emission standards, such as the Euro VI light and heavy vehicle emissions 
standards, recommend the use of alternative diesel blends such as vegetable oil-blended diesel 
as an initiative to reduce ambient air pollution. The combustion of vegetable oil-blended diesel 
produces lower PM mass, PM concentration, carbon monoxide (CO), hydrocarbon (HC) and 
polycyclic aromatic hydrocarbon (PAH) levels [63, 114] than diesel [110, 115-120]. 
Additionally, alternative diesel blends can reduce greenhouse gas emissions and allevia te 
dependency on fossil fuels [115]. However, currently very little is known about the health 
effects of alternative diesel emissions. 
 
Despite the reduction in PM and other pollutants, exposure to vegetable oil-blended diesel such 
as linseed oil and rapeseed oil is associated with inflammation, epithelial cell death and 
mutagenicity [65, 115]. These adverse effects may be due to organic content from fatty acids 
which, when combusted with diesel fuel, may be more biologically active within the airways 
[18], and therefore potentially more toxic.  However, since coconut oil has a low level of 
unsaturated fatty acids, and when combusted with diesel fuel, produces low PM emissions [65], 
coconut oil-blended diesel may be a safer alternative than other vegetable oil diesel blends. 
The aim of this study was to test whether coconut oil substitution in diesel fuel reduced adverse 
effects of diesel emission exposure on human bronchial epithelial cells. 
 
5.2 Methods 
Cell culture  
16HBE (p49) cells (SV-40 transformed human bronchial epithelial cell line), were seeded onto 
Corning Transwell inserts at 50,000 cells per insert and grown in MEMα supplemented with 
PSG and Fungizone. These cells were incubated at 37°C until confluence, then apical media 
was removed to achieve ALI. These cells were maintained at ALI for 7 days prior to exposure. 
See Chapter 2: Methods, section 2.2 for additional details for ALI culture. 
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The 16HBE cell line was used in this chapter due to practical constraints. These aerosol 
exposure studies are performed in collaboration with the International Laboratory for Air 
Quality and Health (ILAQH). ILAQH provide the diesel engine facilities and different fuels to 
test. For this experiment, we were given two weeks’ notice of facility availability, which was  
insufficient time to culture pHBECs at ALI to produce a differentiated cell layer 
(differentiation requires four weeks) . The best alternative was to culture the 16HBE cell line 
at ALI, which is known to be stable at ALI but will remain as a polarized monolayer [3, 4]. 
This cell line has been used in a comparable study [5]. 
 
Engine specifications 
The engine used to generate emissions was a 6 cylinder, common-rail, turbo-charged diesel 
engine (type commonly used in city buses and medium-sized trucks) coupled to an 
electronically-controlled hydraulic dynamometer, which controlled engine load. Technica l 
specifications of the engine are depicted in Table 5-1.  
 
Table 5-1: Diesel engine specifications 
Model      Cummins ISBe220 
Cylinders  6 in-line 
Capacity (L)  5.9 
Bore × stroke (mm)  102 × 120 
Maximum power (kW/rpm)  162/2500 
Maximum torque (N m/rpm)  820/1500 
Compression ratio    17.3 
Aspiration  Turbocharged and after cooled 
Fuel injection  Common rail 
Emissions certification  Euro III 
 
Operating parameters were a quarter load where maximum torque was 820 Nm and speed of 
1500 rpm (rated power 162 KW at 2500 rpm). For each test, the engine was started and warmed 
up for at least 30 minutes. Prior to running the engine with a new fuel, remaining fuel was 
drained out and the lines were flushed to remove any residual fuel left in the combustion 
chamber or lines. 
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Fuels specifications 
Commercial diesel fuel purchased from Caltex (Australia) was compared to commercial diesel 
blended with 10%, 15% and 20% raw coconut oil supplied by Kokonut Pacific Pty Ltd 
(Queanbeyan, Australia). Blend compositions are shown in Table 5-2.  Due to its high viscosity, 
coconut oil solidifies at 20°C, so all blends were made at room temperature (above 20C) to 
avoid solidification and formation of residues inside the combustion chamber. 
 
Table 5-2: Fuel blend compositions 
 Diesel fuel %  Coconut oil 
%  
D100 100 0  
D90C10 90 10  
D85C15 85 15  
D80C20 80 20  
 
 
Diesel/alternative diesel sampling procedure 
The engine exhaust was diluted in a partial flow dilution tunnel by HEPA-filtered laboratory 
air. Dilution ratio was calculated using measured concentrations of CO2 before and after the 
dilution tunnel using the following equation: 
 
𝐷𝑖𝑙𝑢𝑡𝑖𝑜𝑛 𝑅𝑎𝑡𝑖𝑜 (𝐷𝑅) =
𝐶𝑂2 (𝑅𝑎𝑤) − 𝐶𝑂2(𝐵𝑎𝑐𝑘𝑔𝑟𝑜𝑢𝑛𝑑, 𝐶𝐴𝐼)
𝐶𝑂2 (𝐷𝑖𝑙𝑢𝑡𝑒𝑑) − 𝐶𝑂2(𝐵𝑎𝑐𝑘𝑔𝑟𝑜𝑢𝑛𝑑, 𝑆𝐴𝐵𝐿𝐸)
 
 
A CAI (California Analytical Instruments) gas analyser was connected before the dilut ion 
tunnel to measure the gases in raw exhaust. We used a NDIR (non-dispersive infra-red) CAI 
600 CO2 and CO analyser and a CAI 600 CLD (chemiluminescence detector) NOx detector to 
measure concentrations of CO2, CO and NOx. A second CO2 meter (SABLE, CA-10) was used 
to record the CO2 concentration from the diluted exhaust. Background corrected CO2 was used 
as a tracer gas to calculate the dilution ratio. TSI Dustrak (model 8530) measured the mass of 
particles with a PM2.5 impactor installed. Measured PM2.5 masses were converted into 
gravimetric mass using the correction factor explained in [103]. A scanning mobility particle 
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sizer (SMPS) was used to characterize size distribution and concentration of particles. A 
schematic of the sampling equipment set-up is provided in Figure 5-1. 
 
 
Figure 5-1: Set-up for diesel emissions generation and analysis. 
A Scanning Mobility Particle Sizer (SMPS) gives the size distribution of the emissions. Dustrak 
measures particulate mass. The CULTEX system is used for cell exposure. CO2 analysers are 
used before and after dilution system to calculate the dilution ratio. 
 
HBEC exposure and cell response testing 
Immortalised human bronchial epithelial cells (16HBE) were exposures to diesel emission and 
coconut oil-substituted diesel emissions (10%, 15% and 20% substitution with raw coconut oil) 
for 30 minutes (see Chapter 2: Methods, section 2.5). After exposure, MEMα was added to the 
apical surface of the cell layer and incubated for 6 hours (see Chapter 2: Methods, section 2.6). 
The media was collated and stored at -80ºC as supernatant for LDH assay and ELISA analysis. 
Cell viability (cellular metabolism) was measured using the WST-1 assay, which was prepared 
using MEMα and incubated for 30 minutes (see Chapter 2: Methods, section 2.7). The cell 
layer was lysed, collected and stored at -80ºC for RNA extraction and gene expression analysis. 
At a later date, the concentration of IL-6 and IL-8 was measured using Thermo Fisher Scientific 
Novex ELISAs (see Chapter 2: Methods, section 2.9). RNA was extracted from the cell lysate 
and TaqMan gene expression analysis measured the expression of HMOX-1, CYP1A1, SOD1, 
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SOD2, CASP3 and BCL2 mRNA on the BioRad CFX 384 Touch Real-Time PCR Detection 
System (see Chapter 2: Methods, section 2.10).  
 
5.3 Results 
Diesel emissions characterisation 
The physical and chemical characteristics of the diesel emissions were assessed through the 
measurement of gas concentrations (NO2, NOx, CO2 and CO), HC, particle mass and mean PN. 
These characteristics are detailed in Table 5-3. The raw CO2 concentration of the diesel 
emissions was 5.89%. After the dilution tunnel, the CO2 concentration was 0.29%. Therefore, 
the raw diesel emissions were diluted by 19.75x with laboratory air prior to exposure in the 
Cultex RFS. Figure 5-2 illustrates the particle size distribution of the diesel and coconut-diese l 
blends. 
 
 
 
Figure 5-2: Size distribution of D100, D80C20, D85C15 and D90C10. 
Particle number distributions were measured with a scanning mobility particle sizer (SMPS) 
consisting of a TSI 3071A classifier (EC) and a TSI 3010 condensation particle counter (CPC). 
Particles within a 10-400nm size range were measured.  
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Table 5-3: Diesel and alternative diesel emission characterisation data. 
Gas concentrations (NO2, NOx, CO2, and CO), diesel particle mass (DPM), particle number 
(PN) and hydrocarbon (HC) content. 
 
Fuel NO2 (ppm) 
NOx 
(ppm) 
CO 
(ppm) 
HC 
(ppm) 
CO2  
(%) 
DPM 
(mg/m3) 
PN 
(#/cm3) 
D100 13.88 14.53 30.87 40.70 0.30 0.73 1.41x106 
D90C10 11.92 12.35 32.90 41.06 0.29 0.75 1.39x106 
D85C15 11.40 12.45 32.40 41.49 0.28 0.71 1.39x106 
D80C20 11.99 12.59 31.68 42.57 0.29 0.66 1.38x106 
 
 
Cell viability 
The viability of bronchial epithelial cells after exposure to diesel and coconut-diesel emissions 
(Figure 5-3) was assessed through the measurement of cellular metabolism (Figure 5-3a), live 
cell percentage (Figure 5-3b), and gene expression of apoptotic and anti-apoptotic biomarkers, 
CASP3 and BCL2 (Figure 5-3c and Figure 5-3d, respectively).  Compared to the filtered air 
controls, D100 and all coconut-diesel blends (D90C10, D85C15 and D80C20) resulted in 
significantly reduced cellular metabolism (P<0.0001 for all), but metabolism was less affected 
by D80C20 than by D100, D90C10 and D85C15 exposure (P<0.0001, all). D100 exposure had 
no significant effect on live cell percentage, compared to the filtered air control (P>0.05), but 
D80C20 reduced live cell percentage (P=0.0016). CASP3 and BCL2 mRNA expression were 
not significantly affected by D100 or coconut-diesel blends.  
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Figure 5-3: Measurement of cell viability markers: (a) cellular metabolism, (b) 
percentage live cells, (c) CASP3 mRNA expression and (d) BCL2 mRNA expression. 
Measurements were taken after 30-minute exposure to diesel or coconut oil-blended diesel 
emissions with a 3-hour post-exposure incubation. * indicates a statistically significant 
difference (P<0.05), when compared to the filtered air (FA) control. * above an indented line 
indicates a significant difference between the two experimental groups indicated. P values are 
given in the text. Error bars indicate SEM (n=6). The experiment was repeated twice with 
triplicate samples. Values are relative to the filtered air control, which was deemed 100% 
viable and the baseline sample. 
 
Inflammation 
The effect of diesel and coconut-diesel exposure on inflammation from bronchial epithelia l 
cells (Figure 5-4) was assessed by measurement of IL-8 and IL-6 secretion (Figure 5-4a and 
Figure 5-4b, respectively). D100 exposure increased IL-8 and IL-6 secretion over that observed 
with filtered air (P=0.024 and P<0.0001, respectively), but D90C10 and D85C15 both had a 
significantly less effect on IL-6 secretion than D100 (P<0.0001 and P=0.0004, respectively), 
and a similar (not statistically significant) trend was shown for IL-8.  However, higher coconut 
oil substitution (D80C20) increased pro-inflammatory cytokine secretion above that observed 
with filtered air (P<0.0001, for both IL-8 and IL-6 secretion).  
 
FA D100 D90C10 D85C15 D80C20
0
20
40
60
80
100
C
e
ll
u
la
r 
m
e
ta
b
o
li
s
m
 (
%
)
* * *
*
*
FA D100 D90C10 D85C15 D80C20
-2.0
-1.5
-1.0
-0.5
0.0
0.5
1.0
1.5
2.0
2.5
C
A
S
P
3
 e
x
p
re
s
s
io
n
 
(L
o
g
2
 o
f 
fo
ld
 c
h
a
n
g
e
)
FA D100 D90C10 D85C15 D80C20
0
20
40
60
80
100
120
140
L
iv
e
 c
e
ll
s
 (
%
)
*
*
*
FA D100 D90C10 D85C15 D80C20
-2.0
-1.5
-1.0
-0.5
0.0
0.5
1.0
1.5
2.0
2.5
B
C
L
2
 e
x
p
re
s
s
io
n
(L
o
g
2
 o
f 
fo
ld
 c
h
a
n
g
e
)
a. b.
c. d.
 
 
 77 
 
Figure 5-4: Measurement of inflammatory markers; IL-8 protein secretion (a), and IL-6 
protein secretion (b). 
Measurements were taken after 30-minute exposure to diesel or coconut oil-blended diesel 
emissions with 3-hour post-exposure incubation. * indicates a statistically significant 
difference (P<0.05), when compared to the filtered air (FA) control. * above an indented line 
indicates a significant difference between the two experimental groups indicated. P values are 
given in the text. Error bars indicate SEM (n=6). The experiment was repeated twice with 
triplicate samples. Values are relative to the filtered air control, which was deemed 100% 
viable and the baseline sample. 
 
Oxidative stress 
The effect of diesel and coconut-diesel exposure on bronchial epithelial cell antioxidant 
production after diesel emission exposure (Figure 5-5) was assessed by measurement of SOD1 
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(Figure 5-5a), SOD2 (Figure 5-5b) and HMOX-1 (Figure 5-5c) mRNA expression. D100 
exposure increased SOD1 mRNA expression (P=0.03) relative to filtered air, and coconut 
blends (D90C10 and D85C15) produced even higher SOD1 mRNA expression (P=0.0002 and 
P=0.018, respectively) than D100, but with 20% coconut oil (D80C20), SOD1 mRNA 
expression was no higher than with D100 exposure. SOD2 mRNA expression was suppressed 
by D100 exposure (P=0.002), but with coconut-diesel blends (D90C10 and D80C20) SOD2 
mRNA suppression was attenuated in comparison to the effect of D100 (P=0.0038 and 
P=0.0003, respectively). There was a similar trend for coconut-diesel to attenuate suppression 
of HMOX-1 mRNA expression, but responses were not statistically significant (P>0.05). 
 
 
Figure 5-5: Measurement of oxidative stress markers; SOD1 mRNA expression (a), 
SOD2 mRNA expression (b) and HMOX-1 mRNA expression (c). 
Measurements were taken after 30-minute exposure to diesel or coconut oil-blended diesel 
emissions with a 3-hour post-exposure incubation. * indicates a statistically significant 
difference (P<0.05), when compared to the filtered air (FA) control. * above an indented line 
indicates a significant difference between the two experimental groups indicated. Error bars 
indicate SEM (n=6). The experiment was repeated twice with triplicate samples. Values are 
relative to the filtered air control, which was deemed 100% viable and the baseline sample. 
 
Xenobiotic metabolism 
CYP1A1 gene expression was measured to assess changes in xenobiotic metabolism with 
diesel and coconut-diesel (Figure 5-6). All diesel and coconut-diesel exposures significantly 
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increased CYP1A1 mRNA above that observed for filtered air exposure (P<0.0001).  Coconut-
diesel 20 percent blend exposure was associated with significantly higher epithelial CYP1A1 
mRNA expression than D100 exposure (P=0.026), but after exposure to lower percentage 
coconut oil admixtures, expression was similar to that observed with D100. 
 
 
Figure 5-6: Gene expression of xenobiotic metabolism biomarker, CYP1A1. 
Measurements were taken after 30-minute exposure to diesel or coconut oil-blended diesel 
emissions with a 3-hour post-exposure incubation. * indicates a statistically significant 
difference (P<0.05), when compared to the filtered air (FA) control. * above an indented line 
indicates a significant difference between the two experimental groups indicated. Error bars 
indicate SEM (n=6). The experiment was repeated twice with triplicate samples. Values are 
relative to the filtered air control, which was deemed 100% viable and the baseline sample. 
 
5.4 Discussion 
Main findings  
Bronchial epithelial cell responses to diesel emissions were significantly affected by coconut 
oil substitution, according to percentage substitution. Exposure to conventional diesel 
emissions reduced cellular metabolism, increased proinflammatory cytokine secretion, altered 
antioxidant production, and increased CYP1A1 mRNA expression. Compared to conventiona l 
diesel, lower fractional coconut oil substitution (10% and 15%) reduced proinflammato ry 
cytokine secretion, increased SOD1 mRNA expression and attenuated suppression of SOD2 
and HMOX-1 mRNA expression, whereas 20% coconut oil admixture increased cellula r 
metabolism, reduced live cell percentage, increased pro-inflammatory cytokine secretion, 
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attenuated suppression of SOD2 and HMOX-1 mRNA expression, and increased CYP1A1 
mRNA expression. These findings suggest that low to moderate substitution of coconut oil may 
reduce adverse effects of diesel emission exposure, but that higher percentage substitution of 
coconut oil may increase toxicity.  
 
The effect of low and moderate level of coconut oil substitution (10% and 15%) in diesel 
fuel on bronchial epithelial cells  
Diesel emissions may cause inflammation, oxidative stress and loss of bronchial epithelial cell 
viability. If prolonged, these cellular responses may lead to tissue injury and airway 
remodelling, contributing to pathogenesis of chronic lung diseases such as COPD and lung 
cancer. In this study, low to moderate substitution of coconut oil in diesel fuel reduced 
inflammatory indicators and increased antioxidant production (SOD1) in bronchial epithelia l 
cells, compared to conventional diesel emissions.  Increased antioxidant production is a 
defensive mechanism serving to maintain oxidative balance within the cells and prevent 
oxidative stress. By modifying this balance, low to moderate substitution of coconut oil may 
be a safer alternative to diesel emissions.  
 
The effect of high level of coconut oil substitution (20%) in diesel fuel on bronchial 
epithelial cells  
To our knowledge, this is the first study to investigate bronchial epithelial cell response to 
coconut oil-substituted diesel in comparison to conventional diesel. High level coconut oil 
diesel substitution decreased live cell percentage, increased inflammation, attenuated 
suppression of SOD2 and HMOX-1 mRNA expression and increased CYP1A1 mRNA 
expression in our experiments.   The mutagenicity of pure coconut oil combusted in a diesel 
engine has been reported to be similar to that of diesel, but lower than that of rapeseed, palm 
and soybean oils [65].  Canola oil-derived biodiesel at 30% and 100% was associated with 
increased bronchial epithelial cell death [121].  Thirty percent rapeseed oil biodiesel was 
associated with increased genotoxicity [122], but 7% rapeseed biodiesel reduced cell death and 
oxidative potential compared with both 30% biodiesel and conventional diesel [123]. It has 
been suggested that adverse effects of biodiesel are related to the fat content of biodiesel fuel. 
Fatty acids can penetrate cells and form lipid droplets [124], which accumulate lipophilic 
xenobiotics including diesel organic content, potentially amplifying harmful effects [124]. 
Thus, biodiesel fuel blends with low fatty acid content may be a safer alternative.  
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Limitations 
There are limitations of this study to be considered. Firstly, the SV-40 virally transformed 
immortalised cell line, 16HBE, may lack physiological relevance to in vivo airway epithelium. 
In particular, the inherently high proliferative rate of transformed cells could result in more 
robust injury responses than those of in vivo airway epithelium. This possibility of reduced 
sensitivity to emissions exposure must be considered alongside the advantages of cell line 
models which provide experimental internal consistency and reproducibility.   Second, the 
emission exposure levels tested were high in comparison to particulate matter levels in ambient 
air pollution, so testing of lower level substitutions (below 10%) could be important.   
 
5.5 Conclusions 
To our knowledge, this is the first study to investigate cellular responses to coconut-diesel on 
bronchial epithelial cells, in comparison to conventional diesel. Low to moderate substitut ion 
of coconut oil in diesel fuel reduced adverse effects of diesel emissions on bronchial epithelia l 
cells, whereas high percentage substitution increased the toxicity of diesel emissions. In search 
of a safer alternative to conventional diesel, further investigation into the respiratory epithelia l 
effects of low percentage coconut oil substitution in diesel fuel is warranted. 
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Chapter 6:  The effect of N-acetylcysteine treatment on 
bronchial epithelial cells after diesel emission exposure at an air-
liquid interface 
6.1 Rationale 
Prolonged inflammation and oxidative stress in the airways increase the risk of developing 
COPD  [5, 74, 125, 126]. Interventions that prevent these adverse effects may protect against 
lung disease. N-acetylcysteine (NAC) is an antioxidant used clinically as a mucolytic agent 
[69, 127]. In vivo studies of NAC as a management therapy for COPD patients have shown 
reduced ROS, hydrogen peroxide and superoxide anion in exhaled breath and blood, as well as 
reduced levels of the pro-inflammatory cytokine, interleukin-8 (IL-8) in blood [128-132]. In 
vitro studies have shown that NAC reduces ROS and oxidative stress-induced DNA deletion 
in mammalian cells [70].  By inhibiting NF-κB activation, NAC also alters downstream 
phospholipid metabolism, pro-inflammatory cytokine release and protease activity [71]. These 
studies demonstrate that NAC can effectively reduce inflammation and oxidative stress in cells. 
Therefore, NAC has the potential to protect the airway epithelium from adverse effects of diesel 
emission exposure. We proposed that a therapeutic antioxidant, NAC, may prevent cell death, 
prevent inflammation and effectively maintain oxidative balance in bronchial epithelial cells 
after exposure to diesel emissions. Hence, the aim of this study was to test whether post-
exposure NAC antioxidant treatment reduced the adverse effects of diesel emissio n exposure 
on immortalised human bronchial epithelial cells (16HBE) at an air-liquid interface. 
 
6.2 Methods 
Cell culture  
16HBE (p49) cells (SV-40 transformed human bronchial epithelial cell line), were seeded onto 
Corning Transwell inserts at 50,000 cells per insert and grown in MEMα supplemented with 
PSG and Fungizone. These cells were incubated at 37°C until confluence, then apical media 
was removed to achieve ALI. These cells were maintained at ALI for 7 days prior to exposure. 
See Chapter 2: Methods, section 2.2 for additional details for ALI culture. 
 
Engine specifications 
The engine used to generate emissions was a 6 cylinder, common-rail, turbo-charged diesel 
engine coupled to an electronically-controlled hydraulic dynamometer, which controlled 
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engine load. Technical specifications of the engine are depicted in Table 6-1. Operating 
parameters were a quarter load where maximum torque was 820 Nm and speed of 1500 rpm 
(rated power 162 KW at 2500 rpm). For each test, the engine was started and warmed up for 
at least 30 minutes. Commercial diesel fuel was purchased from Caltex (Australia). 
 
Table 6-1: Diesel engine specifications. 
Model      Cummins ISBe220 
Cylinders  6 in-line 
Capacity (L)  5.9 
Bore × stroke (mm)  102 × 120 
Maximum power (kW/rpm)  162/2500 
Maximum torque (N m/rpm)  820/1500 
Compression ratio    17.3 
Aspiration  Turbocharged and after cooled 
Fuel injection  Common rail 
Emissions certification  Euro III 
 
Diesel sampling procedure 
The engine exhaust was diluted in a partial flow dilution tunnel by HEPA-filtered laboratory 
air. Dilution ratio was calculated using measured concentrations of CO2 before and after the 
dilution tunnel using the following equation: 
 
𝐷𝑖𝑙𝑢𝑡𝑖𝑜𝑛 𝑅𝑎𝑡𝑖𝑜 (𝐷𝑅) =
𝐶𝑂2 (𝑅𝑎𝑤) − 𝐶𝑂2(𝐵𝑎𝑐𝑘𝑔𝑟𝑜𝑢𝑛𝑑, 𝐶𝐴𝐼)
𝐶𝑂2 (𝐷𝑖𝑙𝑢𝑡𝑒𝑑) − 𝐶𝑂2(𝐵𝑎𝑐𝑘𝑔𝑟𝑜𝑢𝑛𝑑, 𝑆𝐴𝐵𝐿𝐸)
 
 
A CAI (California Analytical Instruments) gas analyser was connected before the dilut ion 
tunnel to measure the gases in raw exhaust. We used a NDIR (non-dispersive infra-red) CAI 
600 CO2 and CO analyser and a CAI 600 CLD (chemiluminescence detector) NOx detector to 
measure concentrations of CO2, CO and NOx. A second CO2 meter (SABLE, CA-10) was used 
to record the CO2 concentration from the diluted exhaust. Background corrected CO2 was used 
as a tracer gas to calculate the dilution ratio. TSI Dustrak (model 8530) measured the mass of 
particles with a PM2.5 impactor installed. Measured PM2.5 masses were converted into 
gravimetric mass using the correction factor explained in [103]. A scanning mobility particle 
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sizer (SMPS) was used to characterize size distribution and concentration of particles. The 
sampling equipment set-up is outlined in Figure 6-1. 
 
 
Figure 6-1: Set-up for diesel emissions generation and analysis. 
A Scanning Mobility Particle Sizer (SMPS) gives the size distribution of the emissions. Dustrak 
measures particulate mass. The CULTEX system is used for cell exposure. CO2 analysers are 
used before and after dilution system to calculate the dilution ratio. 
 
 
HBEC exposure and cell response testing 
Immortalised human bronchial epithelial cells (16HBE) were exposed to diesel emission for 
30 minutes with or without a 3 hour post-exposure treatment with 5mM NAC (see Chapter 2: 
Methods, section 2.5). After exposure, MEMα was added to the apical surface of the cell layer 
and incubated for 3 hours (see Chapter 2: Methods, section 2.6). The media was collated and 
stored at -80ºC as supernatant for LDH assay and ELISA analysis. Cell viability (cellula r 
metabolism) was measured using the WST-1 assay, which was prepared using MEMα and 
incubated for 30 minutes (see Chapter 2: Methods, section 2.7). The cell layer was lysed, 
collected and stored at -80ºC for RNA extraction and gene expression analysis. At a later date, 
the concentration of IL-6 and IL-8 was measured using Thermo Fisher Scientific Novex 
ELISAs (see Chapter 2: Methods, section 2.9). RNA was extracted from the cell lysate and 
TaqMan gene expression analysis measured the expression of HMOX-1, SOD1, SOD2, 
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CASP3 and BCL2 mRNA on the BioRad CFX 384 Touch Real-Time PCR Detection System 
(see Chapter 2: Methods, section 2.10).  
 
6.3 Results 
Diesel emission characterisation 
The physical and chemical characteristics of the diesel emissions were assessed through the 
measurement of gas concentrations (NO2, NOx, CO2 and CO), hydrocarbon content (HC), 
mean DPMand mean particle number (PN). These characteristics are detailed in Table 6-2. The 
raw CO2 concentration of the diesel emissions was 5.89%. After the dilution tunnel, the CO2 
concentration was 0.29%. Therefore, the raw diesel emissions were diluted by 19.75x with 
laboratory air prior cell to exposure in the Cultex RFS. The average concentration of NO2, NOx 
and CO were 13.88ppm, 14.5ppm and 30.88ppm, respectively (corrected for dilution). The 
hydrocarbon content, average DPM and average PN were 40.72ppm, 72.55 µg/m3 and 1. 
41x106 particles/cm3 (corrected for dilution).  
 
Table 6-2: Diesel and alternative diesel emission characterisation data. 
Gas concentrations (NO2, NOx, CO2, and CO), HC, DPM, and PN. 
 
 
 
 
 
 
 
Cell viability 
The effect of NAC intervention on cell viability of bronchial epithelial cells after diesel 
emission exposure (Figure 6-2) was assessed through the measurement of cellular metabolism 
(Figure 6-2a: WST-1 cell proliferation assay), live cell percentage (Figure 6-2b: LDH assay), 
and gene expression of apoptotic and anti-apoptotic biomarkers, CASP3 (Figure 6-2c) and 
BCL2 (Figure 6-2d), respectively (qRT-PCR). Diesel emission exposure resulted in a 
significant decrease in cellular metabolism (P<0.0001), relative to the filtered air control. Live 
cell percentage, CASP3 mRNA expression and BCL2 mRNA expression were unchanged. 
NAC intervention after diesel emission exposure resulted in a significant reduction in live cell 
CO2 
(Raw) 
(%) 
CO2 
(dilute) 
(%) 
NO2 
(ppm) 
NOx 
(ppm) 
CO 
(ppm) 
HC 
(ppm) 
DPM 
(µg/m3) 
PN 
(#/cm3) 
5.894 0.2983 13.88 14.5 30.88 40.72 72.55 1.41x106 
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percentage (P<0.0001) and increase in CASP3 mRNA expression (P=0.0018), when compared 
to diesel emission exposure without NAC intervention. Cellular metabolism was unchanged 
after NAC intervention when compared to diesel emission exposure without NAC intervention.  
 
 
Figure 6-2: Measurement of cell viability markers: cellular metabolism (a), percentage 
live cells (b), CASP3 mRNA expression (c) and BCL2 mRNA expression (d). 
Measurements were taken after 30-minute exposure to diesel emissions with or without a 3-
hour post-exposure treatment with NAC (5mM) or media only. * indicates a statistically 
significant difference (P<0.05), when compared to the filtered air (FA) control. * above an 
indented line indicates a significant difference between the two experimental groups indicated. 
P values are given in the text. Error bars indicate SEM (n=6). The experiment was repeated 
twice with triplicate samples. Cellular metabolism values are relative to the filtered air control, 
which was deemed the baseline (steady state) metabolic level. Gene expression levels are 
relative to the filtered air control samples. 
 
Inflammation 
The effect of NAC intervention on the proinflammatory response of bronchial epithelial cells 
after diesel emission exposure (Figure 6-3) was assessed through the measurement of IL-8 
(Figure 6-3a) and IL-6 secretion (Figure 6-3b) with ELISAs. Diesel emission exposure resulted 
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in a significant increase in IL-6 secretion from bronchial epithelial cells, when compared to the 
filtered air control (P=0.0003). NAC intervention after diesel emission exposure resulted in a 
significant increase in IL-6 secretion, when compared to both the filtered air control (P<0.0001) 
and diesel emission exposure without NAC intervention (P=0.029). A similar trend was shown 
for IL-8 secretion; however, this was statistically non-significant.  
 
 
Figure 6-3: Measurement of proinflammatory cytokine secretion: IL-8 protein secretion 
(a), and IL-6 protein secretion (b). 
Measurements were taken after 30-minute exposure to diesel emissions with or without a 3-
hour post-exposure treatment with NAC (5mM) or media only. *indicates a statistically 
significant difference (P<0.05), when compared to the filtered air (FA) control. *above an 
indented line indicates a significant difference between the two experimental groups indicated. 
P values are given in the text. Error bars indicate SEM (n=6). The experiment was repeated 
twice with triplicate samples. 
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Antioxidant production 
The effect of NAC intervention on antioxidant production of bronchial epithelial cells after 
diesel emission exposure (Figure 6-4) was assessed by the measurement of SOD1 (Figure 6-
4a), SOD2 (Figure 6-4b) and HMOX-1 (Figure 6-4c) mRNA expression (qRT-PCR). Diesel 
emission exposure resulted in an increase in SOD1 mRNA expression and a suppression of 
HMOX-1 and SOD2 mRNA expression. NAC intervention significantly increased SOD1 
mRNA expression (P=0.014) and significantly attenuated SOD2 mRNA suppression 
(P=0.0027), when compared to diesel emission exposure without NAC intervention. There was 
an attenuation of the suppression of HMOX-1 mRNA expression but it was statistically non-
significant (P>0.05). 
 
 
Figure 6-4: Measurement of antioxidant production; SOD1 mRNA expression (a), 
SOD2 mRNA expression (b) and HMOX-1 mRNA expression (c). 
Measurements were taken after 30-minute exposure to diesel emissions with or without a 3-
hour post-treatment with NAC (5mM) or media only. * indicates a statistically significant 
difference (P<0.05), when compared to the filtered air (FA) control. * above an indented line 
indicates a significant difference between the two experimental groups indicated. Error bars 
indicate SEM (n=6). The experiment was repeated twice with triplicate samples. Gene 
expression is relative to the filtered air control samples. 
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6.4 Discussion 
Main findings 
The aim of this study was to test an antioxidant therapy, N-acetylcysteine, as a potential 
protective intervention against the adverse effects of diesel emission exposure on immortalised 
bronchial epithelial cells (16HBE). It was hypothesised that NAC would prevent the loss of 
cell viability, prevent inflammation and effectively maintain oxidative balance in epithelia l 
cells after exposure to diesel emissions. This study has three main findings which contradict 
this hypothesis. Firstly, NAC intervention reduced cell viability after diesel emission exposure, 
indicated by a reduction in cell metabolism, a decrease in live cells and an increase CASP3 
mRNA expression. Secondly, NAC intervention increased the proinflammatory response after  
diesel emissions exposure, indicated by an increase in IL-8 and IL-6 secretion. Lastly, NAC 
altered antioxidant production from bronchial epithelial cells in response to diesel emission 
exposure. Previous studies have shown that transformed cells, with tumour-like characteristic s, 
have a heightened sensitivity to NAC, causing apoptosis in cancer-derived cell lines [133]. 
Although seemingly adverse, these findings suggest that NAC intervention may protect against 
pre-malignant cells after diesel emission exposure.   
 
The effect of NAC intervention on cell viability 
Oxidative stress is a common effect of diesel emission exposure and is a key driver in the 
pathogenesis of respiratory diseases including chronic obstructive pulmonary disease. 
Therefore, it was expected that an antioxidant intervention with NAC would prevent the loss 
of cell viability, effectively protecting these bronchial epithelial cells after diesel emission. 
Previous research has demonstrated that treatment with NAC can have a protective effect 
through the prevention of oxidative stress and inflammation in the airways [70, 71, 134], which 
can lead to cell death. In contrast, the administration of NAC to immortalised bronchia l 
epithelial cells after exposure to diesel emissions resulted in a significant decrease in live cell 
percentage and an increase in CASP3 mRNA expression. Although seemingly adverse, the cell 
death demonstrated in this study may be an unexpected protective effect. 16HBE cells are an 
immortalised bronchial epithelial cell line, which can have tumour-like characteristics [135]. 
These cells are immortalised through SV-40 viral transformation, which alters the expression 
of p53, resulting in enhanced proliferative abilities, similar to pre-malignant cells. Previous 
research has demonstrated that immortalised or tumour-like cells have increased sensitivity to 
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NAC treatment, which can cause apoptosis in these cells. [133, 136].  Therefore, in this instance, 
a loss of cell viability of these transformed bronchial epithelial cells after NAC treatment might 
demonstrate a protective effect against pre-malignant cells after diesel emission exposure.  
 
The effect of NAC intervention on proinflammatory responses 
Diesel emission exposure leads to inflammation, and when prolonged, can lead to oxidative 
stress-induced cell death [81, 137, 138]. Chronic inflammation is a key driver of the 
pathogenesis of respiratory diseases. When testing a potential protective intervention, it is 
essential to assess the effectiveness of the intervention in attenuating the inflammation caused 
by diesel emission exposure. NAC intervention has been shown to reduce inflammation in the 
airways [139]. It was expected that NAC intervention would attenuate the proinflammato ry 
signalling from immortalised bronchial epithelial cells after diesel emission exposure. 
Conversely, there was a significant increase in IL-6 secretion in response to diesel emission 
exposure, which was significantly exacerbated by the post-exposure treatment with NAC. This 
exacerbation of pro-inflammatory signalling may be a result of the viral transformation of the 
cell line. NF-κB signalling is one of the key mediators of epithelial inflammatory responses to 
external stressors [140]. Transformation using the SV-40 vector may alter NF-κB expression 
and signalling [141]. Research has demonstrated that viral transformation of cells increases the 
sensitivity of these cells to NAC [133]. Although this previous research focused on apoptosis, 
it is possible that these genetic alterations from viral transformation may have interrupted NF-
κB signalling and possibly enhanced proinflammatory signalling responses. This heightened 
IL-6 response is also seen in pre-malignant lung epithelial cells [142]. These findings support 
the notion that these human bronchial epithelial cells may have a heightened sensitivity to NAC 
intervention due to their tumour-like characteristics. Therefore, NAC intervention after diesel 
emission exposure may have a proinflammatory effect on immortalised bronchial epithelia l 
cells. 
 
NAC alters antioxidant production to promote intrinsic apoptosis 
This study showed a significant increase in SOD1 mRNA expression after NAC intervention, 
when compared to diesel emission exposure without NAC intervention. SOD1 expression has 
been implicated in the initiation of mitochondrial apoptosis [143]. This study has demonstrated 
a significant reduction in live cell percentage after treatment with NAC, as well as a reduction 
in cellular metabolism. The reduction in cellular metabolism may suggest mitochondria l 
dysfunction, which can initiate intrinsic apoptosis pathways [144]. Therefore, the increase in 
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SOD1 mRNA expression along with the decrease in cellular metabolism and live cell 
percentage suggest NAC intervention may promote intrinsic apoptosis in bronchial epithelia l 
cells after diesel emission exposure through altered antioxidant production.  
 
Limitations 
This study has some potential limitations that need to be considered. Firstly, this study was 
conducted using the SV-40 immortalised cell line, 16HBE. As stated previous ly, 
immortalisation using SV-40 increases the sensitivity of these cells to NAC treatment [133]. It 
is possible that this transformation may have contributed to the results shown in this study. 
This cell line was chosen because it was derived from healthy bronchial epithelium and is a 
widely used commercial cell lines with reproducible results. The use of this cell line has 
produced a novel insight into the potential for NAC to protect against pre-malignant cells after 
diesel emission exposure. Secondly, the NAC dose used in this study (5mM) may have 
influenced epithelial cell responses. A previous study has also demonstrated comparable toxic 
effects of NAC treatment on a cancer-derived cell line [133].  However, this study used  a much 
higher dose (50mM) and longer exposure times compared to the present study [133]. 
Conversely, a study that used comparative NAC dose and treatment time demonstrated a 
protective effect of NAC treatment on BET-1A cells (transformed bronchial epithelial cells) 
[139]. It is likely that cell line characteristics and NAC dose are strong mediators of epithelia l 
cell responses to NAC treatment. Finally, this study did not compare the effects of NAC 
treatment at different time points. There is potential for NAC intervention to have a differe nt 
effect of bronchial epithelial cells if administered before or during diesel emission exposure. 
However, preliminary studies investigating the effect of NAC treatment of 16HBE cells after 
cigarette smoke condensate exposure showed post-exposure treatment with NAC had a positive 
effect on these cells (Figure 6-5). These limitations will be considered in future studies of NAC 
intervention. 
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Figure 6-5: Measurement of cell proliferation after exposure to 250µg /mL cigarette 
smoke condensate (CSC) for 24 hours with or without 5mM NAC post exposure 
treatment. 
Media: media only. NAC: 5mM of NAC only. CSC: 250g/mL of CSC only. CSC+NAC: 
250g/mL of CSC with 5mM NAC post-exposure intervention. There were no significant 
changes in cell proliferation when compared to the media control. Cell proliferation is relative 
to the media control, which is deemed 100% viable.  
 
 
6.5 Conclusions 
NAC intervention increased cell death and inflammation of 16HBE cells after diesel emission 
exposure. 16HBE is an immortalised cell line, with tumour-like characteristics, includ ing 
enhanced proliferative abilities. These results suggest that NAC intervention may have a 
protective effect against the development and proliferation of pre-malignant cells after diesel 
emission exposure. Future studies will investigate the potential of NAC intervention to prevent 
oncogenesis through its toxic effects on pre-malignant cells. 
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Chapter 7:  The effect of diesel emission exposure on primary 
human bronchial epithelial cells from a COPD cohort: N-
acetylcysteine as a potential protective intervention 
 
7.1 Rationale 
The World Health Organisation (WHO) has estimated that 3 million people die of chronic 
obstructive pulmonary disease (COPD) each year and that it will be the third leading cause of 
death in 2020 [8]. Diesel emissions exposure, if prolonged, can have a severe impact on the 
airway epithelium, causing inflammation, oxidative stress and tissue injury [38, 40]. Damage 
to the airway epithelium is a key driver of the pathogenesis and progression of COPD. An 
effective therapeutic intervention to protect the airway epithelium from diesel emission 
exposure may prevent inflammation and oxidative stress in the airways, and potentially, the 
progression of COPD. Unfortunately, there are currently no targeted interventions to protect 
the airways from diesel emission exposure.  
 
Current therapeutic interventions for COPD include bronchodilators, antibiotics and 
corticosteroids to reduce inflammation [8]. These interventions work to reduce airflow 
obstruction, suppress inflammation and prevent exacerbation. Currently interventions to reduce 
diesel emissions, including engine emission standards and after-treatment devices on engines, 
work to reduce the particulate matter produced from vehicles. However, these strategies do not 
address current air pollution levels and the benefits of these strategies will take years to appear. 
A novel therapy to protect the airways from air pollution is needed to protect vulnerab le 
airways such as in COPD patients.  
 
Research into protective interventions against the environmental risk factors of COPD 
progression, such as diesel emission exposure, will provide novel insight into COPD 
pathogenesis and potential prevention strategies. The aim of this study was to test the 
effectiveness of an antioxidant therapy, N-acetylcysteine (NAC), as a protective intervention 
against diesel emission exposure on primary human bronchial epithelial cells from COPD 
patients.  
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7.2 Methods 
Establishing primary cell lines 
The primary human bronchial epithelial cells (pHBEC) were established at the University of 
Queensland Thoracic Research Centre (UQTRC) from clinical samples donated, with written 
informed consent, by patients undergoing lung cancer resection surgery at The Prince Charles 
Hospital (see Chapter 2: Methods, section 2.1).  
 
Participants 
This study included pHBECsfrom 25 patients with or without COPD (summarised in Table 
7-1): 11 patients without COPD and 14 patients with COPD. Patients with COPD were 
classified by chronic airflow obstruction consistent with COPD (FEV1/FVC <70%). All 
patients were diagnosed with lung adenocarcinoma and underwent lung resection surgery, from 
which bronchial resection was collected for pHBEC culture. Demographic data were obtained 
from the UQTRC Tissue Bank database: age, sex, smoking history, respiratory function tests 
(spirometry, gas transfer) and lung cancer histology. 
 
Table 7-1: Summarised demographics for the patient cohorts. 
 
Control 
Demographic Value SD 
No. of patients 11 N/A  
Sex (M/F) 6(55%)/5(45%) N/A 
FEV1/FVC 76.60 3.69 
Age (years) 63.55 10.53 
Smoking history (Pack years) 40.43 22.83 
COPD 
Demographic Value SEM 
No. of patients 14 N/A 
Sex (M/F) 9(65%)/5(35%) N/A 
FEV1/FVC 59.96 3.84 
Age (years) 68.18 7.7 
Smoking history (Pack years) 54.84 34.80 
 
 
 95 
Air-liquid interface culture   
Primary HBECs were grown and differentiated at ALI for at least 28 days before exposure to 
diesel emissions (see Chapter 2: Methods, section 2.2). 
 
Engine specifications 
The engine used to generate emissions was a 6 cylinder, common-rail, turbo-charged diesel 
engine coupled to an electronically-controlled hydraulic dynamometer, which controlled 
engine load. Technical specifications of the engine are depicted in Table 7-2. Operating 
parameters were a quarter load where maximum torque was 820 Nm and speed of 1500 rpm. 
The engine ran for 30 minutes after ignition until engine exhaust temperature was stable. 
Commercial diesel fuel was purchased from Caltex (Australia). 
 
Table 7-2: Diesel engine specifications 
Model      Cummins ISBe220 
Cylinders  6 in-line 
Capacity (L)  5.9 
Bore × stroke (mm)  102 × 120 
Maximum power (kW/rpm)  162/2500 
Maximum torque (N m/rpm)  820/1500 
Compression ratio    17.3 
Aspiration  Turbocharged and after cooled 
Fuel injection  Common rail 
Emissions certification  Euro III 
 
Diesel sampling procedure 
The engine exhaust was diluted in a partial flow dilution tunnel by HEPA-filtered laboratory 
air. Dilution ratio was calculated using measured concentrations of CO2 before and after the 
dilution tunnel using the following equation: 
 
𝐷𝑖𝑙𝑢𝑡𝑖𝑜𝑛 𝑅𝑎𝑡𝑖𝑜 (𝐷𝑅) =
𝐶𝑂2 (𝑅𝑎𝑤) − 𝐶𝑂2(𝐵𝑎𝑐𝑘𝑔𝑟𝑜𝑢𝑛𝑑, 𝐶𝐴𝐼)
𝐶𝑂2 (𝐷𝑖𝑙𝑢𝑡𝑒𝑑) − 𝐶𝑂2(𝐵𝑎𝑐𝑘𝑔𝑟𝑜𝑢𝑛𝑑, 𝑆𝐴𝐵𝐿𝐸)
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A California Analytical Instruments (CAI) gas analyser was connected before the dilut ion 
tunnel to measure the gases in raw exhaust. Gas concentrations of CO2, CO and NOx were 
measured using a non-dispersive infra-red (NDIR) CAI 600 CO2 and CO analyser and a CAI 
600 chemiluminescence detector (CLD) NOx detector. A second CO2 meter (SABLE, CA-10) 
was used to record the CO2 concentration of the exhaust after dilution. Background corrected 
CO2 was used as a tracer gas to calculate the dilution ratio. Particle mass was measured using 
a TSI Dustrak (model 8530) with a PM2.5 impactor installed. Measured PM2.5 masses were 
converted into gravimetric mass using a correction factor [103]. Particle concentration and size 
distribution were characterised using a scanning mobility particle sizer (SMPS). 
 
Cell exposure 
pHBEC cell lines were exposed to diesel emissions for 30 minutes with or without a 3-hour 
post-exposure treatment with 5mM NAC. After exposure, MEMα with or without 5mM NAC 
was added to the apical surface of the cell layer and incubated for 3 hours (see Chapter 2: 
Methods, section 2.6). The media was collated and stored at -80ºC as supernatant for LDH 
assay and ELISA analysis. Cellular metabolism was measured using the WST-1 assay, which 
was prepared using MEMα and incubated for 30 minutes (see Chapter 2: Methods, section 2.7). 
The cell layer was lysed, collected and stored at -80ºC for RNA extraction and gene expression 
analysis. At a later date, the concentration of IL-8 was measured using Thermo Fisher Scientific 
Novex ELISAs (see Chapter 2: Methods, section 2.9). RNA was extracted from the cell lysate 
and TaqMan gene expression analysis measured the expression of HMOX-1 SOD1, SOD2, IL-
8, CYP1A1, CASP3 and BCL2 mRNA on the Thermo Fisher Scientific Viia7 Real-Time PCR 
Detection System. A Nanostring nCounter Vantage 3D Intracellular Signalling and a GX 
Immunology panel loaded onto a Nanostring Sprint cartridge and the panels were run on the 
Nanostring nCounter SPRINT Profiler (see Chapter 2: Methods, section 2.10). 
 
Nanostring data analysis 
Mass array gene expression data from the Nanostring gene expression panels were analysed 
using the nSolver 4.0 software with the Advanced Analysis package. nSolver is an integrated 
analysis platform for storage, custom QC, custom normalisation and semi-automated analysis 
of Nanostring data.  
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7.3 Results 
Diesel emission characterisation 
The physical and chemical characteristics of the diesel emissions were assessed through the 
measurement of particle size distribution (Figure 7-1), gas concentrations, particle number and 
particles mass (Table 7-3). The particle size distribution was comparable to previous research 
with the same engine parameters [137]. The average concentration of CO2, CO and NOx were 
0.24ppm, 7.8ppm and 20.4ppm, respectively. The particle number was 1.93x106 with an 
average particle mass of 390µg/m3. Although these particle characteristics are high in 
comparison to ambient air [145], this data is comparable to similar studies [138]. 
 
 
 
Figure 7-1: Size distribution of the diesel emissions. 
Particle number distributions were measured with a scanning mobility particle sizer (SMPS) 
consisting of a TSI 3071A classifier (EC) and a TSI 3010 condensation particle counter (CPC). 
Particles within a 10-500 nm size range were measured.  
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Table 7-3: Diesel emission characterisation data 
raw and diluted gas concentrations (CO2, CO and NOx), diesel particle mass (DPM) and 
particle number (PN). 
 
 
CO2 
(raw) 
(%) 
CO2 
(diluted) 
(%) 
CO 
(raw) 
(PPM
) 
CO 
(corrected) 
(PPM) 
NOx 
(raw) 
(PPM) 
NOx 
(corrected) 
(PPM) 
PN  
(#/cm3) 
DPM 
(mg/m3) 
Mean 
+ SD 
4.9 
+/- 0.07 
0.24  
+/- 0.003 
140  
+/- 
3.9 
7.8 
 
167.9  
+/- 5.09 
20.4 
 
1.93x106  
+/-5.66 x104 
0.39 
+/- 0.02 
 
 
Cell viability 
The effect of diesel emission exposure on cell viability of pHBECs (Figure 7-2) was assessed 
by measuring cellular metabolism (Figure 7-2a), live cell percentage (Figure 7-2b), CASP3 
expression (Figure 7-2c) and BCL2 expression (Figure 7-2d). Exposure of pHBECs to diesel 
emissions had no significant effect on markers of cell viability in non-COPD, COPD, or 
collated cohorts, when compared to filtered air controls (P>0.05).  
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Figure 7-2: Measurement of cell viability markers: (a) percentage proliferative cells, (b) 
percentage live cells, (c) CASP3 mRNA expression. (d) and BCL2 mRNA expression. 
Measurements were taken after 30-minute exposure to diesel emissions (white) or filtered 
laboratory air (FA: black). Error bars indicate SEM (Control cohort: n=8 with triplicate 
samples. COPD cohort: n=10 with triplicate samples. Collated cohort: n-18 with triplicate 
samples). Cellular metabolism and live cell percentage values are relative to the filtered air 
control, which was deemed 100% viable and the baseline sample. 
 
Inflammation 
The effect of diesel emissions and NAC intervention on the pro-inflammatory response of 
pHBECs (Figure 7-3) was assessed by the measurement of IL-8 secretion (Figure 7-3a) and 
IL8 expression (Figure 7-3b). Diesel emission exposure significantly increased IL-8 secretion 
in the non-COPD, COPD and collated cohorts (P=0.007, P=0.001, P=0.007, respectively), with 
parallel alterations in IL8 expression in the non-COPD and collated cohorts (P=0.027 and 
P=0.034, respectively). There was no significant change in IL-8 secretion or IL8 expression 
with NAC intervention; however, there was a trend for reduced IL-8 secretion.  
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Figure 7-3: Measurement of inflammatory markers: (a) IL-8 protein secretion and (b) 
IL-8 mRNA expression. 
Measurements were taken after 30-minute exposure to diesel (DE) with a 3-hour post-exposure 
treatment with or without NAC. Error bars indicate SEM (Control cohort: n=8 with triplicate 
samples. COPD cohort: n=10 with triplicate samples). * indicates a statistically significant 
difference (P<0.05), when compared to the filtered air (FA) control. * above an indented line 
indicates a significant difference between the two experimental groups indicated. P values are 
given in the text. IL-8 secretion values are expressed as fold change to the filtered air control 
of each cell line, as the baseline IL-8 secretion levels vary between primary cell lines.  
 
Oxidative stress 
Production of antioxidants is a cellular defence mechanism to protect against oxidative stress. 
The effect of diesel emissions on the oxidative stress response of pHBECs (Figure 7-4) was 
assessed by measurement of SOD1 (Figure 7-4a), SOD2 (Figure 7-4b), and HO-1 (Figure 7-
4c) gene expression. In the non-COPD cohort, there was a significant increase in SOD1 mRNA 
expression after exposure to diesel emissions (P=0.009).. In the COPD cohort, SOD-1 
expression was significantly suppressed after diesel exposure, and this was not altered by NAC.  
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In the collated cohort, SOD1 expression was significantly suppressed by diesel emission 
exposure with NAC intervention (P<0.0001). Diesel emission exposure and NAC intervention 
had no significant effect of SOD2 and HMOX1 expression. 
 
 
Figure 7-4: Measurement of oxidative stress markers: (a) HMOX-1 mRNA expression, 
(b) BCL2 mRNA expression, (c) SOD1 mRNA expression and (d) SOD2 mRNA 
expression. 
Measurements were taken after 30-minute exposure to diesel (DE) with a 3-hour post-exposure 
treatment with or without NAC. Error bars indicate SEM (Control cohort: n=8 with triplicate 
samples. COPD cohort: n=10 with triplicate samples). * above an indented line indicates a 
significant difference between the two experimental groups indicated. P values are given in the 
text. 
 
Xenobiotic metabolism 
The effect of diesel emission exposure and NAC intervention on xenobiotic metabolism of 
pHBECs was assessed by measuring CYP1A1 mRNA expression (Figure 7-5). In the non-
COPD cohort, there was no significant change in pHBEC CYP1A1 mRNA expression in 
response to diesel emission exposure compared to filtered air control (P>0.05). In the COPD 
and collated cohort, there was a significant increase in CYP1A1 mRNA expression by pHBECs 
after exposure to diesel (P=0.025 and P=0.016, respectively). This response was not 
significantly altered by treatment with NAC. However, there was a trend for attenuation. 
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Figure 7-5: Gene expression of a marker for xenobiotic metabolism, CYP1A1 mRNA. 
Measurements were taken after 30-minute exposure to diesel (DE) with a 3-hour post-exposure 
treatment with or without NAC. Error bars indicate SEM (Control cohort: n=8 with triplicate 
samples. COPD cohort: n=10 with triplicate samples). Values are relative to the filtered air 
control (FA), which was deemed 100% viable and the baseline comparative group. 
 
Nanostring GX Intracellular signalling and Immunology gene expression profiling 
Gene expression profiling were performed using Nanostring nCounter intracellular signalling 
and immune response pathway panels and identified differential gene expression profiles 
related to COPD, diesel emission exposure, and NAC intervention. There were 44 genes with 
significantly altered gene expression in COPD, compared with non-COPD controls (Table 7-4). 
33 genes had significantly altered gene expression after exposure to diesel emissions, when 
compared to filtered air controls ( 
 
 
 
 
 
 
 
Table 7-5). 4 genes were significantly altered in association with NAC intervention, compared 
to without intervention (Table 7-6). These significantly altered genes were related to the 
complement system (Figure 7-6), cytokine signalling (Figure 7-7) interferon signalling (Figure 
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7-8), MHC II molecules (Figure 7-9) and signal transduction (Figure 7-10). NAC intervention 
had differential effects on gene expression after exposure to diesel emissions. Interestingly, the 
COPD cohort showed a strong signal for the upregulation of interferon signalling genes (Figure 
7-8) and MHC class II molecules (Figure 7-9) for the filtered air control samples, which was 
suppressed by NAC intervention. 
 
 
Figure 7-6: Expression level of genes related to the complement system in response to 
diesel emission exposure with or without NAC intervention. 
Expression values are Log2 of fold change, relative to the non-COPD cohort. Gene targets 
were identified using differential expression advanced analysis on the Nanostring nSolver 
Software.  FA: filtered air, DE: diesel emissions: No NAC: Exposure without NAC intervention. 
NAC: Exposure with NAC intervention. 
 
Figure 7-7: Expression level of genes related to the cytokine signalling in response to 
diesel emission exposure with or without NAC intervention. 
Expression values are Log2 of fold change, relative to the non-COPD cohort. Gene targets 
were identified using differential expression advanced analysis on the Nanostring nSolver 
Software.  FA: filtered air, DE: diesel emissions: No NAC: exposure without NAC intervention. 
NAC: Exposure with NAC intervention. 
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Figure 7-8: Expression level of genes related to the interferon signalling in response to 
diesel emission exposure with or without NAC intervention. 
Expression values are Log2 of fold change, relative to the non-COPD cohort. Gene targets 
were identified using differential expression advanced analysis on the Nanostring nSolver 
Software.  FA: filtered air, DE: diesel emissions: No NAC: exposure without NAC intervention. 
NAC: Exposure with NAC intervention. 
 
 
Figure 7-9: Expression level of genes related to the MHC II molecules in response to 
diesel emission exposure with or without NAC intervention. 
Expression values are Log2 of fold change, relative to the non-COPD cohort. Gene targets 
were identified using differential expression advanced analysis on the Nanostring nSolver 
Software.  FA: filtered air, DE: diesel emissions: No NAC: exposure without NAC intervention. 
NAC: Exposure with NAC intervention. 
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Figure 7-10: Expression level of genes related to signal transduction in response to 
diesel emission exposure with or without NAC intervention. 
Expression values are Log2 of fold change, relative to the non-COPD cohort. Gene targets 
were identified using differential expression advanced analysis on the Nanostring nSolver 
Software.  FA: filtered air, DE: diesel emissions: No NAC: exposure without NAC intervention. 
NAC: Exposure with NAC intervention. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 106 
Table 7-4: Identified of genes with significantly altered expression levels of pHBECs 
from COPD patients, relative to the control cohort. 
BY adjusted P-Values are P-values corrected  for multiple comparisons using the Benjamini 
& Yekutieli correction [146]. 
 
Gene name Fold change Std. error P-value BY Adjusted P-value 
ITGB2-mRNA 2.95 0.25 0.000000047 0.000089 
HLA-DMA-mRNA 1.51 0.15 0.00024 0.23 
KCNJ2-mRNA 1.53 0.17 0.00074 0.38 
PDGFRA-mRNA 1.57 0.19 0.00089 0.38 
HLA-DPB1-mRNA 2.28 0.34 0.00100 0.38 
HLA-DRB3-mRNA 1.87 0.27 0.0013 0.41 
CD46-mRNA -0.17 0.06 0.0028 0.75 
LITAF-mRNA -0.29 0.09 0.0032 0.77 
HLA-DMB-mRNA 1.81 0.29 0.0047 0.99 
ICAM3-mRNA 1.59 0.23 0.0055 1 
C2-mRNA 1.48 0.20 0.0063 1 
HLA-DPA1-mRNA 1.98 0.36 0.0079 1 
IRF7-mRNA 1.47 0.20 0.0085 1 
APP-mRNA -0.32 0.12 0.0087 1 
PIK3CD-mRNA 1.29 0.14 0.0090 1 
NT5E-mRNA 1.62 0.27 0.011 1 
IFIH1-mRNA 1.30 0.15 0.013 1 
IL18-mRNA 1.24 0.13 0.015 1 
CD9-mRNA -0.38 0.15 0.016 1 
RELB-mRNA 1.28 0.14 0.017 1 
BAX-mRNA -0.28 0.12 0.017 1 
MX1-mRNA 1.52 0.25 0.017 1 
DUSP4-mRNA -0.31 0.13 0.018 1 
S100A8-mRNA 1.47 0.23 0.020 1 
AKT3-mRNA 1.43 0.22 0.021 1 
PSMB7-mRNA -0.16 0.07 0.023 1 
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PTPN6-mRNA 1.28 0.15 0.023 1 
TNFSF10-mRNA 1.15 0.09 0.024 1 
HLA-C-mRNA -0.42 0.19 0.026 1 
TNFRSF14-mRNA 1.22 0.13 0.028 1 
TBK1-mRNA 1.29 0.16 0.028 1 
TNFRSF11A-
mRNA 
1.38 0.21 0.031 1 
TLR4-mRNA 1.32 0.18 0.031 1 
HLA-DRA-mRNA 1.66 0.33 0.032 1 
C3-mRNA -0.52 0.24 0.033 1 
IRF1-mRNA 1.26 0.16 0.034 1 
BATF-mRNA 1.38 0.21 0.035 1 
MIF-mRNA -0.25 0.12 0.037 1 
SERPING1-mRNA 1.21 0.13 0.038 1 
ITGB1-mRNA -0.28 0.13 0.040 1 
SLC2A1-mRNA -0.38 0.18 0.040 1 
EP300-mRNA -0.21 0.10 0.041 1 
BLNK-mRNA 1.39 0.23 0.043 1 
CASP8-mRNA 1.26 0.16 0.046 1 
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Table 7-5: Identified genes with significantly altered expression levels of pHBECs after 
exposure to diesel emissions, relative to the filtered air control. 
BY adjusted P-Values are P-values corrected  for multiple comparisons using the Benjamini 
& Yekutieli correction [146]. 
 
 
Gene name Fold change Std. error P-value BY Adjusted P-value 
SOCS3-mRNA 1.51 0.10 0.00000019 0.00036 
SERPING1-
mRNA 
-0.47 0.11 0.000028 0.027 
C1R-mRNA -0.42 0.13 0.0017 0.94 
IL6-mRNA 1.72 0.25 0.0022 0.94 
IL1RN-mRNA 1.28 0.12 0.0030 0.94 
MYC-mRNA 1.32 0.13 0.0030 0.94 
CD59-mRNA -0.27 0.09 0.0036 0.97 
SYK-mRNA 1.18 0.08 0.0044 1 
SOCS1-mRNA 1.42 0.17 0.0050 1 
DEFB4A-mRNA 1.71 0.27 0.0053 1 
CD24-mRNA -0.52 0.18 0.0060 1 
CEACAM6-
mRNA 
-0.41 0.16 0.013 1 
TFRC-mRNA 1.19 0.10 0.016 1 
FKBP5-mRNA 1.14 0.08 0.016 1 
MBP-mRNA 1.23 0.12 0.018 1 
SPRY1-mRNA -0.31 0.13 0.018 1 
GATA3-mRNA -0.42 0.18 0.020 1 
LIF-mRNA 1.32 0.17 0.021 1 
RELB-mRNA 1.21 0.12 0.021 1 
S100A8-mRNA 1.36 0.19 0.021 1 
IRAK2-mRNA 1.25 0.14 0.024 1 
IL6R-mRNA 1.22 0.13 0.025 1 
BAX-mRNA -0.21 0.09 0.028 1 
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CEBPD-mRNA 1.13 0.08 0.030 1 
TNF-mRNA -0.54 0.25 0.031 1 
APP-mRNA -0.21 0.10 0.032 1 
C1S-mRNA -0.23 0.11 0.035 1 
PTAFR-mRNA 1.19 0.12 0.035 1 
LTB4R2-mRNA 1.42 0.24 0.037 1 
IRF1-mRNA 1.20 0.13 0.037 1 
GBP1-mRNA -0.29 0.14 0.039 1 
MIF-mRNA -0.20 0.10 0.042 1 
DUSP4-mRNA 1.16 0.10 0.043 1 
 
Table 7-6: Identified genes with significantly altered expression levels of pHBECs 
associated with NAC intervention, relative to no NAC intervention. 
BY adjusted P-Values are P-values corrected  for multiple comparisons using the Benjamini 
& Yekutieli correction [146]. 
 
Gene name Fold change Std. error P-value BY Adjusted P-value 
BLNK-mRNA -0.43 0.19 0.023 1 
ABL1-mRNA -0.24 0.11 0.036 1 
STAT3-mRNA -0.09 0.04 0.038 1 
NFATC3-mRNA -0.23 0.11 0.038 1 
 
 
7.4 Discussion 
The aim of this study was to test the efficiency of an antioxidant therapy, N-acetylcyste ine 
(NAC), as a protective intervention against diesel emission exposure on primary human 
bronchial epithelial cells from a COPD cohort. There are four main findings from this study. 
First, SOD1 was suppressed after diesel emission exposure in COPD bronchial epithelial cells. 
Second, COPD bronchial epithelial cells had a stronger metabolic response to diesel emissions 
with increased CYP1A1 mRNA expression when compared with bronchial epithelial cells 
from the non-COPD cohort. Third, COPD bronchial epithelial cells were primed for CD4+ Th1 
immune response indicated by elevated expression of MHC class II proteins and an interferon-
associated signalling profile. Finally, NAC intervention did not effectively attenuate the 
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adverse effects of diesel emissions in the COPD cohort. These findings are consistent with 
vulnerability of COPD bronchial epithelial cells to diesel emissions due to reduced antioxidant 
capacity and promotion of CD4+ Th1 immune response phenotype. 
 
Under normal conditions, bronchial epithelial cells produce antioxidants to maintain oxidative 
balance and prevent oxidative stress after diesel emission exposure [138]. The results of this 
study indicate that COPD epithelial cells may have a reduced antioxidant capacity in response 
to diesel emission exposure. In the COPD cohort, SOD1 expression was significantly 
suppressed after exposure to diesel emissions, whereas SOD1 was significantly upregulated in 
the non-COPD cohort. Similar yet non-significant changes in SOD2 expression were produced. 
SOD1 and SOD2 genes encode two forms of superoxide dismutase, a prominent antioxidant 
protein produced by bronchial epithelial cells. Reduced antioxidant levels have been found in 
serum and lung tissue of COPD patients [147-149], and may be due to key pathogenic 
mechanisms in COPD progression. For instance, neutrophil elastase, a key driver of COPD 
pathogenesis [5, 150], can suppress HMOX1 expression in COPD lungs [151]. Additionally, 
inflamed epithelial cells have a reduced antioxidant response to diesel emissions exposure, 
which increases the cytotoxic effect of diesel emission exposure [152]. The production of 
antioxidants after exposure to diesel emissions is a vital protective mechanism to guard against 
endogenous ROS produced from common cellular responses including inflammation and 
xenobiotic metabolism after diesel emission exposure [153]. 
 
Xenobiotic metabolism is the intracellular metabolism of foreign agents for which CYP1A1 
expression is a biomarker [137]. Polymorphisms in the CYP1A1 gene have been linked to 
COPD susceptibility, increased inducibility of CYP1A1 expression, oxidative stress and 
reduced antioxidant capacity [39, 154, 155]. Xenobiotic metabolism increases after diesel 
emission exposure to remove diesel organic compounds after entering the cell. In this study, 
diesel emission exposure was associated with increased CYP1A1 expression, and higher levels 
of CYP1A1 expression were observed in COPD bronchial epithelial cells than in those from 
non-COPD subjects. As CYP1A1 activity produces endogenous ROS, an increase in CYP1A1 
mRNA expression may result in a greater oxidant load and potential for oxidative stress. 
Therefore, the airway epithelium of COPD patients may be vulnerable to oxidative stress and 
injury through heightened expression of CYP1A1 and suppressed antioxidant production after 
diesel emission exposure. 
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Airway epithelium is a physical barrier, but also regulates immune responses to foreign inhaled 
agents. In a healthy state, HBECs initiate innate or proinflammatory immune responses to 
diesel emissions in order to recruit immune cells to the airways and clear foreign inhaled agents. 
Previously, an increase in the secretion and production of the proinflammatory cytokine, IL-8, 
was found in response to diesel exposure [137, 156]. In the COPD cohort, we found only 
increased secretion, not production of IL-8.  Nanostring profiling showed suppressed 
expression of other pro-inflammatory cytokines (IL-6 and TNF ⍺), suggesting that COPD 
epithelial cells have diminished or aberrant proinflammatory signalling responses to diesel 
emission exposure.  
 
We found that COPD epithelial cells have increased expression of MHC class II and an 
interferon signalling profile. MHC class II molecules play an essential role in the initiation of 
the adaptive immune system by their ability to present peptide antigens to CD4+ T-
lymphocytes [157]. MHC class II molecules are expressed on epithelial cells following 
inflammatory signals, are strongly linked to immune responses to the external environment, 
and when presented to a naïve CD4+ T-cell, can produce a mature CD4+ T-cell [158]. Severe 
emphysema is associated with CD4+ cells in COPD [159] and T-cell characterisation in COPD 
is CD4+ Th1 commitment mediated by interferon gamma expression [160-162]. In our studies 
the combination of elevated expression MHC class II and interferon-associated signalling 
suggests promotion of a CD4+ Th1 immune response in COPD airways, and diesel emission 
exposure did not alter this expression profile. However, NAC strongly suppressed mRNA 
expression of MHC class II and interferon-associated signalling proteins.  
 
The effect of NAC intervention after diesel emission exposure was limited. There was a trend 
towards reduced proinflammatory responses (IL-8), and antioxidant production (SOD1 and 
SOD2) in bronchial epithelial cells in response to diesel emissions. This is consistent with 
previous studies finding that NAC can reduce airway IL-8  secretion and production [163, 164], 
and reduce SOD expression [165]. This anti-inflammatory effect may be protective in COPD 
since airway inflammation can lead to exacerbations and worsening of the disease [166]. As 
antioxidant production is one of the main defences against diesel emission exposure and COPD 
bronchial epithelial cells may already have diminished antioxidant capacity [147, 149], reduced 
antioxidant production may be detrimental, increasing the vulnerability of these cells to tissue 
injury, and promoting COPD progression.  
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Limitations 
A limitation of this study is that the pHBECs from the non-COPD cohort used as controls were 
not from disease-free lungs. In both non-COPD and COPD cohorts HBECs were obtained from 
bronchi within resected lung donated by patients undergoing surgery for lung cancer. Both 
pHBECs lines were matched for a diagnosis of lung adenocarcinoma. Hence, observed 
differences in epithelial cell responses between the two groups are likely due to presence or 
absence of COPD than to lung cancer. 
 
Two normal pHBEC lines and two COPD-pHBEC lines were purchased from Lonza and tested 
as negative and positive controls. Nanostring gene expression profiling showed strong 
upregulation of epidermal growth factor receptor (EGFR) expression in both cohorts, which 
was not seen in the in-house pHBEC lines. EGFR mediates key cellular  processes includ ing 
cell proliferation, apoptosis and differentiation [167]. Therefore, these commercially availab le 
diseased pHBEC lines were not suitable for comparison with our in-house pHBEC lines.  
 
Another consideration is whether 30-minute exposure time was sufficient to demonstrate the 
cytotoxic effect of diesel emissions on pHBECs. Future research will test multiple exposure 
times to determine whether NAC can protect HBEC viability after diesel emissions exposure.  
 
7.5 Conclusion 
This study has shown evidence that bronchial epithelial cells from COPD patients may be 
vulnerable to diesel emission exposure due to reduced antioxidant capacity and heightened 
CYP1A1 mRNA expression. NAC was not an effective intervention against the adverse effects 
of COPD. These findings provide new insight into the epithelial responses of the COPD lung 
to diesel emission exposure. Future research will focus on characterising the epithelial immune 
phenotype in the COPD lung and other means of restoring anti-oxidant capacity in COPD 
airways. 
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Chapter 8:  Identification of potential novel targets for 
intervention from the COPD lung transcriptome 
 
8.1 Aims and hypothesis 
Rationale 
Environmental exposures have been shown to have a strong impact on the gene expression 
profiles of lung tissue. For instance, the lungs of smokers have a similar gene expression profile 
to patients with moderate COPD [72]. Current therapeutic interventions for COPD include 
bronchodilators, antibiotics and corticosteroids [8]. These interventions work to reduce airflow 
obstruction, suppress inflammation and prevent exacerbation. There are currently no 
therapeutic interventions to protect vulnerable lungs from the adverse effects of diesel emission 
exposure. The aim of this study is to identify potential novel targets for intervention by 
transcriptomic profiling of the COPD lung. 
 
8.2 Methods 
Participants 
This study included 24 lung cancer patients with or without COPD (summarised in Table 8-1). 
Out of the 24 participants, 8 patients had lung cancer without COPD and 16 patients had lung 
cancer with COPD. Patients with COPD were classified by chronic airflow obstruction 
consistent with COPD (FEV1/FVC <70%). All the patients were matched for age and smoking 
history. Clinical data was obtained from the UQTRC Tissue Bank database: age, sex, smoking 
history, respiratory function tests (spirometry, gas transfer) and lung cancer histology. 
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Table 8-1: Summary of participants’ personal and clinical demographics 
 
Cohort 
Lung cancer 
histology Smoking status 
Smoking 
History (Pk 
yrs.) Age at Surgery Gender FEV1|FVC% 
Non-
COPD  
(n=9) Adenocarcinoma 
Past (n=4)  
Current (n=5) 
41.78  
SD=21 
59.89  
SD=6.81 
F=7 
M=2 
78.08 
SD=4.51 
COPD  
(n=15) Adenocarcinoma 
Past (n=9)  
Current (n=6) 
57.89   
SD=11.67 
68.22  
SD=5.89 
F=7 
M=8 
49.36  
SD=5.8 
 
Sample collection 
Fresh frozen lung tissue samples were collected from resected specimens donated by patients, 
with written informed consent, after surgery for removal of non-small cell lung cancer, 
specifically adenocarcinoma. These samples were collected by a pathologist from the lung 
tissue which is the most distal from the resected tumour. The samples were immediately frozen 
in liquid nitrogen and stored at -80°C. 
 
Nuclei acid extraction 
Lung tissue samples were homogenised and lysed using the Qiagen TissueRuptor and RLT 
buffer. Using the initial genomic DNA isolation filtration step from a Qiagen AllPrep 
DNA/RNA mini kit, the flow through was collected and used for the extraction of total RNA 
using the Ambion mirVana total RNA isolation kit. RNA was quantified using Qubit RNA 
HS assay kit. Quality assessment was performed by measurement of A260/A280 (>1.75 
indicating good quality) and A260/A230 ratios (>1.75 indicating good quality), representing 
Nucleic acid/protein and Nucleic acid/contaminant absorbance, respectively. 
 
RNAseq 
Targeted transcriptome profiling was performed using Ion AmpliSeq Transcriptome Human 
Gene expression kit on the Ion Proton sequencer. This platform is a 21000plex RT-PCR, with 
1 primer set for each gene, spanning 2 exons. This targeted transcriptome work was performed 
by Richard Allcock from the University of Western Australia as a part of a sequencing grant 
awarded to Dr Felicia Goh by Life Technologies. 
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8.3 Results 
The global transcriptomic profile of the COPD lung versus non-COPD lung is illustrated in a 
heat map (Figure 8-1). The transcriptome for the non-COPD lung and the COPD lung were 
comparable, with no obvious clustering for the disease pathology, gender or age. Differential 
gene expression analysis identified 16 genes with significantly altered gene expression levels 
when comparing between the non-COPD lung and the COPD lung. Annotations of gene-
protein associated function can be found in  
 
 
 
 
 
 
 
 
 
 
 
 
Table 8-2. These 16 differentially expressed genes can be categorised into 4 groups relating to 
COPD pathogenesis, cancer/oncogenesis, cell growth and more generalised or ubiquitous 
functions. The gene expression data is summarised in Table 8-3. 
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Figure 8-1: Targeted gene expression profile of lung tissue from lung cancer patients with 
and without COPD.  
 
 
In the COPD pathogenesis group, IFNAR1, TAPT1, CSF3 and LANCL1 were identified as 
differentially expressed when comparing between the non-COPD and COPD lung. There was 
a significant reduction in expression of IFNAR1 (P=0.0044), TAPT1 (P=0.0044), CSF3 
(P=0.019) and LANCL1 (P=0.02) in the COPD lung. In the cancer/oncogenesis group, BRMS1, 
PTPN12, PDGFB, HDGFRP2 and AFF3 were identified as differentially expressed when 
comparing between the non-COPD and COPD lung. There was a significant reduction in 
expression of PTPN12 (P=0.0044), PDGFB (P=0.023) and AFF3 (P=0.024), and a significant 
increase in expression of BRMS1 (P=0.0044) and HDGFRP2 (P=0.023) in the COPD lung. In 
the cell growth group, CDK2, GADD45GIP1 and SOCS2 were identified as differentia lly 
expressed when comparing between the non-COPD and COPD lung. There was a significant 
reduction in expression of CDK2 (P=0.012) and SOCS2 (P=0.0044), and a significant increase 
in expression of GADD45GIP1 (P=0.0075) in the COPD lung. 
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Table 8-2: Gene targets with significantly altered gene expression between lung cancer 
cohort with or without COPD 
Gene name Protein name Function 
IFNAR1 Interferon alpha/beta receptor 1 Interferon signalling 
TAPT1 Transmembrane anterior posterior 
transformation protein 1 
Cilia formation 
CSF3 Granulocyte colony-stimulating 
factor 
Increased expression in COPD 
LANCL1 LanC-like protein 1 Oxidative defence 
BRMS1 Breast cancer metastasis-suppressor 
1 
Suppresses metastasis 
PTPN12 Tyrosine-protein phosphate non-
receptor type 12 
Tumour suppression 
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PDGFB Platelet-derived growth factor 
subunit B 
Growth factor implicated in 
oncogenesis 
HDGFRP2 Hepatoma-derived growth factor-
related protein 2 
DNA repair after damage 
AFF3 AF4/FMR2 family member 3 Transcription factor – implicated in 
oncogenesis 
CDK2 Cyclin-dependant kinase 2 Cell cycle – promotes proliferation 
GADD45GIP1 Growth arrest and DNA damage-
inducible proteins-interacting 
protein 1 
Regulation of cell cycle, tumour 
suppression 
SOCS2 Suppressor of cytokine signalling 2 Cell growth and apoptosis 
SNRPD2 Small nuclear ribonucleoprotein 
Sm D2 
Involved in splicing cellular pre-
mRNA 
NEDD4 E3 ubiquitin-protein ligase Involved in ubiquitination -
degradation of proteins 
KRTCAP2 Keratinocyte-associated protein 2 Involved in the glycosylation of 
proteins 
NECAP1 Adaptin ear-binding coat-associated 
protein 1 
Involved in endocytosis 
 
Table 8-3: Changes in expression of identified gene targets in the COPD lung. 
Gene name Log2 Fold Change Adjusted P-value 
COPD pathogenesis 
IFNAR1 -0.31 0.0044 
TAPT1 -0.56 0.0044 
CSF3 -0.71 0.019 
LANCL1 -0.30 0.020 
Cancer/oncogenesis 
BRMS1 0.36 0.0044 
PTPN12 -0.46 0.0044 
PDGFB -0.65 0.023 
HDGFRP2 0.27 0.023 
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AFF3 -0.57 0.024 
Cell growth (cell cycle, proliferation, apoptosis) 
CDK2 -0.30 0.012 
GADD45GIP1 0.33 0.0075 
SOCS2 -0.95 0.0044 
General or ubiquitous functions 
SNRPD2 0.28 0.015 
NEDD4 -0.49 0.034 
KRTCAP2 0.27 0.043 
NECAP1 -0.27 0.045 
 
 
Figure 8-2: Expression levels of genes related to COPD pathogenesis: a) CSF3, b) 
IFNAR1, c) LANCL1, and d) TAPT1. 
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Figure 8-3: Expression levels of genes related to cancer/oncogenesis: a) BRMS1, b) 
HDGFRP2, c) PTPN12, d) AFF3, and e)PDGFB. 
 
Figure 8-4: Expression levels of genes related to cell cycle (cell growth, proliferation and 
apoptosis): a) SOCS2, b) CDK2 and c) GADD45GIP1. 
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8.4 Discussion 
Main results 
This study found 16 differentially expressed genes in the COPD lung, when compared to the 
non-COPD lung. These genes have been categorised into 4 groups related to function and 
disease; 4 genes (IFNAR1, TAPT1, CSF3 and LANCL1) may be associated with COPD 
pathogenesis, 5 genes (BRMS1, PTPN12, PDGFB, HDGFRP2 and AFF3) may be associated 
with cancer/oncogenesis, 3 genes (CDK2, GADD45GIP1, and SOCS2) are associated with cell 
growth (cell cycle, proliferation and apoptosis) and 4 genes (SNRPD2, NEDD4, KRTCAP2 
and NECAP1) are related to a general or ubiquitous cellular functions. The genes allocated to 
the general or ubiquitous group have a protein-associated function that can be found 
ubiquitously within most cell types and mediates general cell functions including the 
degradation of protein, regulation of protein production and endocytosis. Therefore, these 
genes were not considered as candidates as a potential target for intervention, except PDGFB, 
which has been linked to airway remodelling. The aim of this study is to identify potential 
targets for intervention against diesel emissions exposure in the COPD lung; therefore, genes 
related to cancer and oncogenesis were also excluded as potential targets. Therefore, 8 genes 
will be discussed as potential targets for intervention against diesel emission exposure in COPD.  
 
IFNAR1 
IFNAR1 is the gene encoding the interferon-alpha/beta receptor alpha chain, which is one of 
two chains in the receptor for interferon alpha and beta. Hence, IFNAR1 is a gene directly 
involved in interferon signalling. Cytokines that belong to the family of type 1 interferons (IFN) 
protect the host against viruses and tumours [168]. IFN acts on cells through engaging a cell 
surface receptor (formed by IFNAR1 and IFNAR2 chains) and subsequent stimulation of the 
signal transduction cascade, including the activation of the Janus kinases (JAK) and signa l 
transduction and activators of transcription (STAT1/2) proteins [169]. The latter interact with 
IRF9 to form a specific transcriptionally active complex capable of inducing a plethora of IFN-
stimulated proteins that act in concert to mediate the anti-viral, anti-tumorigenic and 
immunomodulatory effects of IFNs. As viral infections are a common trigger for COPD 
exacerbations, interferon signalling may be a key protective mechanism involved in the 
prevention and severity of COPD exacerbations [170]. Additionally, inflammatory stimuli such 
as IL1β and TNFα trigger IFNAR1 phosphorylation, ubiquitination and degradation [171], 
independently of IFN. This can deprive cells of the ability to respond to a future encounter with 
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IFN in vitro [171-173]. This is counterintuitive for host defence as it may limit the anti-vira l 
benefits of endogenously produced IFN if the airways are inflamed [174] which may increase 
susceptibility to viral infections. COPD patients are susceptible to viral infections [170], which 
may be due in part to smoking induced impairment of interferon release [175]. In a mouse 
model of COPD, persistent rhinovirus infection was reported alongside increased airway 
inflammation and deficient induction of interferons [176]. Additionally, BAL cells from COPD 
patients were infected ex vivo with rhinovirus. These cells were also deficient in inducing 
interferon signalling [177]. This study has shown a significantly lower level of IFNAR1 
expression in the COPD lung, when compared to the non-COPD lung. This lower level of 
IFNAR1 expression may reduce the availability of this IFN receptor component, which may 
produce a deficiency in IFN signalling in the COPD lung, in accordance with previous research. 
Targeting IFNAR1 in order to increase IFN signalling and associated anti-viral effects may be 
a potentially useful intervention to protect against exacerbations in COPD. 
 
 
 
TAPT1 
TAPT1 is the gene encoding transmembrane anterior posterior transformation 1 protein. In a 
study by Symoens (2015), it was established that TAPT1 localises to the ciliary basal body and 
is essential for normal primary cilia formation [178]. Primary cilia are a cellular organelle 
which plays a critical role in COPD pathogenesis through airway remodelling [179] and 
mucociliary dysfunction [180]. Mucociliary clearance is essential for the capture, degradation 
and clearance of inhaled pathogens and foreign agents. Mucociliary dysfunction is responsible 
for the build-up of excess mucus in the airways in COPD. Tissue injury can damage the ciliary 
epithelial cell, resulting in cell death. These ciliary epithelial cells are replenished by the 
differentiation of basal cells. Therefore, under-expressed or defective TAPT1 may result in 
poor ciliary formation during tissue repair and contribute to the mucociliary formation in 
COPD. In this study, it was found that TAPT1 is under-expressed in the COPD lung, when 
compared to non-COPD lung. Research into the regulation of TAPT1 expression in COPD and 
its effects of tissue repair and primary ciliary formations may reveal TAPT1 as a novel target 
for intervention. 
 
CSF3 
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CSF3 is the gene ending for granulocyte colony-stimulating factor, which initiates the 
production and differentiation of granulocytes. Granulocyte colony-stimulating factor mediates 
the survival and proliferation of neutrophils. Neutrophils and CSF3 have been implicated in 
the pathogenesis of COPD. For instance, there is an association between genetic alterations of 
CSF3 and lung function in smoking- induced COPD. Additionally, genetic alterations of the 
CSF gene increase the odds ratio associated with low lung function (OR=0.73) [181]. This 
association between CSF3 and COPD may be a result of CSF3s mediation of neutrophil 
survival and proliferation. CSF3 may promote the infiltration of neutrophils into the lung [182]. 
A high level of neutrophils in the airways is a common pathogenic marker in COPD [183]. 
Neutrophils secrete neutrophil elastase which has been implicated in the pathogenesis of COPD 
[184]. This study has shown a reduced level of expression of CSF3 in the COPD lung tissue 
versus the non-COPD lung tissue. This maybe a defensive response to a high neutrophil 
presence, which is common in the COPD lung. As CSF3 is a mediating factor in a key 
pathogenic pathway of COPD, this gene is potential target for intervention against the 
development and progression of COPD. 
 
 
LANCL1 
LANCL1 is the gene encoding lanthionine synthase C-like protein 1 (LanCL1) [185]. LanCL1 
is a sensor of oxidative stress and a regulator of cystathionine B-synthase (CBS), which is 
important for glutathione (GSH) synthesis [186]. GSH is the most abundant antioxidant in 
mammalian cells and plays a role in maintaining intracellular redox homeostasis and 
intracellular defence against oxidative stress. LanCL1 catalyses the first of two steps in the 
transsulfuration pathway that converts homocysteine to cysteine [187], a precursor for GSH. 
LanCL1 also binds directly to GSH [188]. LanCL1 mRNA and protein are most abundantly 
expressed in the brain [189]. To date, most of the work shows that LANCL1 is involved in the 
oxidative defence of neuronal cells [186, 190]. Loss of LanCL1 caused progressive oxidative 
damage and neuronal death [190]. Oxidative stress is one of the main drivers of tissue injury 
in the airways after insult and drives the pathogenies of COPD. This study has shown that there 
is a lower level of expression of LANCL1 in the COPD lung, when compared to the non-COPD 
lung. As a potential target for intervention to against diesel emission exposure and prevent 
COPD pathogenesis, the regulation of LANCL1 expression and LanCL1 activity may be 
protective in the COPD lung. 
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CDK2 
CDK2 is the gene encoding cyclin dependant kinase 2. Cyclin dependent kinase 2 is a catalyt ic 
subunit of the cyclin dependent kinase complex, and is essential for the G1/S transition in cell 
cycle regulation and promotes cell proliferation. Risk factors for COPD including cigarette 
smoke can cause DNA damage, resulting in the increased expression of CDK inhibitors and 
cell cycle arrest [166, 191], which is an indicator of cell ageing. COPD is considered a disease 
of accelerated lung aging caused by oxidative stress leading to DNA damage, cell cycle arrest 
or reduced proliferation and a process called non-programmed aging [192]. This study showed 
a reduced expression of CDK2 in the COPD lung, when compared to the non-COPD lung. As 
a potential target for intervention against diesel emission exposure, CDK2 expression and 
activity were increased, and may recover cell proliferation and slow the aging of the lung 
caused by cigarette smoke and other environmental risk factors.  
 
PDGFB 
PDGFB is the gene encoding platelet-derived growth factor (PDGF), which is a growth factor 
that regulates cell growth and division. PDGF is known to be a potent stimulant of airway 
skeletal muscle proliferation (ASM) [193, 194].  ASM hypertrophy occurs in the small airways 
[195]. Hence, ASM hypertrophy may contribute to airway wall remodelling, and the 
pathogenesis of COPD [196]. As COPD severity increases, so does the airway smooth muscle 
mass [196]. Airway smooth muscle cells can also produce inflammatory cytokines, proteases 
and growth factors which can further contribute to airway remodelling [196]. Regulation of 
this protein and gene expression can assist in preventing COPD pathogenesis. 
 
GADD45GIP1 
GADD45GIP1, also known as CRIF1, encodes growth arrest and DNA-damage-inducib le, 
gamma interacting protein 1. Expression of GADD45GIP1 decreases cell proliferation and 
increases apoptosis. In this study, GADD45GIP1 expression is upregulated in the COPD lung 
versus the non-COPD lung. This gene may moderate oxidative stress through the interact ion 
with the mitochondrial membrane [197]. This gene has been implicated in antioxidant defence 
of alveolar type 2 cells in emphysema [198]. As a potential target for intervention against the 
adverse effects of diesel emission exposure, the regulation of GADD45GIP1expression and 
activity may support oxidative defences in the airway epithelium and prevent tissue injury from 
oxidative stress. 
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SOCS2 
SOCS2 encodes the suppressor of cytokine 2 protein. SOCS2 is a negative regulator of the 
growth hormone-STAT5 pathway [199]. COPD patients have elevated plasma growth 
hormone levels[200]. The role of SOCS2 in COPD is unknown, but the SOCS2 growth 
hormone-STAT5 axis has been implicated in the development of cancer [201, 202]. This study 
found that there was a lower level of SOCS2 expression in the COPD lung, when compared to 
the non-COPD lung. As a negative regulator of the growth hormone-STAT5 pathway, SOCS2 
may be linked to the increased plasma growth hormone levels in COPD. Increased growth 
hormone levels may be linked to pathogenic mechanisms including airway remodelling. As a 
potential target for intervention against the development and progression of COPD, regulat ing 
SOCS2 expression may positively regulate growth hormone levels and the potential side-
effects from elevated levels.  
 
Limitations 
There are some limitations to this study that need to be addressed. Firstly, the genes that have 
been discussed in this study have not been validated with quantitative PCR methods. 
Transcriptome profiling can produce false positives. Therefore, it is important to validate the 
expression changes with qPCR, a more robust and targeted technique. In this study, this 
validation step has not been performed. However, prior to any future intervention studies, these 
genes should be validated. This discussion has focused on summarising previous research on 
these genes that may be relevant to COPD and the potential for these targets as interventions. 
The identification of these genes has highlighted genes that may play a role in COPD 
pathogenesis and deserve further validation and investigation as potential targets for 
intervention. The other limitation of this study is that the samples were from lung cancer 
patients, which will have a strong influence on the gene expression profiles. However, both the 
cohorts were lung cancer patients with adenocarcinoma and the global transcriptome profiles 
were comparable. Therefore, any differentially expressed genes are likely due to the presence 
of COPD. 
 
8.5 Conclusions 
Transcriptomic profiling of the COPD lung in comparison to non-COPD lung has revealed 16 
differentially expressed genes. 8 genes relating to interferon signalling, cilia formation, 
immune cell proliferation and differentiation, cell cycle regulation and oxidative defences have 
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been identified as potential targets for intervention. Future research will validate these genes 
using quantitative PCR, and investigate validated genes as potential targets for intervention 
against COPD development and progression after diesel emissions exposure.  
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Chapter 9:  Discussion 
9.1 Main findings 
This study has produced four main results. Firstly, HBEC responses to diesel emissions are 
dependent on the physical and chemical composition of the emissions. Secondly, biodiesel 
emission exposure may be a safe alternative to diesel emissions with limitations on the 
percentage substitution with vegetable oils. Thirdly, antioxidant intervention may attenuate the 
adverse effects of diesel emission exposure to HBECs. And lastly, transcriptomic profiling of 
the COPD lung identified 8 potential targets for future intervention studies. These findings 
were established by addressing 6 aims of this PhD:  
 Aim 1 was to investigate the role of diesel organic content on mediating cellular 
responses of primary HBECs cultured at ALI. This study showed that diesel with or without 
organic content play an important role in determining HBEC responses in vitro. 
 Aim 2 was to compare the effects of biodiesel and triacetin/biodiesel emission 
exposure on primary HBECs compared to neat diesel emission exposure at ALI. This study 
showed that biodiesel substitution in diesel fuel and triacetin substitution in biodiesel can 
increase the adverse effects of diesel emissions of primary HBECs.  
 Aim 3 was to test whether coconut oil substitution in diesel fuel reduces the adverse  
effect of diesel emission exposure on immortalised bronchial epithelial cells, 16HBE. This 
study found that low to moderate substitution of raw coconut oil in diesel fuel reduced the 
adverse effect of diesel emissions on 16HBE cells, whereas high percentage substitut ion 
heightened the adverse effect. 
 Aim 4 was to test the effectiveness of post-exposure treatment of an antioxidant, 
N-acetylcysteine (NAC), in reducing the adverse effects of diesel emission exposure on 
immortalised bronchial epithelial cells, 16HBE, at ALI. Post-exposure antioxidant intervention 
with 5mM NAC potentiates, rather than reduces, adverse cellular responses of 16HBE cell to 
diesel emission exposure. 
 Aim 5 was to test the effectiveness of a therapeutic antioxidant, N-acetylcyste ine 
(NAC), as a protective intervention against the adverse effect of diesel emission exposure on 
primary HBECs from a COPD cohort. This study showed that NAC intervention was not an 
effective intervention against the adverse effects of COPD. 
 Aim 6 was to investigate potential novel targets for intervention by transcriptomic 
profiling of the COPD lung. 8 differentially expressed genes were identified as potential targets 
for interventions against diesel emission exposure and COPD progression. 
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9.2 Different fuels and their effects 
Diesel emissions are a major contributor to outdoor air pollution and more specifically, 
particulate matter pollution [18]. Diesel particulate matter is considered the more toxic 
component of diesel emissions as these particles are considered more biologically active due 
to absorbed organic content on the particle [18]. Interventions to reduce the diesel particula te 
matter include the use of biodiesels and fuel additives such as triacetin [60, 61].  This PhD has 
studied the effect of conventional diesel compared to altered diesel emissions includ ing 
residual diesel emissions (without organic content), coconut oil-substituted diesel (raw oil 
blended with diesel), biodiesel derived from coconut oil (transesterified coconut oil blended 
with diesel) and biodiesel/triacetin blends. These are common alternative fuel blends used 
globally due to the cost-effectiveness or the availability of the biodiesel or additive. Coconut 
oil-substituted diesel and coconut oil biodiesel are a common alternative diesel used in Asia, 
due to the strong coconut oil production, making coconut oil readily available as a fuel 
substitute [64, 203]. Triacetin effectively increases the oxygen content of biodiesel fuel and 
can be made from the by-products of biodiesel production, making is a viable fuel additive for 
biodiesel [66]. These alternative fuels are considered a safer alternative to diesel emissions due 
to the emissions containing less particulate matter content, when compared to conventiona l 
diesel. Particulate matter and its absorbed organic content are believed to be a major diesel 
component, which drives the adverse effects of diesel emission exposure [18]. Hence, reducing 
the particulate matter may reduce the adverse effects of diesel emission exposure. 
Unfortunately, very little is known about the adverse effects of these alternative diesel 
emissions on the airways.  
 
Throughout this PhD, exposure to these alternative diesel emissions have consistently resulted 
in unaltered or worsened adverse effects on HBECs when compared to conventional diesel 
emissions (summarised in Table 9-1). This conclusion was derived from four key findings (aim 
1-3): 
 Firstly, diesel emission exposure has resulted in an increase in inflammation, 
antioxidant production and xenobiotic metabolism. The diesel emission dose (average particle 
mass) and exposure times were not sufficient to significantly alter cell viability. These results 
are consistent with previous research demonstrating that diesel emission exposure increases 
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inflammation, increases oxidative defences and induces xenobiotic metabolism in HBECs [53, 
79-81, 83, 138].  
 Secondly, the removal of organic content from the diesel PM worsened HBEC 
responses to diesel emissions. This finding contradicts previous research which suggests that 
diesel organic content is a major toxic component of diesel emissions [88, 98, 152, 204]. 
Libalova (2016) has shown that exposure to diesel organic extracts decreases cell viability, 
increases oxidative defences and induces xenobiotic metabolism [205]. Therefore, it was 
expected that the removal of organic content from the diesel PM would improve the cell 
response to diesel emissions; however, there was an increase in inflammation, antioxidant 
production and xenobiotic metabolism. Similarly, Totlandsdal (2012) showed an increase in 
xenobiotic metabolism after the removal of organic content from diesel PM [82]. However, 
this study also showed that diesel PM without organics had a reduced inflammatory effect on 
HBECs compared to diesel emissions [82]. The results of the current and previous studies 
highlight our lack of understanding of how diesel emission exposure leads to these adverse 
effects in HBECs.  
 Thirdly, there was a limited but positive effect of low percentage coconut oil-
substituted diesel (10%) on HBEC responses to biodiesel emissions, compared to conventiona l 
diesel emissions. Exposure to low percentage coconut oil-substituted diesel resulted in an 
increase in antioxidant production and xenobiotic metabolism. This was an expected and 
‘healthy’ reaction to diesel emission exposure as the cells work to maintain oxidative balance 
by producing antioxidants and remove the foreign agents by inducing xenobiotic metabolism. 
HBEC viability was maintained after exposure to low percentage coconut oil-substituted diesel. 
In accordance with this, Barrand (2017) found that 7% rapeseed oil biodiesel attenuated the 
loss of cell viability that resulted from exposure to conventional diesel emissions [123]. These 
studies indicate that alternative diesels with a low-percentage substitution of vegetable oils may 
be a safer alternative to diesel emissions. 
 Lastly, exposure to high percentage coconut oil-substituted diesel (20%) resulted 
in a loss of cell viability, increased inflammation, increased antioxidant production and 
xenobiotic metabolism. These responses were also seen after exposure to coconut oil biodiesel 
and triacetin/biodiesel blends. In accordance with this, previous research has shown that 
various vegetable oil-derived biodiesels have heightened adverse effects on HBECs when 
compared to conventional diesel. For instance, Hawley (2014) exposed differentiated normal 
HBECs to diesel and commercial grade B99 biodiesel emissions. This study found that 
biodiesel emissions elicited a greater cellular response through the production of biomarkers 
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for oxidative stress and xenobiotic metabolism, when compared to conventional diesel. 
Additionally, Mehus (2015) exposed health subjects to conventional diesel and 75% soy 
biodiesel. This biodiesel exposure resulted in a higher level of inflammatory markers in plasma 
and sputum samples when compared to those exposed to conventional diesel [206].  Therefore, 
high percentage biodiesel emissions (>20%) can be more harmful than diesel emissions. It has 
been hypothesised that this may be due to the fatty acid content [207]. The fatty acids can 
accumulate in the cells and aggregate the lipophilic xenobiotics such as PAH [207]. This allows 
the PAH to have a prolonged presence in the cells, which can potentiate the adverse effects of 
these compounds [207].  
 In summary, these results, in accordance with previous research, suggest that 
biodiesel emissions with low percentage vegetable oil substitution may have a positive effect 
on HBEC responses compared to diesel emissions. However, our results suggest a limitat ion 
on the maximum percentage of vegetable oil substitution that can be used in biodiesel before 
adverse effects may occur, at least for HBEC exposure. The increased fatty acid and organic 
content of high percentage vegetable oil biodiesel can potentially heighten the adverse effect 
of diesel emissions.   
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Table 9-1: Summary of HBEC responses to conventional diesel and alternative diesel 
emission exposure. 
Fuel type HBEC type 
Cell 
viability Inflammation 
Antioxidant 
production 
Xenobiotic 
metabolism 
Diesel # Immortalised - ↑   -  ↑ 
Diesel # Primary - COPD - ↑ ↑  
Diesel # Primary - ↑ ↑ ↑ 
Residual diesel (no 
organics) *# Primary - ↑ ↑ ↑ 
Low % coconut oil-
substituted diesel *# Immortalised - -  ↑  ↑ 
High % coconut oil-
substituted diesel *# Immortalised ↓  ↑  ↑  ↑ 
Coconut oil biodiesel 
*#  Primary ↓  ↑  ↑  ↑ 
Coconut oil biodiesel 
with triacetin *#  Primary ↓  ↑  ↑  ↑ 
*Indicates a comparison with conventional diesel emissions  
# Indicates a comparison with the filtered air control 
 
9.3 NAC intervention 
NAC treatment has been shown to decrease inflammation and oxidative stress in COPD [128], 
and therefore could be a plausible intervention to use against the adverse effects of diesel 
emission exposure in the lungs. Inflammation and oxidative stress are key cellular responses 
to diesel emissions [18]. If prolonged these cellular responses are attributed to the pathogenesis 
of COPD [5]. This PhD has investigated NAC as a potential intervention to reduce the adverse 
effect of diesel emissions on bronchial epithelial cells and protect the COPD lung from diesel 
emissions exposure. This study has shown that NAC may effectively protect against the 
adverse effects of diesel emissions (results summarised in Table 9-2).  
 In the collated cohort of 25 primary HBEC lines, NAC intervention after diesel 
emissions exposure decreased inflammation, antioxidant production and xenobiot ic 
metabolism. These effects were not statistically significant when compared to diesel emission 
exposure without NAC intervention. However, the effect of diesel emission exposure alone 
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was minimal. Without a strong response signal after diesel emission exposure, it is difficult to 
determine the magnitude of response to NAC intervention. Nevertheless, the effect of NAC 
intervention did show a trend for attenuation of adverse cellular responses after diesel 
emissions exposure. These findings are in accordance with previous research [134, 208] [163]. 
Kumar (2016) has shown that NAC treatment can effectively reduce oxidative stress-induced 
inflammation in vitro [163].  
 In the COPD cohort, NAC intervention had no effect on the HBEC response to 
diesel emissions except to show a slight reduction in xenobiotic metabolism. This suggests that 
NAC intervention may not be an effective intervention against the adverse effects of diesel 
emission exposure in the COPD lung. In contrast to this, Wang (2015) found that NAC 
intervention can reduce inflammation, oxidative stress and overall pulmonary damage after 
exposure to cigarette smoke exposure [134]. Additionally, Rogliani (2016) demonstrated that 
in an ex vivo model of COPD exacerbation, NAC intervention can improve oxidative imbalance  
of the bronchial tissue [208]. These findings suggest NAC intervention may protect the COPD 
lung from the adverse effects of diesel emission exposure, and the in vitro model used in the 
present study is inadequate for the accurate study of NAC intervention in COPD.  
 NAC may have the potential to protect against tumour-like or pre-malignant cells 
after diesel emission exposure. This PhD has shown that NAC intervention has a toxic effect 
on immortalised HBECs. These cells have a tumour- like phenotype through an enhanced 
proliferative ability, similar to pre-malignant cells. Diesel emissions are a human carcinogen 
and diesel emission exposure has been associated with an increased risk of lung cancer [209]. 
Bassig (2017) has compared plasma immunological markers of human subjects after exposure 
to diesel emissions and found changes associated with an increased risk of lung cancer [210]. 
This effect of NAC on tumour-like cells may be a potential protective effect against the growth 
and proliferation of pre-malignant cells after diesel emissions exposure.  
 In summary, NAC intervention may protect against the adverse effects of diesel 
emission exposure on HBECs in vitro and in the COPD lung. NAC intervention may also 
protect against the growth and proliferation of pre-malignant cells. COPD is a major risk factor 
for lung cancer, so future experiments could explore NAC intervention in COPD as a possible 
protective intervention against the development of lung cancer in COPD patients. 
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Table 9-2: Summary of HBEC response to diesel emissions with a NAC post-exposure 
intervention, compared to diesel emission exposure without NAC intervention. 
HBEC type 
Cell 
viability Inflammation 
Antioxidant 
production 
Xenobiotic 
metabolism 
Immortalised (tumour-like)  ↓  ↑   ↑   - 
Primary – collated cohort  -  ↓  ↓  ↓ 
Primary – COPD cohort - - - ↓ 
 
9.4 Novel targets for intervention 
Transcriptomic profiling has revealed 16 differentially expressed genes in the COPD lung 
compared to the non-COPD lung. 8 genes relating to mechanisms of COPD pathogenesis and 
cell cycle have been identified as potential targets for intervention. Of these 8 genes, IFNAR1, 
TAPT1, CSF3, PDGFB and SOCS2 are associated with key mechanisms in the pathogenesis 
of COPD including interferon signalling, cilia formation, neutrophil activity, and airway 
remodelling. LANCL1 and GADD45GIP1 have been associated with the maintenance of 
cellular oxidative balance. Finally, CDK2 is associated with cellular ageing. A summary of 
how these genes may participate in exacerbations and the pathogenesis of COPD is provided 
in Figure 9-1. These genes still need to be validated by qPCR; nonetheless, future research will 
investigate validated genes as potential targets for intervention against the adverse effects of 
diesel emission exposure and the development and progression COPD.  
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Figure 9-1: Schematic of the events involved in COPD exacerbation (red), COPD 
pathogenesis (blue) and points in which identified gene targets (green) may be involved. 
 
9.5 Types of outcome measures 
This PhD investigated the effect of conventional diesel and alternative diesel emissions on 
pHBECs through the measurement of classical cell responses to external stressors; 
inflammation, antioxidant production (indicator of oxidative defences to oxidative stress), 
xenobiotic metabolism and cell viability. These cellular responses are triggered by many 
noxious inhalants that are considered risk factors for COPD including cigarette smoke, dust, 
fumes and biomass smoke [59, 211-213]. These are also common epithelial cell responses 
which are dysregulated and perpetuated in COPD pathogenesis [6, 16, 170]. Hence, studying 
the effects of different interventions (alternative diesel fuels or NAC treatment) on these 
responses is essential to determine the impact of these interventions on disease pathogenesis. 
Other outcomes which this PhD did not measure include cell adhesion, DNA damage and repair, 
mitochondrial dysfunction, cell migration, genotoxicity and mutagenicity. Immune cell 
migration, DNA damage and repair and mitochondrial dysfunction are all key pathways which 
have been altered in the pathogenesis of COPD [6, 16, 170]. Dysregulation of cell adhesion, 
DNA damage and repair, genotoxicity and mutagenicity are all processes associated with the 
development and progression of lung cancer [214-216]. These outcomes would also be 
insightful about whether these interventions are effective in preventing the development and 
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progression of COPD. However, this PhD has focused on the key cellular responses associated 
with diesel emission exposure and COPD pathogenesis. Also, the use of ALI culture does have 
limitations in the type of testing and analysis that can be performed after exposure, due to 
sample size (protein and nucleic acid content) and the culture vessel itself. Future research will 
endeavour to include these additional outcomes, to allow more comprehensive assessment of 
the toxic effects of diesel fuels on bronchial epithelial cells.   
 
9.6 Pros and cons of different cell models 
The classical model for the study of diesel emission toxicity is the submerged cell culture model, 
where diesel exhaust particles are collected on a filter, isolated and submerged in cell culture 
media where they are then administered to the cells. This model introduces numerous 
limitations to the study of diesel emission toxicity on bronchial epithelial cells as the 
suspension of particulate matter in media may alter the composition of the particles and the 
interaction between the particles and the cells.  Also, there may be components of the emissions 
are not collected on the filter, such as gas components, which are not represented in the diesel 
particulate matter solution. Therefore, these key components of the diesel emissions are not 
included in the toxicity testing. In addition to this, the submerged cell culture model is 
comprised of a cell monolayer with a basal cell phenotype, which does not accurately represent  
the airway epithelium. To overcome these limitations, this PhD has consistently used the air-
liquid interface cell culture method. This method produces a physiologically relevant cell 
culture model to test the effects of aerosol diesel and biodiesel emissions generated in real-time 
on differentiated bronchial epithelial cells. Air-liquid interface cell culture and aerosol 
exposure preserve the physical and chemical composition of the diesel emissions, as well as 
representing the airway epithelium more accurately than submerged cell culture methods. 
 
Previous research has shown that the cell response to diesel emissions is dependent on the 
exposure method [55]. There are significant differences in cell responses when the cells are 
administered with submerged particles versus aerosol emissions in real time. The use of air-
liquid interface culture has shown contrasting results to other studies using the classica l 
submerged culture [55]. Previous research using the classical submerged cell culture has shown 
that the organic component of diesel emissions is what triggers xenobiotic metabolism. 
However, using direct aerosol exposure, this PhD has demonstrated that the residual 
components (no organics) can also trigger xenobiotic metabolism. As xenobiotic metabolism 
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is a major contributor to endogenous ROS production and oxidative stress after diesel emission 
exposure, this finding provides essential insight into the way diesel emissions and its 
components interact with the airways. This model has also confirmed the findings of research 
using the submerged cell culture model. Diesel emission exposure increases inflammation, 
xenobiotic metabolism and antioxidant defences such as antioxidant production from HBECs.  
As the main objective of this PhD was to study the effects of diesel emissions and potential 
interventions such as biodiesel emissions and NAC intervention, it is essential to use the most 
physiologically relevant model of diesel emission exposure.  
 
 
9.7 Overall health effects and implications for public health 
The main findings of this PhD are that low percentage biodiesel substitution in diesel may 
reduce the adverse effects of diesel emissions and that NAC intervention may protect against 
pre-malignant cells and the adverse effects of diesel emission exposure. Diesel emission 
exposure is associated with increased risk of COPD [14]. Research has shown that the 
reduction in pollution in the occupational setting can significantly reduce the risk of COPD 
[217]. A decrease in particulate matter pollution has also been associated with respiratory 
health benefits [218]. For instance, the Swiss Study on Air Quality and Lung Diseases in Adults 
found that a reduction in PM10 by 5-6µg/m3 is associated with the attenuation in the annual rate 
of decline in lung function [219]and fewer reports of cough (regular and chronic), wheeze, and 
breathlessness in adults [220]. Additionally, a reduction in PM10 is associated with improved 
respiratory heath in children [221]. In a US cohort, a study found a strong association between 
reduced ambient PM and an increase in life expectancy by 2.7 years [222]. Therefore, biodiesel 
fuels which lower diesel PM pollution may positively impact COPD patients by reducing the 
burden of pollution in the airways, reducing risk of exacerbation and improving respiratory 
health outcomes.   In addition to this, the present study has demonstrated positive effects of 
NAC interventions after exposure to diesel emissions. This therapeutic antioxidant intervention 
may be beneficial for at-risk populations, such as individuals working in an occupation with a 
high risk of diesel emission exposure, i.e. construction and transportation [14]. These 
individuals have a greater exposure to PM pollution than the general population and may 
require additional intervention to the use of biodiesels. This PhD has shown that NAC 
intervention reduced the adverse effects of diesel emission exposure on bronchial epithelia l 
cells and may protect against pre-malignant cells after diesel emission exposure. Therefore, 
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intervention may potentially prevent the development of lung cancer and COPD in vulnerab le, 
at-risk populations.  
 
9.8 Conclusions 
By studying the effects of diesel emissions with varied physical and chemical compositions, 
this PhD project has improved our current understanding of how HBECs respond to diesel and 
biodiesel emissions, and how these responses impact on the COPD lung. Biodiesel emissions 
may be a safer alternative to diesel emissions with limitations on the percentage substitut ion 
with vegetable oils. Antioxidant therapy may attenuate the adverse effect of diesel emission 
exposure on HBECs. Both interventions have the potential to protect vulnerable populations 
from diesel emissions exposure. Intervention studies will continue to explore biodiesel blends 
that reduce diesel emissions and the adverse effects of diesel emission exposures and 
investigate the potential of NAC to protect against pre-malignant cells. Transcriptomic 
profiling of the COPD lung has identified novel targets for future intervention studies. Future 
research will look to validate these potential targets and assess their potential for intervention. 
These findings provide the foundation for testing interventions in other lung cell types 
including co-culture migration studies with inflammatory cells, testing in animal models for 
chronic air pollution exposure and finally, clinical intervention studies in patients. The 
successful identification of effective interventions for the development and progression of 
COPD may slow the progression of COPD, reducing COPD morbidity and mortality rates and 
overall burden of COPD. 
 
  
 
 
 138 
Chapter 10:  References 
1. Tam, A., et al., The airway epithelium: more than just a structural barrier. 
Therapeutic Advances in Respiratory Disease, 2011. 5(4): p. 255-273. 
2. Seriani, R., et al., Organic and inorganic fractions of diesel exhaust particles produce 
changes in mucin profile of mouse trachea explants. J Toxicol Environ Health A, 2015. 
78(4): p. 215-25. 
3. Lam, H.C., et al., Histone deacetylase 6–mediated selective autophagy regulates 
COPD-associated cilia dysfunction. The Journal of clinical investigation, 2013. 
123(12): p. 5212. 
4. Andersen, Z.J., et al., Chronic obstructive pulmonary disease and long-term exposure 
to traffic-related air pollution: a cohort study. American Journal of Respiratory and 
Critical Care Medicine, 2011. 183(4): p. 455-61. 
5. Shaw, J.G., et al., Biomarkers of progression of chronic obstructive pulmonary disease 
(COPD). Journal of Thoracic Disease, 2014. 6(11): p. 1532-1547. 
6. Yang, I.A., et al., Common pathogenic mechanisms and pathways in the development 
of COPD and lung cancer. Expert Opin Ther Targets, 2011. 15(4): p. 439-56. 
7. López-Campos, J.L., W. Tan, and J.B. Soriano, Global burden of COPD. Respirology, 
2016. 21(1): p. 14-23. 
8. GOLD, From the Global Strategy for the Diagnosis, Management and Prevention of 
COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2018. Available 
from: http://goldcopd.org/. 2018. 
9. Anzueto, A., S. Sethi, and F.J. Martinez, Exacerbations of chronic obstructive 
pulmonary disease. Proc Am Thorac Soc, 2007. 4(7): p. 554-64. 
10. Kim, J., et al., The health care burden of high grade chronic obstructive pulmonary 
disease in Korea: analysis of the Korean Health Insurance Review and Assessment 
Service data. Int J Chron Obstruct Pulmon Dis, 2013. 8: p. 561-8. 
11. Vos, T., et al., Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and 
injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 
2010. Lancet, 2012. 380(9859): p. 2163-96. 
12. Rabe, K.F., et al., Global Strategy for the Diagnosis, Management, and Prevention of 
Chronic Obstructive Pulmonary Disease. 2007. 176(6): p. 532-555. 
 
 
 139 
13. Blanc, P. and K. Toren, Occupation in chronic obstructive pulmonary disease and 
chronic bronchitis: an update [State of the Art Series. Occupational lung disease in 
high-and low-income countries, Edited by M. Chan-Yeung. Number 2 in the series]. 
The International Journal of Tuberculosis and Lung Disease, 2007. 11(3): p. 251-257. 
14. Hart, J.E., E.A. Eisen, and F. Laden, Occupational diesel exhaust exposure as a risk 
factor for COPD. Current opinion in pulmonary medicine, 2012. 18(2): p. 151. 
15. López‐Campos, J.L., W. Tan, and J.B. Soriano, Global burden of COPD. Respirology, 
2016. 21(1): p. 14-23. 
16. Postma, D.S., A. Bush, and M. van den Berge, Risk factors and early origins of chronic 
obstructive pulmonary disease. Lancet, 2015. 385(9971): p. 899-909. 
17. Künzli, N., et al., Public-health impact of outdoor and traffic-related air pollution: a 
European assessment. The Lancet, 2000. 356(9232): p. 795-801. 
18. Ristovski, Z.D., et al., Respiratory health effects of diesel particulate matter. 
Respirology, 2012. 17(2): p. 201-12. 
19. Gan, W.Q., et al., Associations of ambient air pollution with chronic obstructive 
pulmonary disease hospitalization and mortality. Am J Respir Crit Care Med, 2013. 
187(7): p. 721-7. 
20. Chen, Y., et al., Influence of Relatively Low Level of Particulate Air Pollution on 
Hospitalization for COPD in Elderly People. Inhalation Toxicology, 2004. 16(1): p. 21-
25. 
21. Li, M.-H., et al., Short-term Exposure to Ambient Fine Particulate Matter Increases 
Hospitalizations and Mortality in COPD: A Systematic Review and Meta-analysis. 
Chest, 2016. 149(2): p. 447-458. 
22. DeVries, R., D. Kriebel, and S. Sama, Outdoor Air Pollution and COPD-Related 
Emergency Department Visits, Hospital Admissions, and Mortality: A Meta-Analysis. 
COPD: Journal of Chronic Obstructive Pulmonary Disease, 2017. 14(1): p. 113-121. 
23. Becklake, M.R., Occupational exposures: evidence for a causal association with 
chronic obstructive pulmonary disease. Am Rev Respir Dis, 1989. 140(3 Pt 2): p. S85-
S91. 
24. Boschetto, P., et al., Chronic obstructive pulmonary disease (COPD) and occupational 
exposures. Journal of Occupational Medicine and Toxicology, 2006. 1(1): p. 11. 
 
 
 140 
25. Hnizdo, E., et al., Association between chronic obstructive pulmonary disease and 
employment by industry and occupation in the US population: a study of data from 
the Third National Health and Nutrition Examination Survey. American Journal of 
Epidemiology, 2002. 156(8): p. 738-746. 
26. Weinmann, S., et al., COPD and occupational exposures: a case-control study. Journal 
of occupational and environmental medicine, 2008. 50(5): p. 561-569. 
27. Li, D.-g., et al., Physico-chemical properties of ethanol–diesel blend fuel and its effect 
on performance and emissions of diesel engines. Renewable energy, 2005. 30(6): p. 
967-976. 
28. Ling, S.H. and S.F. van Eeden, Particulate matter air pollution exposure: role in the 
development and exacerbation of chronic obstructive pulmonary disease. 
International Journal of Chronic Obstructive Pulmonary Disease, 2009. 4: p. 233-243. 
29. Bayram, H., et al., The effect of diesel exhaust particles on cell function and release of 
inflammatory mediators from human bronchial epithelial cells in vitro. American 
Journal of Respiratory Cell and Molecular Biology, 1998. 18(3): p. 441-448. 
30. Boland, S., et al., Diesel exhaust particles are taken up by human airway epithelial 
cells in vitro and alter cytokine production. American Journal of Physiology-Lung 
Cellular and Molecular Physiology, 1999. 276(4): p. L604-L613. 
31. Boland, S., et al., Mechanisms of GM-CSF increase by diesel exhaust particles in 
human airway epithelial cells. American Journal of Physiology-Lung Cellular and 
Molecular Physiology, 2000. 278(1): p. L25-L32. 
32. Steerenberg, P.A., et al., Diesel exhaust particles induced release of interleukin 6 and 
8 by (primed) human bronchial epithelial cells (BEAS 2B) in vitro. Experimental Lung 
Research, 1998. 24(1): p. 85-100. 
33. Bayram, H., et al., Comparison of ciliary activity and inflammatory mediator release 
from bronchial epithelial cells of nonatopic nonasthmatic subjects and atopic 
asthmatic patients and the effect of diesel exhaust particles in vitro.  Journal of 
Allergy and Clinical Immunology, 1998. 102(5): p. 771-782. 
34. Ohtoshi, T., et al., Diesel exhaust particles stimulate human airway epithelial cells to 
produce cytokines relevant to airway inflammation in vitro. Journal of Allergy and 
Clinical Immunology, 1998. 101(6): p. 778-785. 
 
 
 141 
35. Sydbom, A., et al., Health effects of diesel exhaust emissions. European Respiratory 
Journal, 2001. 17(4): p. 733-746. 
36. Brusselle, G.G., G.F. Joos, and K.R. Bracke, New insights into the immunology of 
chronic obstructive pulmonary disease. The Lancet, 2011. 378(9795): p. 1015-1026. 
37. Li, N., et al., Ultrafine Particulate Pollutants Induce Oxidative Stress and 
Mitochondrial Damage. Environmental Health Perspectives, 2002. 111(4): p. 455-
460. 
38. Li, N., T. Xia, and A.E. Nel, The role of oxidative stress in ambient particulate matter-
induced lung diseases and its implications in the toxicity of engineered nanoparticles. 
Free Radic Biol Med, 2008. 44(9): p. 1689-99. 
39. Vibhuti, A., et al., CYP1A1, CYP1A2 and CYBA gene polymorphisms associated with 
oxidative stress in COPD. Clin Chim Acta, 2010. 411(7-8): p. 474-80. 
40. Durga, M., et al., Effects of ultrafine petrol exhaust particles on cytotoxicity, oxidative 
stress generation, DNA damage and inflammation in human A549 lung cells and 
murine RAW 264.7 macrophages. Environ Toxicol Pharmacol, 2014. 38(2): p. 518-30. 
41. Sundaresan, M., et al., Regulation of reactive-oxygen-species generation in 
fibroblasts by Rac1. Biochem. j, 1996. 318: p. 379-382. 
42. Sheppard, F.R., et al., Structural organization of the neutrophil NADPH oxidase: 
phosphorylation and translocation during priming and activation. Journal of 
leukocyte biology, 2005. 78(5): p. 1025-1042. 
43. Rahman, I. and W. MacNee, Role of oxidants/antioxidants in smoking-induced lung 
diseases. Free Radical Biology and Medicine, 1996. 21(5): p. 669-681. 
44. Franco, R., et al., Oxidative stress, DNA methylation and carcinogenesis. Cancer Lett, 
2008. 266(1): p. 6-11. 
45. Rahman, I. and W. MacNee, Lung glutathione and oxidative stress: implications in 
cigarette smoke-induced airway disease. American Journal of Physiology-Lung 
Cellular and Molecular Physiology, 1999. 277(6): p. L1067-L1088. 
46. Rahman, I. and W. MacNee, Role of transcription factors in inflammatory lung 
diseases. Thorax, 1998. 53(7): p. 601-612. 
47. Rahman, I., Oxidative stress in pathogenesis of chronic obstructive pulmonary 
disease. Cell biochemistry and biophysics, 2005. 43(1): p. 167-188. 
 
 
 142 
48. Russell, A. and W.S. Epling, Diesel Oxidation Catalysts. Catalysis Reviews, 2011. 53(4): 
p. 337-423. 
49. Caliskan, H. and K. Mori, Environmental, enviroeconomic and enhanced 
thermodynamic analyses of a diesel engine with diesel oxidation catalyst (DOC) and 
diesel particulate filter (DPF) after treatment systems. Energy, 2017. 128: p. 128-144. 
50. Silbajoris, R., et al., Ambient Particulate Matter Induces Interleukin-8 Expression 
through an Alternative NF-κB (Nuclear Factor-Kappa B) Mechanism in Human Airway 
Epithelial Cells. Environmental Health Perspectives, 2011. 119(10): p. 1379. 
51. Wijte, D., et al., Toxic effects following phosgene exposure of human epithelial lung 
cells in vitro using a CULTEX® system. Toxicology In Vitro, 2011. 25(8): p. 2080-2087. 
52. Aufderheide, M., et al., Analytical in vitro approach for studying cyto- and genotoxic 
effects of particulate airborne material. Analytical and Bioanalytical Chemistry, 2011. 
401(10): p. 3213-20. 
53. Tsukue, N., et al., Toxicological evaluation of diesel emissions on A549 cells. 
Toxicology in Vitro, 2010. 24(2): p. 363-369. 
54. Xiao, C., et al., Defective epithelial barrier function in asthma. Journal of Allergy and 
Clinical Immunology, 2011. 128(3): p. 549-556. e12. 
55. Holder, A.L., et al., Cellular response to diesel exhaust particles strongly depends on 
the exposure method. Toxicological Sciences, 2008. 103(1): p. 108-15. 
56. Aufderheide, M. and U. Mohr, CULTEX — an alternative technique for cultivation and 
exposure of cells of the respiratory tract to airborne pollutants at the air/liquid 
interface. Experimental and Toxicologic Pathology, 2000. 52(3): p. 265-270. 
57. Goh, F., et al., Personalizing and targeting therapy for COPD - the role of molecular 
and clinical biomarkers. Expert Rev Respir Med, 2013. 7(6): p. 593-605. 
58. Kooter, I.M., et al., Alveolar epithelial cells (A549) exposed at the air-liquid interface 
to diesel exhaust: First study in TNO's powertrain test center. Toxicol In Vitro, 2013. 
27(8): p. 2342-9. 
59. Mathis, C., et al., Human bronchial epithelial cells exposed in vitro to cigarette smoke 
at the air-liquid interface resemble bronchial epithelium from human smokers. 
American Journal of Physiology-Lung Cellular and Molecular Physiology, 2013. 
304(7): p. L489-L503. 
 
 
 143 
60. Lin, L., et al., Opportunities and challenges for biodiesel fuel. Applied Energy, 2011. 
88(4): p. 1020-1031. 
61. Zare, A., et al., The effect of triacetin as a fuel additive to waste cooking biodiesel on 
engine performance and exhaust emissions. Fuel, 2016. 182: p. 640-649. 
62. Kulkarni, M.G. and A. Dalai, Waste cooking oil-an economical source for biodiesel: A 
review, in Ind. Eng. Chem. Res. 2006. p. 2901-2913. 
63. Kalam, M.A., M. Husnawan, and H.H. Masjuki, Exhaust emission and combustion 
evaluation of coconut oil-powered indirect injection diesel engine. Renewable Energy, 
2003. 28(15): p. 2405-2415. 
64. Jayed, M.H., et al., Environmental aspects and challenges of oilseed produced 
biodiesel in Southeast Asia. Renewable and Sustainable Energy Reviews, 2009. 13(9): 
p. 2452-2462. 
65. Bünger, J., et al., Combusting vegetable oils in diesel engines: the impact of 
unsaturated fatty acids on particle emissions and mutagenic effects of the exhaust. 
Archives of toxicology, 2016. 90(6): p. 1471-1479. 
66. Casas, A., et al., Effects of Triacetin on Biodiesel Quality. Energy & Fuels, 2010. 24(8): 
p. 4481-4489. 
67. Pourkhesalian, A.M., et al., Influence of fuel molecular structure on the volatility and 
oxidative potential of biodiesel particulate matter. Environ Sci Technol, 2014. 48(21): 
p. 12577-85. 
68. Steiner, S., et al., Diesel exhaust: current knowledge of adverse effects and 
underlying cellular mechanisms. Arch Toxicol, 2016. 90(7): p. 1541-53. 
69. Sadowska, A.M., N-Acetylcysteine mucolysis in the management of chronic 
obstructive pulmonary disease. Therapeutic advances in respiratory disease, 2012. 
6(3): p. 127-135. 
70. Reliene, R., E. Fischer, and R.H. Schiestl, Effect of N-acetyl cysteine on oxidative DNA 
damage and the frequency of DNA deletions in atm-deficient mice. Cancer research, 
2004. 64(15): p. 5148-5153. 
71. Lappas, M., M. Permezel, and G.E. Rice, N-acetyl-cysteine inhibits phospholipid 
metabolism, proinflammatory cytokine release, protease activity, and Nuclear 
Factor-κB deoxyribonucleic acid-binding activity in human fetal membranes in vitro. 
The Journal of Clinical Endocrinology & Metabolism, 2003. 88(4): p. 1723-1729. 
 
 
 144 
72. Llinàs, L., et al., Similar gene expression profiles in smokers and patients with 
moderate COPD. Pulmonary Pharmacology & Therapeutics, 2011. 24(1): p. 32-41. 
73. Hackett, T.L., et al., Characterization of side population cells from human airway 
epithelium. Stem Cells, 2008. 26(10): p. 2576-2585. 
74. Andersen, Z.J., et al., Chronic obstructive pulmonary disease and long-term exposure 
to traffic-related air pollution: a cohort study. American journal of respiratory and 
critical care medicine, 2011. 183(4): p. 455-461. 
75. WHO. Burden of disease from joint effects of housold and ambient air pollution for 
2012. 2014. 
76. Pinkerton, K.E., et al., Distribution of particulate matter and tissue remodeling in the 
human lung. Environmental Health Perspectives, 2000. 108(11): p. 1063. 
77. Stanek, L.W., et al., Attributing health effects to apportioned components and 
sources of particulate matter: an evaluation of collective results. Atmospheric 
Environment, 2011. 45(32): p. 5655-5663. 
78. Li, N., et al., The adjuvant effect of ambient particulate matter is closely reflected by 
the particulate oxidant potential. Environmental Health Perspectives, 2009. 117(7): 
p. 1116. 
79. Totlandsdal, A.I., et al., Diesel exhaust particles induce CYP1A1 and pro-inflammatory 
responses via differential pathways in human bronchial epithelial cells. Particle and 
Fibre Toxicology, 2010. 7(1): p. 1-13. 
80. Totlandsdal, A.I., et al., Differential proinflammatory responses induced by diesel 
exhaust particles with contrasting PAH and metal content. Environmental Toxicology, 
2013(Published online: 31 July 2013). 
81. Hawley, B., et al., Time course of bronchial cell inflammation following exposure to 
diesel particulate matter using a modified EAVES. Toxicology in Vitro, 2014. 28(5): p. 
829-837. 
82. Totlandsdal, A.I., et al., Differential effects of the particle core and organic extract of 
diesel exhaust particles. Toxicology Letters, 2012. 208(3): p. 262-8. 
83. Cooney, D.J. and A.J. Hickey, Cellular response to the deposition of diesel exhaust 
particle aerosols onto human lung cells grown at the air–liquid interface by inertial 
impaction. Toxicology in Vitro, 2011. 25(8): p. 1953-1965. 
 
 
 145 
84. Beresford, A.P., CYP1A1: friend or foe? Drug Metabolism Reviews, 1993. 25(4): p. 
503-517. 
85. Aufderheide, M., et al., The CULTEX RFS: A Comprehensive Technical Approach for 
the In Vitro Exposure of Airway Epithelial Cells to the Particulate Matter at the Air-
Liquid Interface. BioMed Research International, 2013. 
http://dx.doi.org/10.1155/2013/734137. 
86. Seagrave, J.C., et al., Responses of differentiated primary human lung epithelial cells 
to exposure to diesel exhaust at an air-liquid interface. Experimental Lung Research, 
2007. 33(1): p. 27-51. 
87. ABS, Leading causes of death, in Causes of death, Australia, 2011. 2011, Australian 
Bureau of Statistics: Canberra. 
88. Bonvallot, V., et al., Organic compounds from diesel exhaust particles elicit a 
proinflammatory response in human airway epithelial cells and induce cytochrome 
p450 1A1 expression. American Journal of Respiratory Cell and Molecular Biology, 
2001. 25(4): p. 515-521. 
89. Shvedova, A.A., et al., Oxidative stress, inflammatory biomarkers, and toxicity in 
mouse lung and liver after inhalation exposure to 100% biodiesel or petroleum diesel 
emissions. J Toxicol Environ Health A, 2013. 76(15): p. 907-21. 
90. Rahman, I. and W. MacNee, Oxidative stress and regulation of glutathione in lung 
inflammation. European Respiratory Journal, 2000. 16(3): p. 534-554. 
91. Stevanovic, S., et al., Influence of Oxygenated Organic Aerosols (OOAs) on the 
Oxidative Potential of Diesel and Biodiesel Particulate Matter. Environmental science 
& technology, 2013. 47(14): p. 7655-7662. 
92. Hiura, T.S., et al., The role of a mitochondrial pathway in the induction of apoptosis 
by chemicals extracted from diesel exhaust particles. The Journal of Immunology, 
2000. 165(5): p. 2703-2711. 
93. Montiel-Dávalos, A., et al., Oxidative stress and apoptosis are induced in human 
endothelial cells exposed to urban particulate matter. Toxicology in vitro, 2010. 
24(1): p. 135-141. 
94. Rottner, M., et al., Increased oxidative stress induces apoptosis in human cystic 
fibrosis cells. PloS one, 2011. 6(9): p. e24880. 
 
 
 146 
95. Gozzelino, R., V. Jeney, and M.P. Soares, Mechanisms of cell protection by heme 
oxygenase-1. Annual Review of Pharmocology and Toxicology, 2010. 50: p. 323-54. 
96. Pae, H.O., et al., A molecular cascade showing nitric oxide-heme oxygenase-1-
vascular endothelial growth factor-interleukin-8 sequence in human endothelial cells. 
Endocrinology, 2005. 146(5): p. 2229-38. 
97. Lin, C.-C., et al., PAHs, PAH-induced carcinogenic potency, and particle-extract-
induced cytotoxicity of traffic-related nano/ultrafine particles. Environmental science 
& technology, 2008. 42(11): p. 4229-4235. 
98. Li, N., et al., Comparison of the pro-oxidative and proinflammatory effects of organic 
diesel exhaust particle chemicals in bronchial epithelial cells and macrophages.  The 
Journal of Immunology, 2002. 169(8): p. 4531-4541. 
99. Rothenbacher, S., A. Messerer, and G. Kasper, Fragmentation and bond strength of 
airborne diesel soot agglomerates. Part Fibre Toxicol, 2008. 5: p. 9. 
100. Voll, R.E., et al., Immunosuppressive effects of apoptotic cells. Nature, 1997. 
390(6658): p. 350-351. 
101. Ma, Q.-Y., et al., Exposure to particulate matter 2.5 (PM2. 5) induced macrophage-
dependent inflammation, characterized by increased Th1/Th17 cytokine secretion 
and cytotoxicity. International Immunopharmacology, 2017. 50: p. 139-145. 
102. Baskar, P. and A. Senthilkumar, Effects of oxygen enriched combustion on pollution 
and performance characteristics of a diesel engine. Engineering Science and 
Technology, an International Journal, 2016. 19(1): p. 438-443. 
103. Jamriska, M., et al., Diesel bus emissions measured in a tunnel study. Environmental 
science & technology, 2004. 38(24): p. 6701-6709. 
104. Giechaskiel, B., B. Alföldy, and Y. Drossinos, A metric for health effects studies of 
diesel exhaust particles. Journal of Aerosol Science, 2009. 40(8): p. 639-651. 
105. RÖnkkÖ, T., et al., Nucleation mode particles with a nonvolatile core in the exhaust of 
a heavy duty diesel vehicle. Environmental science & technology, 2007. 41(18): p. 
6384-6389. 
106. Nel, A., Air pollution-related illness: effects of particles. Science, 2005. 308(5723): p. 
804-806. 
107. Valavanidis, A., K. Fiotakis, and T. Vlachogianni, Airborne particulate matter and 
human health: toxicological assessment and importance of size and composition of 
 
 
 147 
particles for oxidative damage and carcinogenic mechanisms. Journal of 
Environmental Science and Health, Part C, 2008. 26(4): p. 339-362. 
108. Xia, T., et al., Quinones and aromatic chemical compounds in particulate matter 
induce mitochondrial dysfunction: implications for ultrafine particle toxicity.  
Environmental health perspectives, 2004. 112(14): p. 1347. 
109. Li, N., et al., Induction of heme oxygenase-1 expression in macrophages by diesel 
exhaust particle chemicals and quinones via the antioxidant-responsive element. The 
Journal of Immunology, 2000. 165(6): p. 3393-3401. 
110. Lapuerta, M., J. Rodríguez-Fernández, and J.R. Agudelo, Diesel particulate emissions 
from used cooking oil biodiesel. Bioresource Technology, 2008. 99(4): p. 731-740. 
111. Stevanovic, S., et al., Oxidative potential of gas phase combustion emissions-An 
underestimated and potentially harmful component of air pollution from combustion 
processes. Atmospheric environment, 2017. 158: p. 227-235. 
112. Kroll, J.H. and J.H. Seinfeld, Chemistry of secondary organic aerosol: Formation and 
evolution of low-volatility organics in the atmosphere. Atmospheric Environment, 
2008. 42(16): p. 3593-3624. 
113. Ebersviller, S., et al., Gaseous VOCs rapidly modify particulate matter and its 
biological effects–Part 1: Simple VOCs and model PM. Atmospheric Chemistry and 
Physics, 2012. 12(24): p. 12277-12292. 
114. Habibullah, M., et al., Biodiesel production and performance evaluation of coconut, 
palm and their combined blend with diesel in a single-cylinder diesel engine. Energy 
Conversion and Management, 2014. 87: p. 250-257. 
115. Gerlofs-Nijland, M.E., et al., Cell Toxicity and Oxidative Potential of Engine Exhaust 
Particles: Impact of Using Particulate Filter or Biodiesel Fuel Blend. Environmental 
Science & Technology, 2013. 47(11): p. 5931-5938. 
116. Bünger, J., et al., Potential hazards associated with combustion of bio-derived versus 
petroleum-derived diesel fuel. Critical reviews in toxicology, 2012. 42(9): p. 732-750. 
117. Bünger, J., et al., Cytotoxic and mutagenic effects, particle size and concentration 
analysis of diesel engine emissions using biodiesel and petrol diesel as fuel. Archives 
of toxicology, 2000. 74(8): p. 490-498. 
118. Swanson, K.J., M.C. Madden, and A.J. Ghio, Biodiesel exhaust: the need for health 
effects research. Environmental health perspectives, 2007: p. 496-499. 
 
 
 148 
119. Tzamkiozis, T., et al., Monitoring the inflammatory potential of exhaust particles 
from passenger cars in mice. Inhalation toxicology, 2010. 22(sup2): p. 59-69. 
120. Zou, L. and S. Atkinson, Characterising vehicle emissions from the burning of 
biodiesel made from vegetable oil. Environmental technology, 2003. 24(10): p. 1253-
1260. 
121. Mullins, B.J., et al., Biodiesel exhaust–induced cytotoxicity and proinflammatory 
mediator production in human airway epithelial cells. Environmental Toxicology, 
2016. 31(1): p. 44-57. 
122. Cervena, T., et al., DNA Damage Potential of Engine Emissions Measured In Vitro by 
Micronucleus Test in Human Bronchial Epithelial Cells. Basic & Clinical Pharmacology 
& Toxicology, 2017. 121: p. 102-108. 
123. Barraud, C., et al., Impact of after-treatment devices and biofuels on diesel exhausts 
genotoxicity in A549 cells exposed at air-liquid interface. Toxicology in Vitro, 2017. 
45: p. 426-433. 
124. Yanamala, N., et al., Biodiesel versus diesel exposure: enhanced pulmonary 
inflammation, oxidative stress, and differential morphological changes in the mouse 
lung. Toxicol Appl Pharmacol, 2013. 272(2): p. 373-83. 
125. Demetriou, C.A. and P. Vineis, Carcinogenicity of ambient air pollution: use of 
biomarkers, lessons learnt and future directions. J Thorac Dis, 2015. 7(1): p. 67-95. 
126. Valavanidis, A., et al., Pulmonary oxidative stress, inflammation and cancer: 
respirable particulate matter, fibrous dusts and ozone as major causes of lung 
carcinogenesis through reactive oxygen species mechanisms. International journal of 
environmental research and public health, 2013. 10(9): p. 3886-3907. 
127. Sadowska, A.M., et al., Role of N-acetylcysteine in the management of COPD. 
Therapeutics and Clinical Risk Management, 2006. 2(1): p. 3-18. 
128. Sadowska, A.M., Y.K.B. Manuel, and W.A. De Backer, Antioxidant and anti-
inflammatory efficacy of NAC in the treatment of COPD: discordant in vitro and in 
vivo dose-effects: a review. Pulm Pharmacol Ther, 2007. 20(1): p. 9-22. 
129. Szkudlarek, U., et al., Effect of inhaled N-acetylcysteine on hydrogen peroxide 
exhalation in healthy subjects. Pulmonary pharmacology & therapeutics, 2004. 17(3): 
p. 155-162. 
 
 
 149 
130. De Benedetto, F., et al., Long-term oral n-acetylcysteine reduces exhaled hydrogen 
peroxide in stable COPD. Pulmonary pharmacology & therapeutics, 2005. 18(1): p. 
41-47. 
131. Urban, T., et al., Neutrophil function and glutathione-peroxidase (GSH-px) activity in 
healthy individuals after treatment with N-acetyl-L-cysteine. Biomedicine & 
pharmacotherapy, 1997. 51(9): p. 388-390. 
132. Van Overveld, F., et al., New developments in the treatment of COPD: comparing the 
effects of inhaled corticosteroids and N-acetylcysteine. Journal of physiology and 
pharmacology, 2005. 56: p. 135. 
133. Havre, P.A., et al., Transformed and tumor-derived human cells exhibit preferential 
sensitivity to the thiol antioxidants, N-acetyl cysteine and penicillamine. Cancer Res, 
2002. 62(5): p. 1443-9. 
134. Wang, L.S., et al., N-acetylcysteine attenuates cigaret smoke-induced pulmonary 
exacerbation in a mouse model of emphysema. Inhal Toxicol, 2015. 27(14): p. 802-9. 
135. Rudden, R.W., What Makes a Cancer Cell a Cancer cell? In: Hollan-Frei Cancer 
Medicine. 2003, Hamilton (ON): BC Becker. 
136. Guan, D., et al., N-acetyl cysteine and penicillamine induce apoptosis via the ER stress 
response-signaling pathway. Mol Carcinog, 2010. 49(1): p. 68-74. 
137. Vaughan, A., et al., Removal of organic content from diesel exhaust particles alters 
cellular responses of primary human bronchial epithelial cells cultured at an air-liquid 
interface. Journal of Environmental & Analytical Toxicology, 2015. 5(5): p. 1. 
138. Hawley, B., et al., Oxidative stress and aromatic hydrocarbon response of human 
bronchial epithelial cells exposed to petro-or biodiesel exhaust treated with a diesel 
particulate filter. Toxicological Sciences, 2014: p. kfu147. 
139. Hashimoto, S., et al., Diesel exhaust particles activate p38 MAP kinase to produce 
interleukin 8 and RANTES by human bronchial epithelial cells and N-acetylcysteine 
attenuates p38 MAP kinase activation. American Journal of Respiratory and Critical 
Care Medicine, 2000. 161(1): p. 280-285. 
140. Lawrence, T., The Nuclear Factor NF-κB Pathway in Inflammation. Cold Spring Harbor 
Perspectives in Biology, 2009. 1(6): p. a001651. 
141. Hiscott, J., H. Kwon, and P. Génin, Hostile takeovers: viral appropriation of the NF-kB 
pathway. Journal of Clinical Investigation, 2001. 107(2): p. 143. 
 
 
 150 
142. Zou, W., Immunosuppressive networks in the tumour environment and their 
therapeutic relevance. Nature Reviews Cancer, 2005. 5(4): p. 263-274. 
143. Li, Q., et al., A simultaneous release of SOD1 with cytochrome c regulates 
mitochondria-dependent apoptosis. Mol Cell Biochem, 2009. 322(1-2): p. 151-9. 
144. Manfredi, G. and Z. Xu, Mitochondrial dysfunction and its role in motor neuron 
degeneration in ALS. Mitochondrion, 2005. 5(2): p. 77-87. 
145. Bräuner, E.V., et al., Exposure to ultrafine particles from ambient air and oxidative 
stress–induced DNA damage. Environmental health perspectives, 2007. 115(8): p. 
1177. 
146. Benjamini, Y. and D. Yekutieli, The control of the false discovery rate in multiple 
testing     under dependency. Ann. Statist., 2001. 29(4): p. 1165-
1188. 
147. Tomaki, M., et al., Decreased expression of antioxidant enzymes and increased 
expression of chemokines in COPD lung. Pulmonary Pharmacology & Therapeutics, 
2007. 20(5): p. 596-605. 
148. Golpon, H.A., et al., Emphysema lung tissue gene expression profiling. Am J Respir 
Cell Mol Biol, 2004. 31(6): p. 595-600. 
149. Bajpai, J., et al., Study of oxidative stress biomarkers in chronic obstructive pulmonary 
disease and their correlation with disease severity in north Indian population cohort.  
Lung India, 2017. 34(4): p. 324-329. 
150. Rajendrasozhan, S., et al., SIRT1, an antiinflammatory and antiaging protein, is 
decreased in lungs of patients with chronic obstructive pulmonary disease. American 
journal of respiratory and critical care medicine, 2008. 177(8): p. 861-870. 
151. Lee, K.-H., et al., Exogenous neutrophil elastase enters bronchial epithelial cells and 
suppresses cigarette smoke extract-induced heme oxygenase-1 by cleaving sirtuin 1. 
Journal of Biological Chemistry, 2017: p. jbc. M116. 771089. 
152. Manzo, N.D., et al., Susceptibility of inflamed alveolar and airway epithelial cells to 
injury induced by diesel exhaust particles of varying organic carbon content. J Toxicol 
Environ Health A, 2010. 73(8): p. 565-80. 
153. Sies, H., Oxidative stress: oxidants and antioxidants. Experimental Physiology, 1997. 
82(2): p. 291-295. 
 
 
 151 
154. Taioli, E., et al., Radical differences in CYP1A1 genotype and function. Toxicol Lett, 
1995. 77(1-3): p. 357-62. 
155. Schlezinger, J.J., R.D. White, and J.J. Stegeman, Oxidative inactivation of cytochrome 
P-450 1A (CYP1A) stimulated by 3,3',4,4'-tetrachlorobiphenyl: production of reactive 
oxygen by vertebrate CYP1As. Mol Pharmacol, 1999. 56(3): p. 588-97. 
156. Salvi, S.S., et al., Acute exposure to diesel exhaust increases IL-8 and GRO-alpha 
production in healthy human airways. Am J Respir Crit Care Med, 2000. 161(2 Pt 1): 
p. 550-7. 
157. Holling, T.M., E. Schooten, and P.J. van Den Elsen, Function and regulation of MHC 
class II molecules in T-lymphocytes: of mice and men. Hum Immunol, 2004. 65(4): p. 
282-90. 
158. Rock, K.L., E. Reits, and J. Neefjes, Present Yourself! By MHC Class I and MHC Class II 
Molecules. Trends Immunol, 2016. 37(11): p. 724-737. 
159. Hodge, G., et al., Increased intracellular T helper 1 proinflammatory cytokine 
production in peripheral blood, bronchoalveolar lavage and intraepithelial T cells of 
COPD subjects. Clinical & Experimental Immunology, 2007. 150(1): p. 22-29. 
160. Barnes, P.J. and M.G. Cosio, Characterization of T lymphocytes in chronic obstructive 
pulmonary disease. PLoS medicine, 2004. 1(1): p. e20. 
161. Grumelli, S., et al., An immune basis for lung parenchymal destruction in chronic 
obstructive pulmonary disease and emphysema. PLoS medicine, 2004. 1(1): p. e8. 
162. Di Stefano, A., et al., STAT4 activation in smokers and patients with chronic 
obstructive pulmonary disease. European Respiratory Journal, 2004. 24(1): p. 78-85. 
163. Kumar, A., et al., Induction of IL-8(CXCL8) and MCP-1(CCL2) with oxidative stress and 
its inhibition with N-acetyl cysteine (NAC) in cell culture model using HK-2 cell. 
Transplant Immunology, 2016. 35(Supplement C): p. 40-46. 
164. Yan, Z., et al., Oxidative stress and endocytosis are involved in upregulation of 
interleukin-8 expression in airway cells exposed to PM2.5. Environmental Toxicology, 
2016. 31(12): p. 1869-1878. 
165. Kasperczyk, S., et al., Effect of N-acetylcysteine administration on the expression and 
activities of antioxidant enzymes and the malondialdehyde level in the blood of lead-
exposed workers. Environmental toxicology and pharmacology, 2014. 37(2): p. 638-
647. 
 
 
 152 
166. Yao, H. and I. Rahman, Current concepts on the role of inflammation in COPD and 
lung cancer. Current Opinion in Pharmacology, 2009. 9(4): p. 375-383. 
167. Wells, A., EGF receptor. The International Journal of Biochemistry & Cell Biology, 
1999. 31(6): p. 637-643. 
168. Stark, G.R., et al., How cells respond to interferons. 1998, Annual Reviews 4139 El 
Camino Way, PO Box 10139, Palo Alto, CA 94303-0139, USA. 
169. Uze, G., et al., The receptor of the type I interferon family, in Interferon: The 50th 
Anniversary. 2007, Springer. p. 71-95. 
170. Beasley, V., et al., Lung microbiology and exacerbations in COPD. International 
Journal of Chronic Obstructive Pulmonary Disease, 2012. 7: p. 555-569. 
171. HuangFu, W.-C., et al., Inflammatory signaling compromises cell responses to 
interferon alpha. Oncogene, 2012. 31(2): p. 161. 
172. Qian, J., et al., Pathogen recognition receptor signaling accelerates phosphorylation-
dependent degradation of IFNAR1. PLoS pathogens, 2011. 7(6): p. e1002065. 
173. Zheng, H., et al., Vascular endothelial growth factor–induced elimination of the type 
1 interferon receptor is required for efficient angiogenesis. Blood, 2011. 118(14): p. 
4003-4006. 
174. Bhattacharya, S., et al., Triggering ubiquitination of IFNAR1 protects tissues from 
inflammatory injury. EMBO molecular medicine, 2014: p. e201303236. 
175. Sonnenfeld, G. and R.W. Hudgens, Effect of sidestream and mainstream smoke 
exposure on in vitro interferon-alpha/beta production by L-929 cells. Cancer Res, 
1986. 46(6): p. 2779-83. 
176. Sajjan, U., et al., Elastase- and LPS-exposed mice display altered responses to 
rhinovirus infection. Am J Physiol Lung Cell Mol Physiol, 2009. 297(5): p. L931-44. 
177. Mallia, P., et al., Experimental rhinovirus infection as a human model of chronic 
obstructive pulmonary disease exacerbation. Am J Respir Crit Care Med, 2011. 
183(6): p. 734-42. 
178. Symoens, S., et al., Genetic Defects in TAPT1 Disrupt Ciliogenesis and Cause a 
Complex Lethal Osteochondrodysplasia. The American Journal of Human Genetics, 
2015. 97(4): p. 521-534. 
 
 
 153 
179. Trempus, C.S., et al., A novel role for primary cilia in airway remodeling. American 
Journal of Physiology-Lung Cellular and Molecular Physiology, 2017. 313(2): p. L328-
L338. 
180. Rogers, D.F., Mucociliary dysfunction in COPD: effect of current pharmacotherapeutic 
options. Pulmonary pharmacology & therapeutics, 2005. 18(1): p. 1-8. 
181. He, J.Q., et al., Association of genetic variations in the CSF2 and CSF3 genes with lung 
function in smoking-induced COPD. Eur Respir J, 2008. 32(1): p. 25-34. 
182. Hierholzer, C., et al., G-CSF instillation into rat lungs mediates neutrophil recruitment, 
pulmonary edema, and hypoxia. Journal of Leukocyte Biology, 1998. 63(2): p. 169-
174. 
183. Hoenderdos, K. and A. Condliffe, The neutrophil in chronic obstructive pulmonary 
disease. Am J Respir Cell Mol Biol, 2013. 48(5): p. 531-9. 
184. Stockley, R.A., Neutrophils and the pathogenesis of COPD. Chest, 2002. 121(5): p. 
151S-155S. 
185. Zhang, W., et al., Structure of human lanthionine synthetase C-like protein 1 and its 
interaction with Eps8 and glutathione. Genes & development, 2009. 23(12): p. 1387-
1392. 
186. Zhong, W.-x., et al., Lanthionine Synthetase C-like Protein 1 Interacts with and 
Inhibits Cystathionine β-Synthase A TARGET FOR NEURONAL ANTIOXIDANT DEFENSE. 
Journal of Biological Chemistry, 2012. 287(41): p. 34189-34201. 
187. Mosharov, E., M.R. Cranford, and R. Banerjee, The quantitatively important 
relationship between homocysteine metabolism and glutathione synthesis by the 
transsulfuration pathway and its regulation by redox changes. Biochemistry, 2000. 
39(42): p. 13005-11. 
188. Chung, C.H., et al., Identification of lanthionine synthase C-like protein-1 as a 
prominent glutathione binding protein expressed in the mammalian central nervous 
system. Biochemistry, 2007. 46(11): p. 3262-3269. 
189. Bauer, H., et al., Characterization of p40/GPR69A as a peripheral membrane protein 
related to the lantibiotic synthetase component C. Biochemical and biophysical 
research communications, 2000. 275(1): p. 69-74. 
 
 
 154 
190. Huang, C., et al., Developmental and Activity-Dependent Expression of LanCL1 
Confers Antioxidant Activity Required for Neuronal Survival. Developmental Cell, 
2014. 30(4): p. 479-487. 
191. Marwick, J.A., et al., Cigarette Smoke-Induced Oxidative Stress and TGF-β1 Increase 
p21waf1/cip1 Expression in Alveolar Epithelial Cells. Annals of the New York 
Academy of Sciences, 2002. 973(1): p. 278-283. 
192. Ito, K. and P.J. Barnes, COPD as a disease of accelerated lung aging. Chest, 2009. 
135(1): p. 173-180. 
193. Hirst, S.J., P.J. Barnes, and C.H. Twort, Quantifying proliferation of cultured human 
and rabbit airway smooth muscle cells in response to serum and platelet-derived 
growth factor. American Journal of Respiratory Cell and Molecular Biology, 1992. 7: 
p. 574-574. 
194. Aoshiba, K. and A. Nagai, Differences in airway remodeling between asthma and 
chronic obstructive pulmonary disease. Clinical reviews in allergy & immunology, 
2004. 27(1): p. 35-43. 
195. Bosken, C.H., et al., Small airway dimensions in smokers with obstruction to airflow. 
Am Rev Respir Dis, 1990. 142(3): p. 563-70. 
196. Chung, K.F., The role of airway smooth muscle in the pathogenesis of airway wall 
remodeling in chronic obstructive pulmonary disease. Proceedings of the American 
Thoracic Society, 2005. 2(4): p. 347-354. 
197. Kim, S.J., et al., CRIF1 is essential for the synthesis and insertion of oxidative 
phosphorylation polypeptides in the mammalian mitochondrial membrane. Cell 
metabolism, 2012. 16(2): p. 274-283. 
198. Messier, E., et al., Mechanisms Of Alveolar Type Ii Cell Injury In Emphysema. Am J 
Respir Crit Care Med, 2016. 193: p. A5877. 
199. Kubo, M., T. Hanada, and A. Yoshimura, Suppressors of cytokine signaling and 
immunity. Nature Immunology, 2003. 4: p. 1169. 
200. Scalvini, S., et al., Plasma hormone levels and haemodynamics in patients with 
chronic obstructive lung disease. Monaldi archives for chest disease= Archivio 
Monaldi per le malattie del torace, 1996. 51(5): p. 380-386. 
 
 
 155 
201. Sen, B., et al., STAT5A-mediated SOCS2 expression regulates Jak2 and STAT3 activity 
following c-Src inhibition in head and neck squamous carcinoma. Clinical Cancer 
Research, 2012. 18(1): p. 127-139. 
202. Farabegoli, F., et al., Suppressor of cytokine signalling 2 (SOCS-2) expression in breast 
carcinoma. Journal of clinical pathology, 2005. 58(10): p. 1046-1050. 
203. Mahmudul, H.M., et al., Production, characterization and performance of biodiesel as 
an alternative fuel in diesel engines – A review. Renewable and Sustainable Energy 
Reviews, 2017. 72: p. 497-509. 
204. Kawasaki, S., et al., Benzene-extracted components are important for the major 
activity of diesel exhaust particles: effect on interleukin-8 gene expression in human 
bronchial epithelial cells. American journal of respiratory cell and molecular biology, 
2001. 24(4): p. 419-426. 
205. Libalova, H., et al., Comparative analysis of toxic responses of organic extracts from 
diesel and selected alternative fuels engine emissions in human lung BEAS-2B cells. 
International journal of molecular sciences, 2016. 17(11): p. 1833. 
206. Mehus, A.A., et al., Comparison of Acute Health Effects from Exposures to Diesel and 
Biodiesel Fuel Emissions. Journal of occupational and environmental medicine / 
American College of Occupational and Environmental Medicine, 2015. 57(7): p. 705-
712. 
207. Yanamala, N., et al., Biodiesel versus diesel exposure: enhanced pulmonary 
inflammation, oxidative stress, and differential morphological changes in the mouse 
lung. Toxicology and applied pharmacology, 2013. 272(2): p. 373-383. 
208. Rogliani, P., et al., Pharmacological characterization of the anti-oxidant activity of N-
acetylcysteine in an <em>ex vivo</em> model of COPD exacerbation. European 
Respiratory Journal, 2016. 48(suppl 60). 
209. Garshick, E., et al., Lung Cancer in Railroad Workers Exposed to Diesel Exhaust. 
Environmental Health Perspectives, 2004. 112(15): p. 1539-1543. 
210. Bassig, B.A., et al., Occupational exposure to diesel engine exhaust and alterations in 
immune/inflammatory markers: a cross-sectional molecular epidemiology study in 
China. Carcinogenesis, 2017. 38(11): p. 1104-1111. 
 
 
 156 
211. Swiston, J.R., et al., Wood smoke exposure induces a pulmonary and systemic 
inflammatory response in firefighters. European Respiratory Journal, 2008. 32(1): p. 
129-138. 
212. Kode, A., S.-R. Yang, and I. Rahman, Differential effects of cigarette smoke on 
oxidative stress and proinflammatory cytokine release in primary human airway 
epithelial cells and in a variety of transformed alveolar epithelial cells.  Respiratory 
research, 2006. 7(1): p. 132. 
213. Rusznak, C., et al., Interaction of cigarette smoke and house dust mite allergens on 
inflammatory mediator release from primary cultures of human bronchial epithelial 
cells. Clinical & Experimental Allergy, 2001. 31(2): p. 226-238. 
214. Halazonetis, T.D., V.G. Gorgoulis, and J. Bartek, An oncogene-induced DNA damage 
model for cancer development. science, 2008. 319(5868): p. 1352-1355. 
215. Cheetham, S., et al., Long noncoding RNAs and the genetics of cancer. British journal 
of cancer, 2013. 108(12): p. 2419. 
216. Oh, E.-S., et al., Cell adhesion in cancer. International journal of cell biology, 2012. 
2012. 
217. Blanc, P., et al., Occupational exposures and COPD: an ecological analysis of 
international data. European Respiratory Journal, 2009. 33(2): p. 298-304. 
218. Kelly, F.J. and J.C. Fussell, Air pollution and public health: emerging hazards and 
improved understanding of risk. Environmental geochemistry and health, 2015. 
37(4): p. 631-649. 
219. Downs, S.H., et al., Reduced exposure to PM10 and attenuated age-related decline in 
lung function. New England Journal of Medicine, 2007. 357(23): p. 2338-2347. 
220. Schindler, C., et al., Improvements in PM10 exposure and reduced rates of respiratory 
symptoms in a cohort of Swiss adults (SAPALDIA). American journal of respiratory 
and critical care medicine, 2009. 179(7): p. 579-587. 
221. Bayer-Oglesby, L., et al., Decline of ambient air pollution levels and improved 
respiratory health in Swiss children. Environmental Health Perspectives, 2005. 
113(11): p. 1632. 
222. Pope III, C.A., M. Ezzati, and D.W. Dockery, Fine-particulate air pollution and life 
expectancy in the United States. New England Journal of Medicine, 2009. 360(4): p. 
376-386. 
 
 
 157 
 
Chapter 11:  Appendices 
Appendix item 1: TaqMan assays 
 
Table A1: List of TaqMan assays used in qRT-PCR gene expression analysis through this 
PhD thesis. 
Gene target TaqMan assay Chapter No. 
GAPDH Hs02758991_g1 Chapter 3, 5, 6 
GAPDH Hs03929097_g1 Chapter 4, 7 
HMOX-1 Hs01110250_m1 Chapter 3, 5, 6 
HMOX-1 Hs00157965_m1 Chapter 4, 7 
CYP1A1 Hs01054797_g1 Chapter 3, 4, 5 
SOD1 Hs00533490_m1 Chapter 5, 6, 7 
SOD2 Hs00167306_m1 Chapter 5, 6, 7 
IL-8 Hs00174103_m1 Chapter 3, 7 
TNFα Hs01113624_g1 Chapter 3 
CASP3 Hs00234387_m1 Chapter 4, 5, 6, 7 
BCL2 Hs00608023_m1 Chapter 4, 5, 6, 7 
 
Appendix item 2: Nanostring gene targets for the nCounter Intracellular Signalling and 
Immunology panels 
 
Table A2: Nanostring nCounter Human Immunology V2 panel 
Official Symbol Accession Official Full Name 
ABCB1 NM_000927.3 ATP-binding cassette, sub-family B (MDR/TAP), member 1 
ABL1 NM_005157.3 c-abl oncogene 1, non-receptor tyrosine kinase 
ADA NM_000022.2 adenosine deaminase 
AHR NM_001621.3 aryl hydrocarbon receptor 
AICDA NM_020661.1 activation-induced cytidine deaminase 
AIRE NM_000383.2 autoimmune regulator 
APP NM_000484.3 amyloid beta (A4) precursor protein 
ARG1 NM_000045.2 arginase, liver 
ARG2 NM_001172.3 arginase, type II 
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ARHGDIB NM_001175.4 Rho GDP dissociation inhibitor (GDI) beta 
ATG10 ATG10 autophagy related 10 homolog (S. cerevisiae) 
ATG12 NM_004707.2 ATG12 autophagy related 12 homolog (S. cerevisiae) 
ATG16L1 NM_198890.2 ATG16 autophagy related 16-like 1 (S. cerevisiae) 
ATG5 NM_004849.2 ATG5 autophagy related 5 homolog (S. cerevisiae) 
ATG7 NM_001136031.2 ATG7 autophagy related 7 homolog (S. cerevisiae) 
ATM NM_000051.3 ataxia telangiectasia mutated 
B2M NM_004048.2 beta-2-microglobulin 
B3GAT1 NM_018644.3 beta-1,3-glucuronyltransferase 1 (glucuronosyltransferase P) 
BATF NM_006399.3 basic leucine zipper transcription factor, ATF-like 
BATF3 NM_018664.2 basic leucine zipper transcription factor, ATF-like 3 
BAX NM_138761.3 BCL2-associated X protein 
BCAP31 NM_005745.7 B-cell receptor-associated protein 31 
BCL10 NM_003921.2 B-cell CLL/lymphoma 10 
BCL2 NM_000657.2 B-cell CLL/lymphoma 2 
BCL2L11 NM_138621.4 BCL2-like 11 (apoptosis facilitator) 
BCL3 NM_005178.2 B-cell CLL/lymphoma 3 
BCL6 NM_001706.2 B-cell CLL/lymphoma 6 
BID NM_001196.2 BH3 interacting domain death agonist 
BLNK NM_013314.2 B-cell linker 
BST1 NM_004334.2 bone marrow stromal cell antigen 1 
BST2 NM_004335.2 bone marrow stromal cell antigen 2 
BTK NM_000061.1 Bruton agammaglobulinemia tyrosine kinase 
BTLA NM_181780.2 B and T lymphocyte associated 
C14orf166 NM_016039.2 chromosome 14 open reading frame 166 
C1QA NM_015991.2 complement component 1, q subcomponent, A chain 
C1QB NM_000491.3 complement component 1, q subcomponent, B chain 
C1QBP NM_001212.3 complement component 1, q subcomponent binding protein 
C1R NM_001733.4 complement component 1, r subcomponent 
C1S NM_001734.2 complement component 1, s subcomponent 
C2 NM_000063.3 complement component 2 
C3 NM_000064.2 complement component 3 
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C4A/B NM_007293.2 
complement component 4A (Rodgers blood 
group)/complement component 4B (Chido blood group) 
C4BPA NM_000715.3 complement component 4 binding protein, alpha 
C5 NM_001735.2 complement component 5 
C6 NM_000065.2 complement component 6 
C7 NM_000587.2 complement component 7 
C8A NM_000562.2 complement component 8, alpha polypeptide 
C8B NM_000066.2 complement component 8, beta polypeptide 
C8G NM_000606.2 complement component 8, gamma polypeptide 
C9 NM_001737.3 complement component 9 
CAMP NM_004345.3 cathelicidin antimicrobial peptide 
CARD9 NM_052813.4 caspase recruitment domain family, member 9 
CASP1 NM_001223.3 
caspase 1, apoptosis-related cysteine peptidase (interleukin 1, 
beta, convertase) 
CASP10 NM_032977.3 caspase 10, apoptosis-related cysteine peptidase 
CASP2 NM_032982.2 caspase 2, apoptosis-related cysteine peptidase 
CASP3 NM_032991.2 caspase 3, apoptosis-related cysteine peptidase 
CASP8 NM_001228.4 caspase 8, apoptosis-related cysteine peptidase 
CCBP2 NM_001296.3 chemokine binding protein 2 
CCL11 NM_002986.2 chemokine (C-C motif) ligand 11 
CCL13 NM_005408.2 chemokine (C-C motif) ligand 13 
CCL15 NM_032965.3 chemokine (C-C motif) ligand 15 
CCL16 NM_004590.2 chemokine (C-C motif) ligand 16 
CCL18 NM_002988.2 
chemokine (C-C motif) ligand 18 (pulmonary and activation-
regulated) 
CCL19 NM_006274.2 chemokine (C-C motif) ligand 19 
CCL2 NM_002982.3 chemokine (C-C motif) ligand 2 
CCL20 NM_004591.1 chemokine (C-C motif) ligand 20 
CCL22 NM_002990.3 chemokine (C-C motif) ligand 22 
CCL23 NM_145898.1 chemokine (C-C motif) ligand 23 
CCL24 NM_002991.2 chemokine (C-C motif) ligand 24 
CCL26 NM_006072.4 chemokine (C-C motif) ligand 26 
CCL3 NM_002983.2 chemokine (C-C motif) ligand 3 
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CCL4 NM_002984.2 chemokine (C-C motif) ligand 4 
CCL5 NM_002985.2 chemokine (C-C motif) ligand 5 
CCL7 NM_006273.2 chemokine (C-C motif) ligand 7 
CCL8 NM_005623.2 chemokine (C-C motif) ligand 8 
CCND3 NM_001760.2 cyclin D3 
CCR1 NM_001295.2 chemokine (C-C motif) receptor 1 
CCR10 NM_016602.2 chemokine (C-C motif) receptor 10 
CCR2 NM_001123041.2 chemokine (C-C motif) receptor 2 
CCR5 NM_000579.1 chemokine (C-C motif) receptor 5 
CCR6 NM_031409.2 chemokine (C-C motif) receptor 6 
CCR7 NM_001838.2 chemokine (C-C motif) receptor 7 
CCR8 NM_005201.2 chemokine (C-C motif) receptor 8 
CCRL1 NM_016557.2 chemokine (C-C motif) receptor-like 1 
CCRL2 NM_003965.4 chemokine (C-C motif) receptor-like 2 
CD14 NM_000591.2 CD14 molecule 
CD160 NM_007053.2 CD160 molecule 
CD163 NM_004244.4 CD163 molecule 
CD164 NM_006016.4 CD164 molecule, sialomucin 
CD19 NM_001770.4 CD19 molecule 
CD1A NM_001763.2 CD1a molecule 
CD1D NM_001766.3 CD1d molecule 
CD2 NM_001767.3 CD2 molecule 
CD209 NM_021155.2 CD209 molecule 
CD22 NM_001771.2 CD22 molecule 
CD24 NM_013230.2 CD24 molecule 
CD244 NM_016382.2 CD244 molecule, natural killer cell receptor 2B4 
CD247 NM_198053.1 CD247 molecule 
CD27 NM_001242.4 CD27 molecule 
CD274 NM_014143.3 CD274 molecule 
CD276 NM_001024736.1 CD276 molecule 
CD28 NM_001243078.1 CD28 molecule 
CD34 NM_001025109.1 CD34 molecule 
CD36 NM_001001548.2 CD36 molecule (thrombospondin receptor) 
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CD3D NM_000732.4 CD3d molecule, delta (CD3-TCR complex) 
CD3E NM_000733.2 CD3e molecule, epsilon (CD3-TCR complex) 
CD3EAP NM_012099.1 CD3e molecule, epsilon associated protein 
CD4 NM_000616.4 CD4 molecule 
CD40 NM_001250.4 CD40 molecule, TNF receptor superfamily member 5 
CD40LG NM_000074.2 CD40 ligand 
CD44 CD44 molecule (Indian blood group) 
CD46 NM_172350.1 CD46 molecule, complement regulatory protein 
CD48 NM_001778.2 CD48 molecule 
CD5 NM_014207.2 CD5 molecule 
CD53 NM_001040033.1 CD53 molecule 
CD55 NM_000574.3 
CD55 molecule, decay accelerating factor for complement 
(Cromer blood group) 
CD58 NM_001779.2 CD58 molecule 
CD59 NM_000611.4 CD59 molecule, complement regulatory protein 
CD6 NM_006725.3 CD6 molecule 
CD7 NM_006137.6 CD7 molecule 
CD70 NM_001252.2 CD70 molecule 
CD74 NM_001025159.1 
CD74 molecule, major histocompatibility complex, class II 
invariant chain 
CD79A NM_001783.3 CD79a molecule, immunoglobulin-associated alpha 
CD79B NM_021602.2 CD79b molecule, immunoglobulin-associated beta 
CD80 NM_005191.3 CD80 molecule 
CD81 NM_004356.3 CD81 molecule 
CD82 NM_002231.3 CD82 molecule 
CD83 NM_004233.3 CD83 molecule 
CD86 NM_175862.3 CD86 molecule 
CD8A NM_001768.5 CD8a molecule 
CD8B NM_004931.3 CD8b molecule 
CD9 NM_001769.2 CD9 molecule 
CD96 NM_005816.4 CD96 molecule 
CD97 NM_078481.2 CD97 molecule 
CD99 NM_002414.3 CD99 molecule 
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CDH5 NM_001795.3 cadherin 5, type 2 (vascular endothelium) 
CDKN1A NM_000389.2 cyclin-dependent kinase inhibitor 1A (p21, Cip1) 
CEACAM1 NM_001712.3 
carcinoembryonic antigen-related cell adhesion molecule 1 
(biliary glycoprotein) 
CEACAM6 NM_002483.4 
carcinoembryonic antigen-related cell adhesion molecule 6 
(non-specific cross reacting antigen) 
CEACAM8 NM_001816.3 carcinoembryonic antigen-related cell adhesion molecule 8 
CEBPB NM_005194.2 CCAAT/enhancer binding protein (C/EBP), beta 
CFB NM_001710.5 complement factor B 
CFD NM_001928.2 complement factor D (adipsin) 
CFH NM_001014975.2 complement factor H 
CFI NM_000204.3 complement factor I 
CFP NM_002621.2 complement factor properdin 
CHUK NM_001278.3 conserved helix-loop-helix ubiquitous kinase 
CIITA NM_000246.3 class II, major histocompatibility complex, transactivator 
CISH NM_145071.2 cytokine inducible SH2-containing protein 
CLEC4A NM_194448.2 C-type lectin domain family 4, member A 
CLEC4E NM_014358.2 C-type lectin domain family 4, member E 
CLEC5A NM_013252.2 C-type lectin domain family 5, member A 
CLEC6A C-type lectin domain family 6, member A 
CLEC7A NM_197954.2 C-type lectin domain family 7, member A 
CLU NM_001831.2 clusterin 
CMKLR1 NM_004072.1 chemokine-like receptor 1 
CR1 NM_000651.4 
complement component (3b/4b) receptor 1 (Knops blood 
group) 
CR2 NM_001006658.1 complement component (3d/Epstein Barr virus) receptor 2 
CRADD NM_003805.3 
CASP2 and RIPK1 domain containing adaptor with death 
domain 
CSF1 NM_000757.4 colony stimulating factor 1 (macrophage) 
CSF1R NM_005211.2 colony stimulating factor 1 receptor 
CSF2 NM_000758.2 colony stimulating factor 2 (granulocyte-macrophage) 
CSF2RB NM_000395.2 
colony stimulating factor 2 receptor, beta, low-affinity 
(granulocyte-macrophage) 
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CSF3R NM_156038.2 colony stimulating factor 3 receptor (granulocyte) 
CTLA4_all 
(common probe) NM_005214.3 cytotoxic T-lymphocyte-associated protein 4 
CTLA4-TM 
(membrane-bound 
form) NM_005214.3 cytotoxic T-lymphocyte-associated protein 4 
sCTLA4 (soluble 
form) NM_001037631.1 cytotoxic T-lymphocyte-associated protein 4 
CTNNB1 NM_001098210.1 catenin (cadherin-associated protein), beta 1, 88kDa 
CTSC NM_001814.4 cathepsin C 
CTSG NM_001911.2 cathepsin G 
CTSS NM_004079.3 cathepsin S 
CUL9 NM_015089.2 cullin 9 
CX3CL1 NM_002996.3 chemokine (C-X3-C motif) ligand 1 
CX3CR1 NM_001337.3 chemokine (C-X3-C motif) receptor 1 
CXCL1 NM_001511.1 
chemokine (C-X-C motif) ligand 1 (melanoma growth 
stimulating activity, alpha) 
CXCL10 NM_001565.1 chemokine (C-X-C motif) ligand 10 
CXCL11 NM_005409.4 chemokine (C-X-C motif) ligand 11 
CXCL12 NM_000609.5 chemokine (C-X-C motif) ligand 12 
CXCL13 NM_006419.2 chemokine (C-X-C motif) ligand 13 
CXCL2 NM_002089.3 chemokine (C-X-C motif) ligand 2 
CXCL9 NM_002416.1 chemokine (C-X-C motif) ligand 9 
CXCR1 NM_000634.2 chemokine (C-X-C motif) receptor 1 
CXCR2 NM_001557.2 chemokine (C-X-C motif) receptor 2 
CXCR3 NM_001504.1 chemokine (C-X-C motif) receptor 3 
CXCR4 NM_003467.2 chemokine (C-X-C motif) receptor 4 
CXCR6 NM_006564.1 chemokine (C-X-C motif) receptor 6 
CYBB NM_000397.3 cytochrome b-245, beta polypeptide 
DEFB1 NM_005218.3 defensin, beta 1 
DEFB103A NM_001081551.2 defensin, beta 103A 
DEFB103B NM_018661.3 defensin, beta 103B 
DEFB4A NM_004942.2 defensin, beta 4A 
 
 
 164 
DPP4 NM_001935.3 dipeptidyl-peptidase 4 
DUSP4 NM_057158.2 dual specificity phosphatase 4 
EBI3 NM_005755.2 Epstein-Barr virus induced 3 
EDNRB NM_003991.2 endothelin receptor type B 
EGR1 NM_001964.2 early growth response 1 
EGR2 NM_000399.3 early growth response 2 
ENTPD1 NM_001098175.1 ectonucleoside triphosphate diphosphohydrolase 1 
EOMES NM_005442.2 eomesodermin 
ETS1 NM_005238.3 v-ets erythroblastosis virus E26 oncogene homolog 1 (avian) 
FADD NM_003824.2 Fas (TNFRSF6)-associated via death domain 
FAS NM_000043.3 Fas (TNF receptor superfamily, member 6) 
FCAR NM_133280.1 Fc fragment of IgA, receptor for 
FCER1A NM_002001.2 
Fc fragment of IgE, high affinity I, receptor for; alpha 
polypeptide 
FCER1G NM_004106.1 
Fc fragment of IgE, high affinity I, receptor for; gamma 
polypeptide 
FCGR1A/B NM_000566.3 
Fc fragment of IgG, high affinity Ia, receptor (CD64)/Fc fragment 
of IgG, high affinity Ib, receptor (CD64) 
FCGR2A NM_021642.3 Fc fragment of IgG, low affinity IIa, receptor (CD32) 
FCGR2A/C NM_201563.4 
Fc fragment of IgG, low affinity IIa, receptor (CD32)/Fc fragment 
of IgG, low affinity IIc, receptor for (CD32)  
FCGR2B NM_001002273.1 Fc fragment of IgG, low affinity IIb, receptor (CD32) 
FCGR3A/B NM_000570.4 
Fc fragment of IgG, low affinity IIIa, receptor (CD16a)/Fc 
fragment of IgG, low affinity IIIb, receptor (CD16a) 
FCGRT NM_004107.4 Fc fragment of IgG, receptor, transporter, alpha 
FKBP5 NM_001145775.1 FK506 binding protein 5 
FN1 NM_212482.1 fibronectin 1 
FOXP3 NM_014009.3 forkhead box P3 
FYN NM_002037.3 FYN oncogene related to SRC, FGR, YES 
GATA3 NM_001002295.1 GATA binding protein 3 
GBP1 NM_002053.1 guanylate binding protein 1, interferon-inducible 
GBP5 NM_052942.3 guanylate binding protein 5 
GFI1 NM_005263.2 growth factor independent 1 transcription repressor 
 
 
 165 
GNLY NM_006433.2 granulysin 
GP1BB NM_000407.4 glycoprotein Ib (platelet), beta polypeptide 
GPI NM_000175.2 glucose-6-phosphate isomerase 
GPR183 NM_004951.3 G protein-coupled receptor 183 
GZMA NM_006144.2 
granzyme A (granzyme 1, cytotoxic T-lymphocyte-associated 
serine esterase 3) 
GZMB NM_004131.3 
granzyme B (granzyme 2, cytotoxic T-lymphocyte-associated 
serine esterase 1) 
GZMK NM_002104.2 granzyme K (granzyme 3; tryptase II) 
HAMP NM_021175.2 hepcidin antimicrobial peptide 
HAVCR2 NM_032782.3 hepatitis A virus cellular receptor 2 
HFE NM_139011.2 hemochromatosis 
HLA-A NM_002116.5 major histocompatibility complex, class I, A 
HLA-B NM_005514.6 major histocompatibility complex, class I, B 
HLA-C NM_002117.4 major histocompatibility complex, class I, C 
HLA-DMA NM_006120.3 major histocompatibility complex, class II, DM alpha 
HLA-DMB NM_002118.3 major histocompatibility complex, class II, DM beta 
HLA-DOB NM_002120.3 major histocompatibility complex, class II, DO beta 
HLA-DPA1 NM_033554.2 major histocompatibility complex, class II, DP alpha 1 
HLA-DPB1 NM_002121.4 major histocompatibility complex, class II, DP beta 1 
HLA-DQA1 NM_002122.3 major histocompatibility complex, class II, DQ alpha 1 
HLA-DQB1 NM_002123.3 major histocompatibility complex, class II, DQ beta 1 
HLA-DRA NM_019111.3 major histocompatibility complex, class II, DR alpha 
HLA-DRB1 NM_002124.2 major histocompatibility complex, class II, DR beta 1 
HLA-DRB3 NM_022555.3 major histocompatibility complex, class II, DR beta 3 
HRAS NM_005343.2 v-Ha-ras Harvey rat sarcoma viral oncogene homolog 
ICAM1 NM_000201.2 intercellular adhesion molecule 1 
ICAM2 NM_000873.3 intercellular adhesion molecule 2 
ICAM3 NM_002162.3 intercellular adhesion molecule 3 
ICAM4 NM_001039132.1 
intercellular adhesion molecule 4 (Landsteiner-Wiener blood 
group) 
ICAM5 NM_003259.3 intercellular adhesion molecule 5, telencephalin 
ICOS NM_012092.2 inducible T-cell co-stimulator 
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ICOSLG NM_015259.4 inducible T-cell co-stimulator ligand 
IDO1 NM_002164.3 indoleamine 2,3-dioxygenase 1 
IFI16 NM_005531.1 interferon, gamma-inducible protein 16 
IFI35 NM_005533.3 interferon-induced protein 35 
IFIH1 NM_022168.2 interferon induced with helicase C domain 1 
IFIT2 NM_001547.4 interferon-induced protein with tetratricopeptide repeats 2 
IFITM1 NM_003641.3 interferon induced transmembrane protein 1 (9-27) 
IFNA1/13 NM_024013.1 interferon, alpha 1/interferon, alpha 13 
IFNA2 NM_000605.3 interferon, alpha 2 
IFNAR1 NM_000629.2 interferon (alpha, beta and omega) receptor 1 
IFNAR2 NM_000874.3 interferon (alpha, beta and omega) receptor 2 
IFNB1 NM_002176.2 interferon, beta 1, fibroblast 
IFNG NM_000619.2 interferon, gamma 
IFNGR1 NM_000416.1 interferon gamma receptor 1 
IGF2R NM_000876.1 insulin-like growth factor 2 receptor 
IKBKAP NM_003640.3 
inhibitor of kappa light polypeptide gene enhancer in B-cells, 
kinase complex-associated protein 
IKBKB NM_001556.1 
inhibitor of kappa light polypeptide gene enhancer in B-cells, 
kinase beta 
IKBKE NM_014002.2 
inhibitor of kappa light polypeptide gene enhancer in B-cells, 
kinase epsilon 
IKBKG NM_003639.2 
inhibitor of kappa light polypeptide gene enhancer in B-cells, 
kinase gamma 
IKZF1 NM_006060.3 IKAROS family zinc finger 1 (Ikaros) 
IKZF2 NM_016260.2 IKAROS family zinc finger 2 (Helios) 
IKZF3 NM_183232.2 IKAROS family zinc finger 3 (Aiolos) 
IL10 NM_000572.2 interleukin 10 
IL10RA NM_001558.2 interleukin 10 receptor, alpha 
IL11RA NM_147162.1 interleukin 11 receptor, alpha 
IL12A NM_000882.2 
interleukin 12A (natural killer cell stimulatory factor 1, cytotoxic 
lymphocyte maturation factor 1, p35) 
IL12B NM_002187.2 
interleukin 12B (natural killer cell stimulatory factor 2, cytotoxic 
lymphocyte maturation factor 2, p40) 
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IL12RB1 NM_005535.1 interleukin 12 receptor, beta 1 
IL13 NM_002188.2 interleukin 13 
IL13RA1 NM_001560.2 interleukin 13 receptor, alpha 1 
IL15 NM_172174.1 interleukin 15 
IL16 NM_004513.4 interleukin 16 
IL17A NM_002190.2 interleukin 17A 
IL17B NM_014443.2 interleukin 17B 
IL17F NM_052872.3 interleukin 17F 
IL18 NM_001562.2 interleukin 18 (interferon-gamma-inducing factor) 
IL18R1 NM_003855.2 interleukin 18 receptor 1 
IL18RAP NM_003853.2 interleukin 18 receptor accessory protein 
IL19 NM_013371.3 interleukin 19 
IL1A NM_000575.3 interleukin 1, alpha 
IL1B NM_000576.2 interleukin 1, beta 
IL1R1 NM_000877.2 interleukin 1 receptor, type I 
IL1R2 NM_173343.1 interleukin 1 receptor, type II 
IL1RAP NM_002182.2 interleukin 1 receptor accessory protein 
IL1RL1 NM_016232.4 interleukin 1 receptor-like 1 
IL1RL2 NM_003854.2 interleukin 1 receptor-like 2 
IL1RN NM_000577.3 interleukin 1 receptor antagonist 
IL2 NM_000586.2 interleukin 2 
IL20 NM_018724.3 interleukin 20 
IL21 NM_021803.2 interleukin 21 
IL21R NM_021798.2 interleukin 21 receptor 
IL22 NM_020525.4 interleukin 22 
IL22RA2 NM_181310.1 interleukin 22 receptor, alpha 2 
IL23A NM_016584.2 interleukin 23, alpha subunit p19 
IL23R NM_144701.2 interleukin 23 receptor 
IL26 NM_018402.1 interleukin 26 
IL27 NM_145659.3 interleukin 27 
IL28A NM_172138.1 interleukin 28A (interferon, lambda 2) 
IL28A/B NM_172139.2 
interleukin 28A (interferon, lambda 2)/interleukin 28B 
(interferon, lambda 3) 
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IL29 NM_172140.1 interleukin 29 (interferon, lambda 1) 
IL2RA NM_000417.1 interleukin 2 receptor, alpha 
IL2RB NM_000878.2 interleukin 2 receptor, beta 
IL2RG NM_000206.1 interleukin 2 receptor, gamma 
IL3 NM_000588.3 interleukin 3 (colony-stimulating factor, multiple) 
IL32 NM_001012633.1 interleukin 32 
IL4 NM_000589.2 interleukin 4 
IL4R NM_000418.2 interleukin 4 receptor 
IL5 NM_000879.2 interleukin 5 (colony-stimulating factor, eosinophil) 
IL6 NM_000600.1 interleukin 6 (interferon, beta 2) 
IL6R NM_000565.2 interleukin 6 receptor 
IL6ST NM_002184.2 interleukin 6 signal transducer (gp130, oncostatin M receptor)  
IL7 NM_000880.2 interleukin 7 
IL7R NM_002185.2 interleukin 7 receptor 
IL8 NM_000584.2 interleukin 8 
IL9 NM_000590.1 interleukin 9 
ILF3 NM_001137673.1 interleukin enhancer binding factor 3, 90kDa 
IRAK1 NM_001569.3 interleukin-1 receptor-associated kinase 1 
IRAK2 NM_001570.3 interleukin-1 receptor-associated kinase 2 
IRAK3 NM_007199.1 interleukin-1 receptor-associated kinase 3 
IRAK4 NM_016123.1 interleukin-1 receptor-associated kinase 4 
IRF1 NM_002198.1 interferon regulatory factor 1 
IRF3 NM_001571.5 interferon regulatory factor 3 
IRF4 NM_002460.1 interferon regulatory factor 4 
IRF5 NM_002200.3 interferon regulatory factor 5 
IRF7 NM_001572.3 interferon regulatory factor 7 
IRF8 NM_002163.2 interferon regulatory factor 8 
IRGM immunity-related GTPase family, M 
ITGA2B NM_000419.3 
integrin, alpha 2b (platelet glycoprotein IIb of IIb/IIIa complex, 
antigen CD41) 
ITGA4 NM_000885.4 
integrin, alpha 4 (antigen CD49D, alpha 4 subunit of VLA-4 
receptor) 
ITGA5 NM_002205.2 integrin, alpha 5 (fibronectin receptor, alpha polypeptide) 
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ITGA6 NM_000210.1 integrin, alpha 6 
ITGAE NM_002208.4 
integrin, alpha E (antigen CD103, human mucosal lymphocyte 
antigen 1; alpha polypeptide) 
ITGAL NM_002209.2 
integrin, alpha L (antigen CD11A (p180), lymphocyte function-
associated antigen 1; alpha polypeptide) 
ITGAM NM_000632.3 
integrin, alpha M (complement component 3 receptor 3 
subunit) 
ITGAX NM_000887.3 integrin, alpha X (complement component 3 receptor 4 subunit) 
ITGB1 NM_033666.2 
integrin, beta 1 (fibronectin receptor, beta polypeptide, antigen 
CD29 includes MDF2, MSK12) 
ITGB2 NM_000211.2 
integrin, beta 2 (complement component 3 receptor 3 and 4 
subunit) 
ITLN1 NM_017625.2 intelectin 1 (galactofuranose binding) 
ITLN2 NM_080878.2 intelectin 2 
JAK1 NM_002227.1 Janus kinase 1 
JAK2 NM_004972.2 Janus kinase 2 
JAK3 NM_000215.2 Janus kinase 3 
KCNJ2 NM_000891.2 potassium inwardly-rectifying channel, subfamily J, member 2 
KIR_Activating_Sub
group_1 NM_001083539.1 killer cell immunoglobulin-like receptor 
KIR_Activating_Sub
group_2 NM_014512.1 killer cell immunoglobulin-like receptor 
KIR_Inhibiting_Sub
group_1 NM_014218.2 killer cell immunoglobulin-like receptor 
KIR_Inhibiting_Sub
group_2 NM_014511.3 killer cell immunoglobulin-like receptor 
KIR3DL1 NM_013289.2 
killer cell immunoglobulin-like receptor, three domains, long 
cytoplasmic tail, 1 
KIR3DL2 NM_006737.2 
killer cell immunoglobulin-like receptor, three domains, long 
cytoplasmic tail, 2 
KIR3DL3 NM_153443.3 
killer cell immunoglobulin-like receptor, three domains, long 
cytoplasmic tail, 3 
KIT NM_000222.2 
v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene 
homolog 
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KLRAP1 NR_028045.1 killer cell lectin-like receptor subfamily A pseudogene 1 
KLRB1 NM_002258.2 killer cell lectin-like receptor subfamily B, member 1 
KLRC1 NM_002259.3 killer cell lectin-like receptor subfamily C, member 1 
KLRC2 NM_002260.3 killer cell lectin-like receptor subfamily C, member 2 
KLRC3 NM_007333.2 killer cell lectin-like receptor subfamily C, member 3 
KLRC4 NM_013431.2 killer cell lectin-like receptor subfamily C, member 4 
KLRD1 NM_002262.3 killer cell lectin-like receptor subfamily D, member 1 
KLRF1 NM_016523.1 killer cell lectin-like receptor subfamily F, member 1 
KLRF2 killer cell lectin-like receptor subfamily F, member 2 
KLRG1 NM_005810.3 killer cell lectin-like receptor subfamily G, member 1 
KLRG2 NM_198508.2 killer cell lectin-like receptor subfamily G, member 2 
KLRK1 NM_007360.1 killer cell lectin-like receptor subfamily K, member 1 
LAG3 NM_002286.5 lymphocyte-activation gene 3 
LAIR1 NM_002287.3 leukocyte-associated immunoglobulin-like receptor 1 
LAMP3 NM_014398.3 lysosomal-associated membrane protein 3 
LCK NM_005356.2 lymphocyte-specific protein tyrosine kinase 
LCP2 NM_005565.3 
lymphocyte cytosolic protein 2 (SH2 domain containing 
leukocyte protein of 76kDa) 
LEF1 NM_016269.3 lymphoid enhancer-binding factor 1 
LGALS3 NM_001177388.1 lectin, galactoside-binding, soluble, 3 
LIF NM_002309.3 leukemia inhibitory factor (cholinergic differentiation factor)  
LILRA1 NM_006863.1 
leukocyte immunoglobulin-like receptor, subfamily A (with TM 
domain), member 1 
LILRA2 NM_006866.2 
leukocyte immunoglobulin-like receptor, subfamily A (with TM 
domain), member 2 
LILRA3 NM_006865.3 
leukocyte immunoglobulin-like receptor, subfamily A (without 
TM domain), member 3 
LILRA4 NM_012276.3 
leukocyte immunoglobulin-like receptor, subfamily A (with TM 
domain), member 4 
LILRA5 NM_181879.2 
leukocyte immunoglobulin-like receptor, subfamily A (with TM 
domain), member 5 
LILRA6 NM_024318.2 
leukocyte immunoglobulin-like receptor, subfamily A (with TM 
domain), member 6 
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LILRB1 NM_001081637.1 
leukocyte immunoglobulin-like receptor, subfamily B (with TM 
and ITIM domains), member 1 
LILRB2 NM_005874.1 
leukocyte immunoglobulin-like receptor, subfamily B (with TM 
and ITIM domains), member 2 
LILRB3 NM_006864.2 
leukocyte immunoglobulin-like receptor, subfamily B (with TM 
and ITIM domains), member 3 
LILRB4 NM_001081438.1 
leukocyte immunoglobulin-like receptor, subfamily B (with TM 
and ITIM domains), member 4 
LILRB5 NM_001081442.1 
leukocyte immunoglobulin-like receptor, subfamily B (with TM 
and ITIM domains), member 5 
LITAF NM_004862.3 lipopolysaccharide-induced TNF factor 
LTA NM_000595.2 lymphotoxin alpha (TNF superfamily, member 1) 
LTB4R NM_181657.3 leukotriene B4 receptor 
LTB4R2 NM_019839.4 leukotriene B4 receptor 2 
LTBR NM_002342.1 lymphotoxin beta receptor (TNFR superfamily, member 3) 
LTF NM_002343.2 lactotransferrin 
LY96 NM_015364.2 lymphocyte antigen 96 
MAF NM_005360.4 
v-maf musculoaponeurotic fibrosarcoma oncogene homolog 
(avian) 
MALT1 NM_006785.2 
mucosa associated lymphoid tissue lymphoma translocation 
gene 1 
MAP4K1 NM_007181.3 mitogen-activated protein kinase 1 
MAP4K2 NM_004579.2 mitogen-activated protein kinase 2 
MAP4K4 NM_004834.3 mitogen-activated protein kinase 4 
MAPK1 NM_138957.2 mitogen-activated protein kinase 1 
MAPK11 NM_002751.5 mitogen-activated protein kinase 11 
MAPK14 NM_001315.1 mitogen-activated protein kinase 14 
MAPKAPK2 NM_004759.3 mitogen-activated protein kinase-activated protein kinase 2 
MARCO NM_006770.3 macrophage receptor with collagenous structure 
MASP1 NM_139125.3 
mannan-binding lectin serine peptidase 1 (C4/C2 activating 
component of Ra-reactive factor) 
MASP2 NM_139208.1 mannan-binding lectin serine peptidase 2 
MBL2 NM_000242.2 mannose-binding lectin (protein C) 2, soluble 
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MBP NM_002385.2 myelin basic protein 
MCL1 NM_021960.3 myeloid cell leukemia sequence 1 (BCL2-related) 
MIF NM_002415.1 
macrophage migration inhibitory factor (glycosylation-inhibiting 
factor) 
MME NM_000902.2 membrane metallo-endopeptidase 
MR1 NM_001531.2 major histocompatibility complex, class I-related 
MRC1 NM_002438.2 mannose receptor, C type 1 
MS4A1 NM_152866.2 membrane-spanning 4-domains, subfamily A, member 1 
MSR1 NM_002445.3 macrophage scavenger receptor 1 
MUC1 NM_001018017.1 mucin 1, cell surface associated 
MX1 NM_002462.2 
myxovirus (influenza virus) resistance 1, interferon-inducible 
protein p78 (mouse) 
MYD88 NM_002468.3 myeloid differentiation primary response gene (88) 
NCAM1 NM_000615.5 neural cell adhesion molecule 1 
NCF4 NM_000631.4 neutrophil cytosolic factor 4, 40kDa 
NCR1 NM_004829.5 natural cytotoxicity triggering receptor 1 
NFATC1 NM_172389.1 
nuclear factor of activated T-cells, cytoplasmic, calcineurin-
dependent 1 
NFATC2 NM_012340.3 
nuclear factor of activated T-cells, cytoplasmic, calcineurin-
dependent 2 
NFATC3 NM_004555.2 
nuclear factor of activated T-cells, cytoplasmic, calcineurin-
dependent 3 
NFIL3 NM_005384.2 nuclear factor, interleukin 3 regulated 
NFKB1 NM_003998.2 
nuclear factor of kappa light polypeptide gene enhancer in B-
cells 1 
NFKB2 NM_002502.2 
nuclear factor of kappa light polypeptide gene enhancer in B-
cells 2 (p49/p100) 
NFKBIA NM_020529.1 
nuclear factor of kappa light polypeptide gene enhancer in B-
cells inhibitor, alpha 
NFKBIZ 
nuclear factor of kappa light polypeptide gene enhancer in B-
cells inhibitor, zeta 
NLRP3 NM_001079821.2 NLR family, pyrin domain containing 3 
NOD1 NM_006092.1 nucleotide-binding oligomerization domain containing 1 
NOD2 NM_022162.1 nucleotide-binding oligomerization domain containing 2 
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NOS2 NM_000625.4 nitric oxide synthase 2, inducible 
NOTCH1 NM_017617.3 notch 1 
NOTCH2 NM_024408.3 notch 2 
NT5E NM_002526.2 5'-nucleotidase, ecto (CD73) 
PAX5 NM_016734.1 paired box 5 
PDCD1 NM_005018.1 programmed cell death 1 
PDCD1LG2 NM_025239.3 programmed cell death 1 ligand 2 
PDCD2 NM_144781.2 programmed cell death 2 
PDGFB NM_033016.2 platelet-derived growth factor beta polypeptide 
PDGFRB NM_002609.3 platelet-derived growth factor receptor, beta polypeptide 
PECAM1 NM_000442.3 platelet/endothelial cell adhesion molecule 
PIGR NM_002644.2 polymeric immunoglobulin receptor 
PLA2G2A NM_000300.2 phospholipase A2, group IIA (platelets, synovial fluid) 
PLA2G2E NM_014589.1 phospholipase A2, group IIE 
PLAU NM_002658.2 plasminogen activator, urokinase 
PLAUR NM_001005376.1 plasminogen activator, urokinase receptor 
PML NM_002675.3 promyelocytic leukemia 
POU2F2 NM_002698.2 POU class 2 homeobox 2 
PPARG NM_015869.3 peroxisome proliferator-activated receptor gamma 
PPBP NM_002704.2 pro-platelet basic protein (chemokine (C-X-C motif) ligand 7) 
PRDM1 NM_001198.3 PR domain containing 1, with ZNF domain 
PRF1 NM_005041.3 perforin 1 (pore forming protein) 
PRKCD NM_006254.3 protein kinase C, delta 
PSMB10 NM_002801.2 proteasome (prosome, macropain) subunit, beta type, 10 
PSMB5 proteasome (prosome, macropain) subunit, beta type, 5 
PSMB7 NM_002799.2 proteasome (prosome, macropain) subunit, beta type, 7 
PSMB8 NM_004159.4 
proteasome (prosome, macropain) subunit, beta type, 8 (large 
multifunctional peptidase 7) 
PSMB9 NM_002800.4 
proteasome (prosome, macropain) subunit, beta type, 9 (large 
multifunctional peptidase 2) 
PSMC2 NM_002803.3 proteasome (prosome, macropain) 26S subunit, ATPase, 2 
PSMD7 NM_002811.3 proteasome (prosome, macropain) 26S subunit, non-ATPase, 7 
PTAFR NM_000952.3 platelet-activating factor receptor 
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PTGER4 NM_000958.2 prostaglandin E receptor 4 (subtype EP4) 
PTGS2 NM_000963.1 
prostaglandin-endoperoxide synthase 2 (prostaglandin G/H 
synthase and cyclooxygenase) 
PTK2 NM_005607.3 PTK2 protein tyrosine kinase 2 
PTPN2 NM_002828.2 protein tyrosine phosphatase, non-receptor type 2 
PTPN22 NM_015967.4 protein tyrosine phosphatase, non-receptor type 22 (lymphoid) 
PTPN6 NM_002831.5 protein tyrosine phosphatase, non-receptor type 6 
PTPRC_all 
(common probe) NM_080921.2 protein tyrosine phosphatase, receptor type, C 
CD45R0 NM_080921.3 protein tyrosine phosphatase, receptor type, C 
CD45RA NM_002838.4 protein tyrosine phosphatase, receptor type, C 
CD45RB ENST00000367367.1 protein tyrosine phosphatase, receptor type, C 
PYCARD NM_013258.3 PYD and CARD domain containing 
RAF1 NM_002880.2 v-raf-1 murine leukemia viral oncogene homolog 1 
RAG1 NM_000448.2 recombination activating gene 1 
RAG2 NM_000536.3 recombination activating gene 2 
RARRES3 NM_004585.3 retinoic acid receptor responder (tazarotene induced) 3 
RELA NM_021975.2 v-rel reticuloendotheliosis viral oncogene homolog A (avian) 
RELB NM_006509.2 v-rel reticuloendotheliosis viral oncogene homolog B 
RORC RAR-related orphan receptor C 
RUNX1 NM_001754.4 runt-related transcription factor 1 
S100A8 NM_002964.3 S100 calcium binding protein A8 
S100A9 NM_002965.2 S100 calcium binding protein A9 
S1PR1 NM_001400.3 sphingosine-1-phosphate receptor 1 
SELE NM_000450.2 selectin E 
SELL NR_029467.1 selectin L 
SELPLG NM_003006.3 selectin P ligand 
SERPING1 NM_000062.2 serpin peptidase inhibitor, clade G (C1 inhibitor), member 1 
SH2D1A NM_001114937.2 SH2 domain containing 1A 
SIGIRR NM_021805.2 
single immunoglobulin and toll-interleukin 1 receptor (TIR) 
domain 
SKI NM_003036.2 v-ski sarcoma viral oncogene homolog (avian) 
SLAMF1 NM_003037.2 signalling lymphocytic activation molecule family member 1 
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SLAMF6 SLAM family member 6 
SLAMF7 NM_021181.3 SLAM family member 7 
SLC2A1 NM_006516.2 
solute carrier family 2 (facilitated glucose transporter), member 
1 
SMAD3 NM_005902.3 SMAD family member 3 
SMAD5 NM_005903.5 SMAD family member 5 
SOCS1 NM_003745.1 suppressor of cytokine signalling 1 
SOCS3 NM_003955.3 suppressor of cytokine signalling 3 
SPP1 NM_000582.2 secreted phosphoprotein 1 
SRC NM_005417.3 
v-src sarcoma (Schmidt-Ruppin A-2) viral oncogene homolog 
(avian) 
STAT1 NM_007315.2 signal transducer and activator of transcription 1, 91kDa 
STAT2 NM_005419.2 signal transducer and activator of transcription 2, 113kDa 
STAT3 NM_139276.2 
signal transducer and activator of transcription 3 (acute-phase 
response factor) 
STAT4 NM_003151.2 signal transducer and activator of transcription 4 
STAT5A NM_003152.2 signal transducer and activator of transcription 5A 
STAT5B NM_012448.3 signal transducer and activator of transcription 5B 
STAT6 NM_003153.3 
signal transducer and activator of transcription 6, interleukin-4 
induced 
SYK NM_003177.3 spleen tyrosine kinase 
TAGAP NM_054114.3 T-cell activation RhoGTPase activating protein 
TAL1 NM_003189.2 T-cell acute lymphocytic leukemia 1 
TAP1 NM_000593.5 transporter 1, ATP-binding cassette, sub-family B (MDR/TAP) 
TAP2 NM_000544.3 transporter 2, ATP-binding cassette, sub-family B (MDR/TAP) 
TAPBP NM_003190.4 TAP binding protein (tapasin) 
TBK1 NM_013254.2 TANK-binding kinase 1 
TBX21 NM_013351.1 T-box 21 
TCF4 NM_003199.1 transcription factor 4 
TCF7 NM_003202.2 transcription factor 7 (T-cell specific, HMG-box) 
TFRC NM_003234.1 transferrin receptor (p90, CD71) 
TGFB1 NM_000660.3 transforming growth factor, beta 1 
TGFBI NM_000358.2 transforming growth factor, beta-induced, 68kDa 
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TGFBR1 NM_004612.2 transforming growth factor, beta receptor 1 
TGFBR2 NM_001024847.1 transforming growth factor, beta receptor II (70/80kDa) 
THY1 NM_006288.2 Thy-1 cell surface antigen 
TICAM1 NM_014261.1 toll-like receptor adaptor molecule 1 
TIGIT NM_173799.2 T cell immunoreceptor with Ig and ITIM domains 
TIRAP NM_148910.2 
toll-interleukin 1 receptor (TIR) domain containing adaptor 
protein 
TLR1 NM_003263.3 toll-like receptor 1 
TLR2 NM_003264.3 toll-like receptor 2 
TLR3 NM_003265.2 toll-like receptor 3 
TLR4 NM_138554.2 toll-like receptor 4 
TLR5 NM_003268.3 toll-like receptor 5 
TLR7 NM_016562.3 toll-like receptor 7 
TLR8 NM_016610.2 toll-like receptor 8 
TLR9 NM_017442.2 toll-like receptor 9 
TMEM173 NM_198282.1 transmembrane protein 173 
TNF NM_000594.2 tumor necrosis factor 
TNFAIP3 NM_006290.2 tumor necrosis factor, alpha-induced protein 3 
TNFAIP6 NM_007115.2 tumor necrosis factor, alpha-induced protein 6 
TNFRSF10C NM_003841.3 
tumor necrosis factor receptor superfamily, member 10c, decoy 
without an intracellular domain 
TNFRSF11A NM_003839.2 
tumor necrosis factor receptor superfamily, member 11a, NFKB 
activator 
TNFRSF13B NM_012452.2 tumor necrosis factor receptor superfamily, member 13B 
TNFRSF13C NM_052945.3 tumor necrosis factor receptor superfamily, member 13C 
TNFRSF14 NM_003820.2 tumor necrosis factor receptor superfamily, member 14 
TNFRSF17 NM_001192.2 tumor necrosis factor receptor superfamily, member 17 
TNFRSF1B NM_001066.2 tumor necrosis factor receptor superfamily, member 1B 
TNFRSF4 NM_003327.2 tumor necrosis factor receptor superfamily, member 4 
TNFRSF8 NM_152942.2 tumor necrosis factor receptor superfamily, member 8 
TNFRSF9 NM_001561.4 tumor necrosis factor receptor superfamily, member 9 
TNFSF10 NM_003810.2 tumor necrosis factor (ligand) superfamily, member 10 
TNFSF11 NM_003701.2 tumor necrosis factor (ligand) superfamily, member 11 
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TNFSF12 NM_003809.2 tumor necrosis factor (ligand) superfamily, member 12 
TNFSF13B NM_006573.4 tumor necrosis factor (ligand) superfamily, member 13b 
TNFSF15 NM_001204344.1 tumor necrosis factor (ligand) superfamily, member 15 
TNFSF4 NM_003326.2 tumor necrosis factor (ligand) superfamily, member 4 
TNFSF8 NM_001244.3 tumor necrosis factor (ligand) superfamily, member 8 
TOLLIP NM_019009.2 toll interacting protein 
TP53 NM_000546.2 tumor protein p53 
TRAF1 NM_005658.3 TNF receptor-associated factor 1 
TRAF2 NM_021138.3 TNF receptor-associated factor 2 
TRAF3 NM_145725.1 TNF receptor-associated factor 3 
TRAF4 NM_004295.2 TNF receptor-associated factor 4 
TRAF5 NM_004619.3 TNF receptor-associated factor 5 
TRAF6 NM_145803.1 TNF receptor-associated factor 6 
TYK2 NM_003331.3 tyrosine kinase 2 
UBE2L3 NM_198157.1 ubiquitin-conjugating enzyme E2L 3 
VCAM1 NM_001078.3 vascular cell adhesion molecule 1 
VTN NM_000638.3 vitronectin 
XBP1 NM_005080.2 X-box binding protein 1 
XCL1 NM_002995.1 chemokine (C motif) ligand 1 
XCR1 NM_005283.2 chemokine (C motif) receptor 1 
ZAP70 NM_001079.3 zeta-chain (TCR) associated protein kinase 70kDa 
ZBTB16 NM_006006.4 zinc finger and BTB domain containing 16 
ZEB1 NM_001128128.1 zinc finger E-box binding homeobox 1 
Internal 
Reference Genes     
ABCF1 NM_001090.2 ATP-binding cassette, sub-family F (GCN20), member 1 
ALAS1 NM_000688.4 aminolevulinate, delta-, synthase 1 
EEF1G NM_001404.4 eukaryotic translation elongation factor 1 gamma 
G6PD NM_000402.2 glucose-6-phosphate dehydrogenase 
GAPDH NM_002046.3 glyceraldehyde-3-phosphate dehydrogenase 
GUSB NM_000181.1 glucuronidase, beta 
HPRT1 NM_000194.1 hypoxanthine phosphoribosyltransferase 1 
OAZ1 NM_004152.2 ornithine decarboxylase antizyme 1 
 
 
 178 
POLR1B NM_019014.3 polymerase (RNA) I polypeptide B, 128kDa 
POLR2A NM_000937.2 polymerase (RNA) II (DNA directed) polypeptide A, 220kDa 
PPIA NM_021130.2 peptidylprolyl isomerase A (cyclophilin A) 
SDHA NM_004168.1 succinate dehydrogenase complex, subunit A, flavoprotein (Fp)  
TBP NM_001172085.1 TATA box binding protein 
TUBB NM_178014.2 tubulin, beta 
RPL19 NM_000981.3 ribosomal protein L19 
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Table A3: Nanostring nCounter Vantage RNA Intracellular Signalling panel 
Official 
Symbol Accession Official Full Name 
A2M NM_000014.4 alpha-2-macroglobulin 
AKT1 NM_005163.2 v-akt murine thymoma viral oncogene homolog 1 
AKT2 NM_001626.2 v-akt murine thymoma viral oncogene homolog 2 
AKT3 NM_005465.4 v-akt murine thymoma viral oncogene homolog 3 
BAD NM_004322.3 BCL2-associated agonist of cell death 
BCL2 NM_000657.2 B-cell CLL/lymphoma 2 
BCL2L1 NM_138578.1 BCL2-like 1 
CBL NM_005188.2 Cbl proto-oncogene, E3 ubiquitin protein ligase 
CBLC NM_012116.3 Cbl proto-oncogene C, E3 ubiquitin protein ligase 
CCL13 NM_005408.2 chemokine (C-C motif) ligand 13 
CCL16 NM_004590.2 chemokine (C-C motif) ligand 16 
CCL2 NM_002982.3 chemokine (C-C motif) ligand 2 
CCL3 NM_002983.2 chemokine (C-C motif) ligand 3 
CCL4 NM_002984.2 chemokine (C-C motif) ligand 4 
CCL5 NM_002985.2 chemokine (C-C motif) ligand 5 
CCL7 NM_006273.2 chemokine (C-C motif) ligand 7 
CCL8 NM_005623.2 chemokine (C-C motif) ligand 8 
CCND1 NM_053056.2 cyclin D1 
CCND2 NM_001759.2 cyclin D2 
CCND3 NM_001760.2 cyclin D3 
CCR1 NM_001295.2 chemokine (C-C motif) receptor 1 
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CCR2 
NM_00112304
1.2 
chemokine (C-C motif) receptor 2 
CCR3 NM_001837.2 chemokine (C-C motif) receptor 3 
CCR4 NM_005508.4 chemokine (C-C motif) receptor 4 
CCR5 NM_000579.1 chemokine (C-C motif) receptor 5 (gene/pseudogene) 
CCR7 NM_001838.2 chemokine (C-C motif) receptor 7 
CD70 NM_001252.2 CD70 molecule 
CDKN1A NM_000389.2 cyclin-dependent kinase inhibitor 1A (p21, Cip1) 
CEBPD NM_005195.3 CCAAT/enhancer binding protein (C/EBP), delta 
CLCF1 NM_013246.2 cardiotrophin-like cytokine factor 1 
CNTFR NM_147164.1 ciliary neurotrophic factor receptor 
CREBBP 
NM_00107984
6.1 
CREB binding protein 
CRLF2 
NM_00101228
8.1 
cytokine receptor-like factor 2 
CSF1R NM_005211.2 colony stimulating factor 1 receptor 
CSF2 NM_000758.2 colony stimulating factor 2 (granulocyte-macrophage) 
CSF3 NM_000759.3 colony stimulating factor 3 (granulocyte) 
CSF3R NM_156038.2 colony stimulating factor 3 receptor (granulocyte) 
CXCL1 NM_001511.1 
chemokine (C-X-C motif) ligand 1 (melanoma growth stimulating activity, 
alpha) 
CXCL10 NM_001565.1 chemokine (C-X-C motif) ligand 10 
CXCL2 NM_002089.3 chemokine (C-X-C motif) ligand 2 
CXCL3 NM_002090.2 chemokine (C-X-C motif) ligand 3 
CXCL5 NM_002994.3 chemokine (C-X-C motif) ligand 5 
CXCL8 NM_000584.2 chemokine (C-X-C motif) ligand 8 
CXCL9 NM_002416.1 chemokine (C-X-C motif) ligand 9 
EGFR NM_201282.1 epidermal growth factor receptor 
EP300 NM_001429.2 E1A binding protein p300 
EPO NM_000799.2 erythropoietin 
EPOR NM_000121.2 erythropoietin receptor 
FAS NM_152876.1 Fas cell surface death receptor 
FASLG NM_000639.1 Fas ligand (TNF superfamily, member 6) 
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FCGR1A NM_000566.3 Fc fragment of IgG, high affinity Ia, receptor (CD64) 
FLT3LG NM_001459.3 fms-related tyrosine kinase 3 ligand 
GATA3 
NM_00100229
5.1 
GATA binding protein 3 
GHR NM_000163.2 growth hormone receptor 
GRB2 NM_002086.4 growth factor receptor-bound protein 2 
HSP90B1 NM_003299.1 heat shock protein 90kDa beta (Grp94), member 1 
IFNA17 NM_021268.2 interferon, alpha 17 
IFNA2 NM_000605.3 interferon, alpha 2 
IFNA7 NM_021057.2 interferon, alpha 7 
IFNG NM_000619.2 interferon, gamma 
IKBKB NM_001556.1 inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase beta 
IKBKG NM_003639.2 inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase gamma 
IL10 NM_000572.2 interleukin 10 
IL10RA NM_001558.2 interleukin 10 receptor, alpha 
IL11 NM_000641.2 interleukin 11 
IL11RA NM_147162.1 interleukin 11 receptor, alpha 
IL12A NM_000882.2 
interleukin 12A (natural killer cell stimulatory factor 1, cytotoxic lymphocyte 
maturation factor 1, p35) 
IL12B NM_002187.2 
interleukin 12B (natural killer cell stimulatory factor 2, cytotoxic lymphocyte 
maturation factor 2, p40) 
IL12RB2 NM_001559.2 interleukin 12 receptor, beta 2 
IL13 NM_002188.2 interleukin 13 
IL13RA1 NM_001560.2 interleukin 13 receptor, alpha 1 
IL13RA2 NM_000640.2 interleukin 13 receptor, alpha 2 
IL15 NM_172174.1 interleukin 15 
IL17A NM_002190.2 interleukin 17A 
IL18 NM_001562.2 interleukin 18 (interferon-gamma-inducing factor) 
IL19 NM_013371.3 interleukin 19 
IL1A NM_000575.3 interleukin 1, alpha 
IL1B NM_000576.2 interleukin 1, beta 
IL1R2 NM_173343.1 interleukin 1 receptor, type II 
IL1RN NM_000577.3 interleukin 1 receptor antagonist 
 
 
 181 
IL2 NM_000586.2 interleukin 2 
IL20RA NM_014432.2 interleukin 20 receptor, alpha 
IL20RB NM_144717.2 interleukin 20 receptor beta 
IL21 NM_021803.2 interleukin 21 
IL22 NM_020525.4 interleukin 22 
IL22RA1 NM_021258.2 interleukin 22 receptor, alpha 1 
IL22RA2 NM_181310.1 interleukin 22 receptor, alpha 2 
IL23A NM_016584.2 interleukin 23, alpha subunit p19 
IL23R NM_144701.2 interleukin 23 receptor 
IL24 NM_181339.1 interleukin 24 
IL26 NM_018402.1 interleukin 26 
IL2RA NM_000417.1 interleukin 2 receptor, alpha 
IL2RB NM_000878.2 interleukin 2 receptor, beta 
IL3 NM_000588.3 interleukin 3 (colony-stimulating factor, multiple) 
IL3RA NM_002183.2 interleukin 3 receptor, alpha (low affinity) 
IL4R NM_000418.2 interleukin 4 receptor 
IL5 NM_000879.2 interleukin 5 (colony-stimulating factor, eosinophil) 
IL5RA NM_000564.3 interleukin 5 receptor, alpha 
IL6 NM_000600.1 interleukin 6 (interferon, beta 2) 
IL6R NM_000565.2 interleukin 6 receptor 
IL7 NM_000880.2 interleukin 7 
IL7R NM_002185.2 interleukin 7 receptor 
IL9 NM_000590.1 interleukin 9 
IRF1 NM_002198.1 interferon regulatory factor 1 
IRF9 NM_006084.4 interferon regulatory factor 9 
JAK1 NM_002227.1 Janus kinase 1 
JAK2 NM_004972.2 Janus kinase 2 
JAK3 NM_000215.2 Janus kinase 3 
JUN NM_002228.3 jun proto-oncogene 
JUNB NM_002229.2 jun B proto-oncogene 
LEP NM_000230.2 leptin 
LEPR 
NM_00100367
9.1 
leptin receptor 
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LIF NM_002309.3 leukemia inhibitory factor 
LIFR NM_002310.3 leukemia inhibitory factor receptor alpha 
LRG1 NM_052972.2 leucine-rich alpha-2-glycoprotein 1 
LTB NM_002341.1 lymphotoxin beta (TNF superfamily, member 3) 
MAP2K1 NM_002755.2 mitogen-activated protein kinase 1 
MAP2K2 NM_030662.2 mitogen-activated protein kinase 2 
MAPK1 NM_138957.2 mitogen-activated protein kinase 1 
MAPK3 
NM_00104005
6.1 
mitogen-activated protein kinase 3 
MCL1 NM_021960.3 myeloid cell leukemia sequence 1 (BCL2-related) 
MDM2 NM_006878.2 MDM2 oncogene, E3 ubiquitin protein ligase 
MPL NM_005373.2 myeloproliferative leukemia virus oncogene 
MTOR NM_004958.2 mechanistic target of rapamycin (serine/threonine kinase) 
MYC NM_002467.3 v-myc avian myelocytomatosis viral oncogene homolog 
MYD88 NM_002468.3 myeloid differentiation primary response 88 
NFKB1 NM_003998.2 nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 
NOS2 NM_153292.1 nitric oxide synthase 2, inducible 
OAS1 
NM_00103240
9.1 
2'-5'-oligoadenylate synthetase 1, 40/46kDa 
OSM NM_020530.4 oncostatin M 
PDGFRA NM_006206.3 platelet-derived growth factor receptor, alpha polypeptide 
PIAS1 NM_016166.1 protein inhibitor of activated STAT, 1 
PIAS3 NM_006099.3 protein inhibitor of activated STAT, 3 
PIK3CA NM_006218.2 phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha 
PIK3CB NM_006219.1 phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit beta 
PIK3CD NM_005026.3 phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit delta 
PIK3CG NM_002649.2 phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit gamma 
PIK3R1 NM_181504.2 phosphoinositide-3-kinase, regulatory subunit 1 (alpha) 
PIK3R2 NM_005027.2 phosphoinositide-3-kinase, regulatory subunit 2 (beta) 
PIK3R3 NM_003629.3 phosphoinositide-3-kinase, regulatory subunit 3 (gamma) 
PIK3R5 
NM_00114263
3.1 
phosphoinositide-3-kinase, regulatory subunit 5 
PIM1 NM_002648.2 pim-1 oncogene 
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PRL NM_000948.3 prolactin 
PRLR 
NM_00120431
8.1 
prolactin receptor 
PTEN NM_000314.4 phosphatase and tensin homolog 
PTPN11 NM_002834.3 protein tyrosine phosphatase, non-receptor type 11 
RAF1 NM_002880.3 v-raf-1 murine leukemia viral oncogene homolog 1 
RIPK2 NM_003821.5 receptor-interacting serine-threonine kinase 2 
SMAD2 NM_005901.5 SMAD family member 2 
SMAD3 NM_005902.3 SMAD family member 3 
SOCS1 NM_003745.1 suppressor of cytokine signalling 1 
SOCS2 NM_003877.3 suppressor of cytokine signalling 2 
SOCS3 NM_003955.3 suppressor of cytokine signalling 3 
SOS1 NM_005633.2 son of sevenless homolog 1 (Drosophila) 
SOS2 NM_006939.2 son of sevenless homolog 2 (Drosophila) 
SPP1 NM_000582.2 secreted phosphoprotein 1 
SPRY1 NM_005841.1 sprouty homolog 1, antagonist of FGF signalling (Drosophila) 
SPRY2 NM_005842.2 sprouty homolog 2 (Drosophila) 
SPRY4 NM_030964.3 sprouty homolog 4 (Drosophila) 
STAT1 NM_007315.2 signal transducer and activator of transcription 1, 91kDa 
STAT2 NM_005419.2 signal transducer and activator of transcription 2, 113kDa 
STAT3 NM_139276.2 
signal transducer and activator of transcription 3 (acute-phase response 
factor) 
STAT4 NM_003151.2 signal transducer and activator of transcription 4 
STAT5A NM_003152.2 signal transducer and activator of transcription 5A 
STAT5B NM_012448.3 signal transducer and activator of transcription 5B 
STAT6 NM_003153.3 signal transducer and activator of transcription 6, interleukin-4 induced 
SYK NM_003177.3 spleen tyrosine kinase 
TLR1 NM_003263.3 toll-like receptor 1 
TLR3 NM_003265.2 toll-like receptor 3 
TLR4 NM_138554.2 toll-like receptor 4 
TLR6 NM_006068.2 toll-like receptor 6 
TNF NM_000594.2 tumor necrosis factor 
TNFSF10 NM_003810.2 tumor necrosis factor (ligand) superfamily, member 10 
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TNFSF14 NM_003807.3 tumor necrosis factor (ligand) superfamily, member 14 
TNFSF8 NM_001244.3 tumor necrosis factor (ligand) superfamily, member 8 
TP53 NM_000546.2 tumor protein p53 
TPO NM_175722.1 thyroid peroxidase 
TSC1 NM_000368.3 tuberous sclerosis 1 
TSLP NM_033035.4 thymic stromal lymphopoietin 
VEGFA 
NM_00102536
6.1 
vascular endothelial growth factor A 
Internal Reference Genes   
CC2D1B NM_032449.2 coiled-coil and C2 domain containing 1B 
COG7 NM_153603.3 component of oligomeric golgi complex 7 
EDC3 
NM_00114244
3.1 
enhancer of mRNA decapping 3 
GPATCH3 NM_022078.2 G patch domain containing 3 
HDAC3 NM_003883.2 histone deacetylase 3 
MTMR14 NM_022485.3 myotubularin related protein 14 
NUBP1 
NM_00127850
6.1 
nucleotide binding protein 1 
PRPF38A NM_032864.3 pre-mRNA processing factor 38A 
SAP130 NM_024545.3 Sin3A-associated protein, 130kDa 
SF3A3 NM_006802.2 splicing factor 3a, subunit 3, 60kDa 
TLK2 NM_006852.2 tousled-like kinase 2 
ZC3H14 
NM_00116010
3.1 
zinc finger CCCH-type containing 14 
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Appendix item 3: Volcano plots of differentially expressed genes associated with COPD, 
diesel emission exposure and NAC intervention 
 
 
Figure A 1: Volcano plot of differentially expressed genes comparing between 
nonCOPD (LC) and COPD (LC.COPD) cohorts.  
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Figure A 2: Volcano plot of differentially expressed genes after diesel emission exposure 
(DE) relative to the filtered air controls (FA).  
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Figure A 3: Volcano plot of differentially expressed after diesel emission exposure with 
NAC intervention relative to without NAC intervention. 
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Appendix item 4: TPCH Human Ethics Committee approval letter 
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Appendix item 5: UQ Human Ethics Unit approval letter 
 
